[go: up one dir, main page]

WO2022183502A1 - 抗cldn6抗体及其用途 - Google Patents

抗cldn6抗体及其用途 Download PDF

Info

Publication number
WO2022183502A1
WO2022183502A1 PCT/CN2021/079380 CN2021079380W WO2022183502A1 WO 2022183502 A1 WO2022183502 A1 WO 2022183502A1 CN 2021079380 W CN2021079380 W CN 2021079380W WO 2022183502 A1 WO2022183502 A1 WO 2022183502A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
sequence
amino acid
seq
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2021/079380
Other languages
English (en)
French (fr)
Inventor
杜靓
张红艳
金理娜
陈亚莉
万婷婷
徐溜溜
袁纪军
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Genbase Biotechnology Co Ltd
Original Assignee
Shanghai Genbase Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020237033643A priority Critical patent/KR20230154317A/ko
Priority to CN202180095157.5A priority patent/CN116940377A/zh
Priority to PCT/CN2021/079380 priority patent/WO2022183502A1/zh
Priority to CA3212530A priority patent/CA3212530A1/en
Priority to US18/280,379 priority patent/US20240150455A1/en
Priority to EP21928585.5A priority patent/EP4302777A4/en
Application filed by Shanghai Genbase Biotechnology Co Ltd filed Critical Shanghai Genbase Biotechnology Co Ltd
Priority to JP2023553642A priority patent/JP7734753B2/ja
Priority to TW111107215A priority patent/TW202235441A/zh
Publication of WO2022183502A1 publication Critical patent/WO2022183502A1/zh
Anticipated expiration legal-status Critical
Priority to JP2025140700A priority patent/JP2026000918A/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G01N33/5759—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Definitions

  • the present invention relates to the field of disease treatment and immunology, in particular, the present invention relates to anti-CLDN6 antibodies or antigen-binding fragments thereof, nucleic acid molecules encoding the same, immunoconjugates, bispecific molecules, chimeric antigen receptors comprising the same and pharmaceutical compositions, and their use for the prevention and/or treatment of tumors.
  • Ovarian cancer is a common gynecological malignancy and is a highly heterogeneous epithelial tumor with different histological subtypes as well as genetic and biological features, including serous carcinoma, endometrioid carcinoma, clear Cellular and mucinous carcinomas. Every year, there are 310,000 new cases of ovarian cancer and more than 200,000 deaths worldwide (5). 75% of ovarian cancers are serous cancers, with a five-year survival rate of 35%. They are a very malignant type of cancer and are usually diagnosed at an advanced stage.
  • Claudin is a transmembrane protein, which is a membrane protein located at the tight junction between epithelial cells and endothelial cells.
  • the distribution of CLDN family proteins is specific to tissues and organs, and their main functions are intercellular adhesion, maintenance of cell polarity, regulation of paracellular permeability, and participation in the regulation of cell proliferation and differentiation. Recent studies have shown that the expression of some members of the CLDN family is up-regulated during carcinogenesis, and ectopic activation occurs in tissues that are not normally distributed in the case of carcinogenesis. This property makes scientists further consider the possibility of CLDN protein as a tumor target.
  • CLDN6 is only highly expressed during embryonic development and not expressed in normal adult tissues.
  • the highest expression of CLDN6 in normal adult tissues is the testis, and the expression level is only 0.83TPM.
  • CLDN6 protein is a four-transmembrane protein with four transmembrane hydrophobic regions and two extracellular loops. Its recombinant protein is extremely difficult to express, so there is no suitable protein antigen for immunization, which brings difficulties to the immunization and screening of antibodies against CLDN6 .
  • the CLDN family proteins have high homology. When targeting CLDN6, it is necessary to avoid binding to CLDN3 and CLDN4, which are widely expressed in normal tissues and have high homology to CLDN6, so as to avoid possible cross-binding. Toxicity issue. The above are the two major difficulties in the development of anti-CLDN6 antibodies.
  • the antibodies of the present invention can specifically recognize/bind to human CLDN6 and/or CLDN9, and can induce killing of CLDN6-expressing cells (eg, tumor cells) through ADCC and/or CDC. Therefore, the antibodies of the present invention have the potential for preventing and/or treating tumors, and have great clinical value.
  • CLDN6-expressing cells eg, tumor cells
  • VH heavy chain variable region
  • CDRs 3 complementarity determining regions
  • VH CDR2 consisting of the following sequence: SEQ ID NO: 4 or 33, or having one or several amino acid substitutions, deletions or additions therefrom (e.g., 1, 2 or 3 amino acid substitutions) , deletion or addition), and
  • VL CDR1 consisting of the following sequence: SEQ ID NO: 6, or having one or several amino acid substitutions, deletions or additions (e.g. 1, 2 or 3 amino acid substitutions, deletions) therefrom or added) sequence,
  • VL CDR2 consisting of the following sequence: SEQ ID NO: 7, or having one or several amino acid substitutions, deletions or additions therefrom (e.g., 1, 2 or 3 amino acid substitutions, deletions) or addition), and
  • substitutions described in any of (i)-(vi) are conservative substitutions.
  • the CDRs described in any of (i)-(vi) are defined according to the Kabat, IMGT or Chothia numbering systems.
  • the CDRs described in any of (i)-(vi) are defined according to the IMGT numbering system.
  • the antibody or antigen-binding fragment thereof comprises: the following 3 heavy chain CDRs: VH CDR1 of sequence SEQ ID NO:3, VH CDR2 of sequence SEQ ID NO:33, VH of sequence SEQ ID NO:5 CDR3; and/or, the following 3 light chain CDRs: VL CDR1 of sequence SEQ ID NO:6, VL CDR2 of sequence SEQ ID NO:7, and VL CDR3 of sequence SEQ ID NO:8.
  • the antibody, or antigen-binding fragment thereof further comprises framework region sequences derived from humans (eg, human immunoglobulins).
  • VH CDR2 consisting of the following sequence: SEQ ID NO: 4, or with one or several amino acid substitutions, deletions or additions (e.g. 1, 2 or 3 amino acid substitutions, deletions) therefrom or added), and
  • VH CDR3 consisting of the following sequence: SEQ ID NO: 5, or with one or several amino acid substitutions, deletions or additions (e.g. 1, 2 or 3 amino acid substitutions, deletions) therefrom or added);
  • VL CDR2 consisting of the following sequence: SEQ ID NO: 7, or having one or several amino acid substitutions, deletions or additions therefrom (e.g., 1, 2 or 3 amino acid substitutions, deletions) or added), and
  • the CDRs described in any of (i)-(vi) are defined according to the IMGT numbering system.
  • the antibody, or antigen-binding fragment thereof further comprises framework region sequences derived from humans (eg, human immunoglobulins).
  • the human immunoglobulins are selected from human rearranged antibody sequences or human germline antibody sequences.
  • the antibody or antigen-binding fragment thereof has one or more of the following biological functions:
  • the antibody or antigen-binding fragment thereof comprises:
  • the present invention provides an antibody or antigen-binding fragment thereof capable of specifically binding CLDN6, the antibody or antigen-binding fragment thereof comprising:
  • VH heavy chain variable region
  • CDRs 3 complementarity determining regions
  • VH CDR2 consisting of the following sequence: SEQ ID NO: 33, or having one or several amino acid substitutions, deletions or additions (e.g. 1, 2 or 3 amino acid substitutions, deletions) therefrom or added), and
  • VH CDR3 consisting of the following sequence: SEQ ID NO: 5, or with one or several amino acid substitutions, deletions or additions (e.g. 1, 2 or 3 amino acid substitutions, deletions) therefrom or added);
  • VL light chain variable region
  • CDRs 3 complementarity determining regions
  • VL CDR1 consisting of the following sequence: SEQ ID NO: 6, or having one or several amino acid substitutions, deletions or additions (e.g. 1, 2 or 3 amino acid substitutions, deletions) therefrom or added) sequence,
  • VL CDR2 consisting of the following sequence: SEQ ID NO: 7, or having one or several amino acid substitutions, deletions or additions therefrom (e.g., 1, 2 or 3 amino acid substitutions, deletions) or added), and
  • VL CDR3 consisting of the following sequence: SEQ ID NO: 8, or having one or several amino acid substitutions, deletions or additions therefrom (e.g. 1, 2 or 3 amino acid substitutions, deletions) or added) sequence.
  • the CDRs described in any of (i)-(vi) are defined according to the Kabat, IMGT or Chothia numbering systems.
  • the CDRs described in any of (i)-(vi) are defined according to the IMGT numbering system.
  • the antibody or antigen-binding fragment thereof comprises: the following 3 heavy chain CDRs: VH CDR1 of sequence SEQ ID NO: 3, VH CDR2 of sequence SEQ ID NO: 33, VH CDR3 of sequence SEQ ID NO: 5; and/or, the following 3 light chain CDRs: VL CDR1 of sequence SEQ ID NO: 6, VL CDR2 of sequence SEQ ID NO: 7, sequence of SEQ ID NO: 8 VL CDR3.
  • the antibody, or antigen-binding fragment thereof further comprises framework region sequences derived from humans (eg, human immunoglobulins).
  • the antibody or antigen-binding fragment thereof comprises:
  • VH heavy chain variable region
  • VL light chain variable region
  • substitutions described in (ii) or (v) are conservative substitutions.
  • the antibody or antigen-binding fragment thereof comprises: a VH having the sequence set forth in SEQ ID NO:19 and a VL having the sequence set forth in SEQ ID NO:20.
  • the present invention provides an antibody or antigen-binding fragment thereof capable of specifically binding CLDN6 and/or CLDN9, the antibody or antigen-binding fragment thereof comprising:
  • VH heavy chain variable region
  • CDRs 3 complementarity determining regions
  • VH CDR1 consisting of the following sequence: SEQ ID NO: 13, or having one or several amino acid substitutions, deletions or additions therefrom (e.g., 1, 2 or 3 amino acid substitutions, deletions) or added) sequence,
  • VH CDR2 consisting of the following sequence: SEQ ID NO: 14 or 23, or having one or several amino acid substitutions, deletions or additions (e.g. 1, 2 or 3 amino acid substitutions) therefrom , deletion or addition), and
  • VH CDR3 consisting of the following sequence: SEQ ID NO: 15, or having one or several amino acid substitutions, deletions or additions therefrom (e.g. 1, 2 or 3 amino acid substitutions, deletions) or added);
  • VL light chain variable region
  • CDRs 3 complementarity determining regions
  • VL CDR1 consisting of the following sequence: SEQ ID NO: 16 or 24, or having one or several amino acid substitutions, deletions or additions therefrom (e.g. 1, 2 or 3 amino acid substitutions) , deletion or addition) sequences,
  • VL CDR2 consisting of the following sequence: SEQ ID NO: 17, or having one or several amino acid substitutions, deletions or additions (e.g. 1, 2 or 3 amino acid substitutions, deletions) therefrom or added), and
  • VL CDR3 consisting of the following sequence: SEQ ID NO: 18, or having one or several amino acid substitutions, deletions or additions therefrom (e.g. 1, 2 or 3 amino acid substitutions, deletions) or added) sequence.
  • substitutions described in any of (i)-(vi) are conservative substitutions.
  • the CDRs described in any of (i)-(vi) are defined according to the Kabat, IMGT or Chothia numbering systems.
  • the CDRs described in any of (i)-(vi) are defined according to the IMGT numbering system.
  • the antibody or antigen-binding fragment thereof comprises: the following 3 heavy chain CDRs: VH CDR1 of sequence SEQ ID NO: 13, VH CDR2 of sequence SEQ ID NO: 14, VH CDR3 of sequence SEQ ID NO: 15; and/or, the following 3 light chain CDRs: VL CDR1 of sequence SEQ ID NO: 16, VL CDR2 of sequence SEQ ID NO: 17, sequence of SEQ ID NO: VL CDR3 of 18; or,
  • the human immunoglobulins are selected from human rearranged antibody sequences or human germline antibody sequences.
  • the present invention provides an antibody or antigen-binding fragment thereof capable of specifically binding CLDN6 and/or CLDN9, the antibody or antigen-binding fragment thereof comprising:
  • VH heavy chain variable region
  • CDRs 3 complementarity determining regions
  • VH CDR1 consisting of the following sequence: SEQ ID NO: 13, or having one or several amino acid substitutions, deletions or additions therefrom (e.g., 1, 2 or 3 amino acid substitutions, deletions) or added) sequence,
  • VH CDR2 consisting of the following sequence: SEQ ID NO: 14, or with one or several amino acid substitutions, deletions or additions (e.g. 1, 2 or 3 amino acid substitutions, deletions) therefrom or added), and
  • VH CDR3 consisting of the following sequence: SEQ ID NO: 15, or having one or several amino acid substitutions, deletions or additions therefrom (e.g. 1, 2 or 3 amino acid substitutions, deletions) or added);
  • VL light chain variable region
  • CDRs 3 complementarity determining regions
  • VL CDR1 consisting of the following sequence: SEQ ID NO: 16, or having one or several amino acid substitutions, deletions or additions (e.g. 1, 2 or 3 amino acid substitutions, deletions) therefrom or added) sequence,
  • VL CDR3 consisting of the following sequence: SEQ ID NO: 18, or having one or several amino acid substitutions, deletions or additions therefrom (e.g. 1, 2 or 3 amino acid substitutions, deletions) or added) sequence.
  • substitutions described in any of (i)-(vi) are conservative substitutions.
  • the CDRs described in any of (i)-(vi) are defined according to the IMGT numbering system.
  • the antibody or antigen-binding fragment thereof comprises: the following 3 heavy chain CDRs: VH CDR1 of sequence SEQ ID NO: 13, VH CDR2 of sequence SEQ ID NO: 14, VH CDR3 of sequence SEQ ID NO: 15; and/or, the following 3 light chain CDRs: VL CDR1 of sequence SEQ ID NO: 16, VL CDR2 of sequence SEQ ID NO: 17, sequence of SEQ ID NO: VL CDR3 of 18.
  • the antibody, or antigen-binding fragment thereof further comprises framework region sequences derived from humans (eg, human immunoglobulins).
  • the antibody or antigen-binding fragment thereof has one or more of the following biological functions:
  • (c) induce killing of human CLDN6-expressing cells (eg, tumor cells, such as CLDN6-expressing tumor cells) by antibody-dependent cell-mediated cytotoxicity (ADCC);
  • human CLDN6-expressing cells eg, tumor cells, such as CLDN6-expressing tumor cells
  • ADCC antibody-dependent cell-mediated cytotoxicity
  • tumors eg, tumors expressing CLDN6
  • VH heavy chain variable region
  • VL light chain variable region
  • substitutions described in (ii) or (v) are conservative substitutions.
  • the present invention provides an antibody or antigen-binding fragment thereof capable of specifically binding CLDN6 and/or CLDN9, the antibody or antigen-binding fragment thereof comprising:
  • VH heavy chain variable region
  • CDRs 3 complementarity determining regions
  • VH CDR1 consisting of the following sequence: SEQ ID NO: 13, or having one or several amino acid substitutions, deletions or additions therefrom (e.g., 1, 2 or 3 amino acid substitutions, deletions) or added) sequence,
  • VH CDR2 consisting of the following sequence: SEQ ID NO: 23, or having one or several amino acid substitutions, deletions or additions (e.g. 1, 2 or 3 amino acid substitutions, deletions) therefrom or added), and
  • VH CDR3 consisting of the following sequence: SEQ ID NO: 15, or having one or several amino acid substitutions, deletions or additions therefrom (e.g. 1, 2 or 3 amino acid substitutions, deletions) or added);
  • VL light chain variable region
  • CDRs 3 complementarity determining regions
  • VL CDR1 consisting of the following sequence: SEQ ID NO: 24, or having one or several amino acid substitutions, deletions or additions (e.g. 1, 2 or 3 amino acid substitutions, deletions) therefrom or added) sequence,
  • VL CDR3 consisting of the following sequence: SEQ ID NO: 18, or having one or several amino acid substitutions, deletions or additions therefrom (e.g. 1, 2 or 3 amino acid substitutions, deletions) or added) sequence.
  • substitutions described in any of (i)-(vi) are conservative substitutions.
  • the CDRs described in any of (i)-(vi) are defined according to the IMGT numbering system.
  • the antibody or antigen-binding fragment thereof comprises: the following 3 heavy chain CDRs: VH CDR1 of sequence SEQ ID NO: 13, VH CDR2 of sequence SEQ ID NO: 23, VH CDR3 of sequence SEQ ID NO: 15; and/or, the following 3 light chain CDRs: VL CDR1 of sequence SEQ ID NO: 24, VL CDR2 of sequence SEQ ID NO: 17, sequence of SEQ ID NO: VL CDR3 of 18.
  • the human immunoglobulins are selected from human rearranged antibody sequences or human germline antibody sequences.
  • the antibody or antigen-binding fragment thereof has one or more of the following biological functions:
  • tumors eg, tumors expressing CLDN6
  • the antibody or antigen-binding fragment thereof comprises:
  • (iii) have at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, Sequences of at least 97%, at least 98%, at least 99%, or 100% sequence identity;
  • substitutions described in (ii) or (v) are conservative substitutions.
  • the antibody or antigen-binding fragment thereof comprises: a VH having the sequence set forth in SEQ ID NO:9 and a VL having the sequence set forth in SEQ ID NO:10.
  • the VH of the antibody or antigen-binding fragment thereof comprises a heavy chain variable region (VH) framework region (FR) derived from a human immunoglobulin, and/or the antibody or antigen thereof
  • the VL of the binding fragment comprises a light chain variable region (VL) framework region (FR) derived from human immunoglobulin.
  • the heavy chain variable region FR and/or light chain variable region FR of the antibody or antigen-binding fragment thereof may comprise one or more non-human (eg, murine) amino acid residues,
  • the heavy chain framework region FR and/or the light chain framework region FR may comprise one or more amino acid back-mutations in which there are corresponding murine amino acid residues.
  • a heavy chain constant region (CH) of a human immunoglobulin or a variant thereof having one or more amino acid substitutions, deletions or additions eg, up to 20, up to 15, up to 10, or up to 5 amino acid substitutions, deletions, or additions; e.g., 1, 2, 3, 4, or 5 amino acid substitutions, deletions, or additions; and
  • the heavy chain constant region is an IgG heavy chain constant region, eg, an IgGl, IgG2, IgG3 or IgG4 heavy chain constant region.
  • the light chain constant region is a kappa or lambda light chain constant region.
  • the antibody or antigen-binding fragment thereof comprises the light chain constant region (CL) set forth in SEQ ID NO:22.
  • the antigen-binding fragment is selected from the group consisting of Fab, Fab', (Fab') 2 , Fv, disulfide-linked Fv, scFv, diabodies, and single domain antibodies (sdAbs) and/or, the antibody is a murine antibody, a chimeric antibody, a humanized antibody, a bispecific antibody or a multispecific antibody.
  • the antibodies of the present invention can be prepared by various methods known in the art, such as by genetic engineering recombinant techniques. For example, DNA molecules encoding the heavy and light chain genes of the antibodies of the invention are obtained by chemical synthesis or PCR amplification. The resulting DNA molecule is inserted into an expression vector and then transfected into a host cell. Then, the transfected host cells are cultured under specific conditions and express the antibodies of the present invention.
  • Antigen-binding fragments of the present invention can be obtained by hydrolysis of intact antibody molecules (see Morimoto et al., J. Biochem. Biophys. Methods 24:107-117 (1992) and Brennan et al., Science 229:81 (1985)) .
  • these antigen-binding fragments can also be produced directly by recombinant host cells (reviewed in Hudson, Curr. Opin. Immunol. 11:548-557 (1999); Little et al., Immunol. Today, 21:364-370 (2000) )).
  • Fab' fragments can be obtained directly from host cells; Fab' fragments can be chemically coupled to form F(ab') 2 fragments (Carter et al., Bio/Technology, 10:163-167 (1992)).
  • Fv, Fab or F(ab') 2 fragments can also be directly isolated from recombinant host cell culture medium. Other techniques for preparing these antigen-binding fragments are well known to those of ordinary skill in the art.
  • the present invention provides an isolated nucleic acid molecule comprising nucleotides encoding an antibody or antigen-binding fragment thereof of the present invention, or a heavy chain variable region and/or a light chain variable region thereof sequence.
  • the isolated nucleic acid molecule encodes an antibody or antigen-binding fragment thereof of the invention, or a heavy chain variable region and/or a light chain variable region thereof.
  • the present invention provides a vector (eg, a cloning vector or an expression vector) comprising the isolated nucleic acid molecule of the present invention.
  • the vectors of the present invention are, for example, plasmids, cosmids, phages, and the like.
  • the vector is capable of expressing an antibody or antigen-binding fragment thereof of the invention in a subject (eg, a mammal, eg, a human).
  • the present invention provides a host cell comprising an isolated nucleic acid molecule of the present invention or a vector of the present invention.
  • host cells include, but are not limited to, prokaryotic cells such as E. coli cells, and eukaryotic cells such as yeast cells, insect cells, plant cells, and animal cells (eg, mammalian cells, eg, mouse cells, human cells, etc.).
  • the host cells of the present invention are mammalian cells, such as CHO (eg, CHO-K1, CHO-S, CHO DG44).
  • An antibody or antigen-binding fragment thereof of the invention can be derivatized, eg, linked to another molecule (eg, another polypeptide or protein).
  • another molecule eg, another polypeptide or protein.
  • derivatization eg, labeling
  • an antibody or antigen-binding fragment thereof does not adversely affect its binding to CLDN6 and/or CLDN9, particularly human CLDN6 and/or human CLDN9.
  • the antibodies or antigen-binding fragments thereof of the invention are also intended to include such derivatized forms.
  • an antibody or antigen-binding fragment thereof of the invention can be functionally linked (by chemical coupling, genetic fusion, non-covalent attachment, or otherwise) to one or more other molecular moieties, such as another antibody (eg, to form a bispecific antibodies), detection reagents, pharmaceutical reagents, and/or proteins or polypeptides (eg, avidin or polyhistidine tags) capable of mediating binding of an antibody or antigen-binding fragment to another molecule.
  • the antibodies or antigen-binding fragments thereof of the present invention can also be derivatized with chemical groups such as polyethylene glycol (PEG), methyl or ethyl, or glycosyl groups. These groups can be used to improve the biological properties of antibodies, such as increasing serum half-life.
  • Such labels are well known in the art, examples of which include, but are not limited to, enzymes (eg, horseradish peroxidase, alkaline phosphatase, beta-galactosidase, urease, glucose oxidase, etc.), radionuclides Fluorescein (eg, 3 H, 125 I, 35 S, 14 C, or 32 P), fluorescent dyes (eg, fluorescein isothiocyanate (FITC), fluorescein, tetramethylrhodamine isothiocyanate (TRITC) , phycoerythrin (PE), Texas red, rhodamine, quantum dots or cyanine dye derivatives (eg Cy7, Alexa 750)), luminescent substances (eg chemiluminescent substances such as acridine esters), Magnetic beads (eg, ), calorimetric labels such as colloidal gold or colored glass or plastic (eg, polystyrene, polypropylene, latex, etc
  • Patents teaching the use of this marker include, but are not limited to, US Patents 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149; and 4,366,241 (all incorporated herein by reference).
  • Detectable labels as described above can be detected by methods known in the art. For example, radiolabels can be detected using photographic film or a scintillation calculator, and fluorescent labels can be detected using a light detector to detect the emitted light.
  • Enzyme labels are generally detected by providing a substrate to the enzyme and detecting the reaction product produced by the action of the enzyme on the substrate, and calorimetric labels are detected by simply visualizing the colored label.
  • such labels can be suitable for use in immunological detection (eg, enzyme-linked immunoassays, radioimmunoassays, fluorescent immunoassays, chemiluminescence immunoassays, etc.).
  • a detectable label as described above can be attached to an antibody or antigen-binding fragment thereof of the invention via linkers of various lengths to reduce potential steric hindrance.
  • the antibodies or antigen-binding fragments thereof of the invention can be used to form bispecific or multispecific molecules.
  • An antibody or antigen-binding fragment thereof of the invention may be part of a bispecific or multispecific molecule comprising a molecule with a different binding specificity than the antibody or antigen-binding fragment thereof of the invention A second functional moiety (eg, a second antibody), thereby capable of binding at least two different binding sites and/or target molecules.
  • an antibody or antigen-binding fragment thereof of the invention can be linked to a second antibody or antigen-binding fragment thereof capable of specifically binding any protein that can be used as a potential target for combination therapy.
  • an antibody or antigen-binding fragment thereof of the invention can be linked (eg, by chemical conjugation, genetic fusion, non-covalent association, or otherwise) to one or more other Binding molecules (eg, additional antibodies, antibody fragments, peptides, or binding mimetics).
  • Binding molecules eg, additional antibodies, antibody fragments, peptides, or binding mimetics.
  • the present invention provides a bispecific or multispecific molecule comprising an antibody or antigen-binding fragment thereof of the present invention.
  • the bispecific or multispecific molecule further comprises at least one molecule (eg, a second antibody) having a second binding specificity for a second target.
  • Antibodies of the invention or antigen-binding fragments thereof can be linked to therapeutic agents to form immunoconjugates.
  • Immunoconjugates can enhance the present invention due to their ability to selectively deliver one or more therapeutic agents to target tissues (eg, tumor-associated antigens such as tumors expressing CLDN6 and/or CLDN9).
  • Therapeutic efficacy of an antibody or antigen-binding fragment thereof in the treatment of disease eg, cancer.
  • the present invention provides immunoconjugates comprising an antibody or antigen-binding fragment thereof of the present invention and a therapeutic agent linked to the antibody or antigen-binding fragment thereof.
  • the therapeutic agent is a cytotoxic agent.
  • the cytotoxic agent includes any agent that is detrimental to cells (eg, kills cells).
  • the therapeutic agent is selected from the group consisting of alkylating agents, mitotic inhibitors, antitumor antibiotics, antimetabolites, topoisomerase inhibitors, tyrosine kinase inhibitors, radionuclide agents, and any combination thereof.
  • alkylating agents examples include, but are not limited to, nitrogen mustards (eg, diclofenac, chlorambucil, melphalan, cyclophosphamide, etc.), ethyleneimine (such as cetepa, etc.), sulfates and polyols (such as busulfan, dibromomannitol), nitrosoureas (such as carmustine, lomustine, etc.), platinum anti-tumor agents (such as cisplatin, oxaliplatin, carboplatin, etc.).
  • nitrogen mustards eg, diclofenac, chlorambucil, melphalan, cyclophosphamide, etc.
  • ethyleneimine such as cetepa, etc.
  • sulfates and polyols such as busulfan, dibromomannitol
  • nitrosoureas such as carmustine, lomustine, etc.
  • platinum anti-tumor agents such as
  • antitumor antibiotics examples include, but are not limited to, actinomycins, anthracyclines (eg, daunorubicin, doxorubicin, epirubicin, idarubicin, etc.) , calicheamicin, duocarcinomycin, etc.
  • antimetabolites examples include, but are not limited to, folate antagonists (eg, methotrexate, etc.), pyrimidine antagonists (eg, 5-fluorouracil, floxuridine, cytarabine, Pecitabine, gemcitabine, etc.), purine antagonists (such as 6-mercaptopurine, 6-thioguanine, etc.), adenosine deaminase inhibitors (such as cladribine, fludarabine, nelarabine, pentosine tatin, etc.).
  • folate antagonists eg, methotrexate, etc.
  • pyrimidine antagonists eg, 5-fluorouracil, floxuridine, cytarabine, Pecitabine, gemcitabine, etc.
  • purine antagonists such as 6-mercaptopurine, 6-thioguanine, etc.
  • adenosine deaminase inhibitors such as cladribine, fludarabine, ne
  • topoisomerase inhibitors examples include, but are not limited to (camptothecins and their derivatives (eg, irinotecan, topotecan, etc.), amacridine, daunol Mycin, doxorubicin, epipodophyllotoxins, ellipticines, epirubicin, etoposide, propylimine, teniposide, etc.
  • tyrosine kinase inhibitors that can be used in the immunoconjugates of the invention include, but are not limited to, axitinib, bosutinib, cediranib, dasatinib, erlotinib, gefitinib Nilotinib, imatinib, lapatinib, letotinib, nilotinib, simazanib, sunitinib, vandetanib, etc.
  • the therapeutic agent is selected from the group consisting of platinum-based antineoplastic agents, anthracyclines, taxanes, nucleoside analogs, camptothecins, and analogs or homologs thereof , and any combination thereof.
  • the antibodies or antigen-binding fragments thereof of the invention are optionally conjugated to the therapeutic agent through a linker.
  • a cytotoxic agent can be conjugated to an antibody or antigen-binding fragment thereof of the present invention using linker technology available in the art.
  • linker technology available in the art.
  • Examples of the types of linkers that have been used to conjugate cytotoxic agents to antibodies include, but are not limited to, hydrazones, thioethers, esters, disulfides, and peptide-containing linkers.
  • Linkers can be selected that are, for example, susceptible to cleavage by low pH within the lysosomal compartment or by proteases (eg, proteases preferentially expressed in tumor tissues, such as cathepsins, such as cathepsins B, C, D).
  • the antibodies or antigen-binding fragments thereof of the present invention can be used to construct a chimeric antigen receptor (CAR) comprising a CAR that specifically binds CLDN6 and/or CLDN9, linked to a transmembrane domain, and bound to one or more intracellular T cell signaling domain linked extracellular antigen binding domain (eg, scFv).
  • the intracellular T cell signaling domain can include, for example, a T cell receptor signaling domain, a T cell costimulatory signaling domain, or a combination thereof.
  • the T cell receptor signaling domain refers to the portion of the CAR that contains the intracellular domain of the T cell receptor (eg, the intracellular portion of the CD3 ⁇ protein).
  • the costimulatory signaling domain refers to the portion of the CAR that contains the intracellular domain of costimulatory molecules, which are cell surface molecules other than antigen receptors or their ligands required for efficient lymphocyte responses to antigens .
  • CARs of the invention include their ability to direct T-cell specificity and reactivity to cells expressing CLDN6 and/or CLDN9 (eg, tumor cells) in a non-MHC-restricted manner.
  • CLDN6 and/or CLDN9 eg, tumor cells
  • the non-MHC-restricted CLDN6 and/or CLDN9 recognition ability confers the ability of T cells expressing the CARs of the invention to recognize antigen independent of antigen processing.
  • the present invention provides a chimeric antigen receptor (CAR) comprising the antigen-binding domain of the antibody or antigen-binding fragment thereof of the present invention.
  • CAR chimeric antigen receptor
  • the antigen-binding domain comprises the heavy and light chain variable regions of an antibody or antigen-binding fragment thereof of the invention.
  • the antigen binding domain is an scFv.
  • the antigen-binding receptor comprises an antigen-binding fragment (eg, scFv) of an antibody of the invention.
  • the antigen binding receptor is expressed by immune effector cells (eg, T cells).
  • a spacer domain comprising a polypeptide sequence.
  • the spacer domain may comprise up to 300 amino acids, preferably 10 to 100 amino acids, and most preferably 25 to 50 amino acids.
  • the spacer domain may comprise an immunoglobulin domain, eg, a human immunoglobulin sequence.
  • the immunoglobulin domain comprises immunoglobulin CH2 and CH3 domain sequences.
  • the CH2 and CH3 domains extend the antigen-binding domain of the CAR from the membrane of the CAR-expressing cell and may more accurately mimic the size and size of the native TCR and Domain structure.
  • the transmembrane domain may be derived from natural or synthetic sources.
  • the domains can be derived from any membrane-bound or transmembrane protein.
  • Exemplary transmembrane domains that can be used in the CARs of the present invention can comprise at least the transmembrane region of the alpha, beta or zeta chain of a T cell receptor, which can be selected from CD28, CD3 ⁇ , CD45, CD4, CD5, CDS, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154.
  • the transmembrane domain may be synthetic, in which case it will contain predominantly hydrophobic residues such as leucine and valine.
  • the transmembrane domain comprises a transmembrane domain of a T cell receptor, eg, a CD8 transmembrane domain.
  • the transmembrane domain comprises the transmembrane domain of a T cell costimulatory molecule (eg, CD137 or CD28).
  • a T cell costimulatory molecule eg, CD137 or CD28.
  • examples of intracellular T cell domains useful for use in the CAR include cytoplasmic sequences and costimulatory molecules of the T cell receptor (TCR), the T cell receptor ( The cytoplasmic sequences of TCR) and costimulatory molecules cooperate to initiate signal transduction upon antigen receptor engagement, as well as any derivatives or variants of these sequences and any synthetic sequences having the same functional capability.
  • TCR T cell receptor
  • costimulatory molecules of the T cell receptor The cytoplasmic sequences of TCR and costimulatory molecules cooperate to initiate signal transduction upon antigen receptor engagement, as well as any derivatives or variants of these sequences and any synthetic sequences having the same functional capability.
  • the intracellular region of the CAR may comprise an ITAM containing a primary cytoplasmic signaling domain (eg, CD3 ⁇ ) by itself or in combination with any other desired cytoplasmic domain useful in the context of the CAR .
  • a primary cytoplasmic signaling domain eg, CD3 ⁇
  • the cytoplasmic domain of the CAR comprises a CD3 ⁇ chain portion and an intracellular costimulatory signaling domain.
  • the costimulatory signaling domain refers to the portion of the CAR comprising the intracellular domain of the costimulatory molecule.
  • Costimulatory molecules are cell surface molecules other than antigen receptors or their ligands that are required for efficient lymphocyte responses to antigens.
  • Examples of such molecules include CD27, CD28, 4-1BB (CD137), OX40 (CD134), CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen 1 (LFA-1), CD2, CD7, LIGHT, NKG2C and B7-H3.
  • the CAR may comprise a CD3 ⁇ signaling domain, a CD8 signaling domain, a CD28 signaling domain, a CD137 signaling domain, or any combination thereof.
  • the order of the one or more T cell signaling domains on the CAR can be varied as desired by those skilled in the art.
  • a nucleic acid molecule encoding a chimeric antigen binding receptor of the invention can be included in an expression vector (eg, a lentiviral vector) for expression in a host cell, such as a T cell, to manufacture the CAR.
  • an expression vector eg, a lentiviral vector
  • the method of using the chimeric antigen receptor comprises isolating T cells from a subject, transforming the T cells with an expression vector (eg, a lentiviral vector) encoding the chimeric antigen receptor, and The engineered T cells expressing the chimeric antigen receptor are administered to the subject for therapy, eg, for treating a tumor in the subject.
  • an expression vector eg, a lentiviral vector
  • the present invention provides a vector (eg, a cloning vector or an expression vector) comprising an isolated nucleic acid molecule as described above.
  • a vector eg, a cloning vector or an expression vector
  • the vectors of the present invention are, for example, plasmids.
  • the antibody or antigen-binding fragment thereof of the present invention can induce ADCC and/or CDC by binding to CLDN6 and/or CLDN9 to kill cells, thereby being useful for preventing and/or treating tumors.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising an antibody or antigen-binding fragment thereof, bispecific or multispecific molecule, or immunoconjugate of the invention, and a pharmaceutically acceptable carrier and/or excipient.
  • the pharmaceutical composition may further comprise additional pharmaceutically active agents.
  • the additional pharmaceutically active agent is a drug with anti-tumor activity, eg, alkylating agents, mitotic inhibitors, anti-tumor antibiotics, antimetabolites, topoisomerase inhibitors, tyrosine Acid kinase inhibitors, radionuclide agents, radiosensitizers (eg, gemcitabine, 5-fluorouracil, taxane, cisplatin, etc.), anti-angiogenic agents, cytokines (eg, GM-CSF, IL-7, IL- 12.
  • cytokines eg, GM-CSF, IL-7, IL- 12.
  • IL-15 IL-18, IL-21, etc.
  • molecular targeted drugs for example, CD20 antibodies such as rituximab, Her2 antibodies such as trastuzumab, VEGF antibodies such as bevacizumab, EGFR antibodies such as cetuximab, etc.
  • immune checkpoint inhibitors eg, PD-1 antibody, PD-L1 antibody, CTLA-4 antibody, LAG-3 antibody, etc.
  • oncolytic viruses etc.
  • an antibody or antigen-binding fragment thereof, bispecific or multispecific molecule, or immunoconjugate of the invention is combined with the additional pharmaceutically active agent as Separate components or provided as components of the same composition.
  • the antibody or antigen-binding fragment thereof, bispecific or multispecific molecule, or immunoconjugate of the invention and the additional pharmaceutically active agent can be administered simultaneously, separately or sequentially.
  • the pharmaceutical compositions comprise sterile injectable liquids (eg, aqueous or non-aqueous suspensions or solutions).
  • sterile injectable liquids are selected from the group consisting of water for injection (WFI), bacteriostatic water for injection (BWFI), sodium chloride solution (eg, 0.9% (w/v) NaCl), dextrose Solutions (eg, 5% dextrose), surfactant-containing solutions (eg, 0.01% polysorbate 20), pH buffered solutions (eg, phosphate buffered solution), Ringer's solution, and any combination thereof.
  • the present invention provides a method for reducing the expression level of CLDN6 and/or CLDN9 on a cell surface, comprising combining said cell with an antibody or antigen-binding fragment, bispecific or multispecific thereof of the present invention Contacting the molecule, immunoconjugate, or pharmaceutical composition results in a reduced level of expression of CLDN6 and/or CLDN9 on the cell surface; wherein the cell expresses CLDN6 and/or CLDN9 on its surface.
  • the cells are tumor cells expressing CLDN6 and/or CLDN9.
  • the methods are used to reduce cell surface expression levels of CLDN6 and/or CLDN9 in vitro for non-diagnostic purposes.
  • an antibody or antigen-binding fragment thereof, bispecific or multispecific molecule, immunoconjugate, or pharmaceutical composition of the invention in the manufacture of a medicament for reducing CLDN6 and and/or the expression level of CLDN9 on the cell surface.
  • an antibody or antigen-binding fragment thereof, bispecific or multispecific molecule, immunoconjugate, or pharmaceutical composition of the invention for use in reducing cell surface expression of CLDN6 and/or CLDN9 Level.
  • the present invention provides a method for inhibiting the growth of and/or killing tumor cells expressing CLDN6 and/or CLDN9, comprising combining the tumor cells with an effective amount of the antibody of the present invention or its Antigen-binding fragments, bispecific or multispecific molecules, immunoconjugates, pharmaceutical compositions, chimeric antigen receptors, or host cells expressing said chimeric antigen receptors (e.g., chimeric antigen receptor T cells (CARs). -T)) contact.
  • CARs chimeric antigen receptor T cells
  • the method may be used for therapeutic purposes, or for non-therapeutic purposes.
  • the methods may be used for non-therapeutic purposes for inhibiting the growth and/or killing of tumor cells expressing CLDN6 and/or CLDN9 in vitro.
  • an antibody or antigen-binding fragment thereof, bispecific or multispecific molecule, immunoconjugate, pharmaceutical composition, chimeric antigen receptor or an antibody expressing said chimeric antigen receptor of the invention is provided.
  • a host cell such as a chimeric antigen receptor T cell (CAR-T)
  • CAR-T chimeric antigen receptor T cell
  • an antibody or antigen-binding fragment thereof, bispecific or multispecific molecule, immunoconjugate, pharmaceutical composition, chimeric antigen receptor or an antibody expressing said chimeric antigen receptor of the invention e.g, chimeric antigen receptor T cells (CAR-T)) for inhibiting the growth and/or killing tumor cells expressing CLDN6 and/or CLDN9.
  • Host cells eg, chimeric antigen receptor T cells (CAR-T) for inhibiting the growth and/or killing tumor cells expressing CLDN6 and/or CLDN9.
  • the present invention provides a method for preventing and/or treating a tumor in a subject (eg, a human), the method comprising administering to a subject in need thereof an effective amount of a Antibodies or antigen-binding fragments thereof, bispecific or multispecific molecules, immunoconjugates, pharmaceutical compositions, chimeric antigen receptors, or host cells expressing said chimeric antigen receptors (eg, chimeric antigen receptor T cells (CAR-T)).
  • a subject eg, a human
  • the tumor involves tumor cells expressing CLDN6 and/or CLDN9.
  • the CLDN6 and/or CLDN9 are expressed on the surface of the tumor cells.
  • the tumor expresses CLDN6 and/or CLDN9.
  • the tumor is selected from ovarian cancer, testicular cancer, gastric cancer, endometrial cancer, lung cancer, esophageal cancer, pancreatic cancer, bronchial cancer, breast cancer, ear nose and throat (ENT) cancer, colon cancer , liver cancer, head and neck cancer, gallbladder cancer and their metastases (eg, gastric cancer metastasis such as Krukenberg tumor, peritoneal metastasis or lymph node metastasis).
  • metastases eg, gastric cancer metastasis such as Krukenberg tumor, peritoneal metastasis or lymph node metastasis.
  • an antibody or antigen-binding fragment thereof, bispecific or multispecific molecule, immunoconjugate, pharmaceutical composition, chimeric antigen receptor or expression of said chimeric antigen of the invention is The recipient's host cells (eg, chimeric antigen receptor T cells (CAR-T)) are used in combination with another drug with antitumor activity.
  • additional drugs with anti-tumor activity may be administered after the antibody or antigen-binding fragment thereof, bispecific or multispecific molecule, immunoconjugate, pharmaceutical composition, chimeric antigen receptor or expression of the chimeric Administered before, at the same time, or after the antigen receptor-conjugated host cell (eg, CAR-T).
  • an antibody or antigen-binding fragment thereof, bispecific or multispecific molecule, immunoconjugate, pharmaceutical composition, chimeric antigen receptor or expression of said chimeric antigen of the invention is The recipient's host cell (eg, CAR-T) is administered in combination with additional therapy.
  • This additional therapy can be any therapy known for tumors such as surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy, hormone therapy, gene therapy, or palliative care.
  • Such additional therapy may be administered upon administration of an antibody or antigen-binding fragment thereof, bispecific or multispecific molecule, immunoconjugate, pharmaceutical composition, chimeric antigen receptor, or expression of said chimeric antigen receptor of the invention administered before, simultaneously with, or after the host cell (eg, CAR-T).
  • compositions of the present invention should be sterile and stable under the conditions of manufacture and storage.
  • a preferred dosage form is an injection.
  • injectable preparations can be sterile injectable solutions.
  • Sterile injectable solutions can be prepared, for example, by incorporating the required amount of an antibody of the invention in the appropriate solvent, optionally with other desired ingredients including, but not limited to, pH adjusting agents , surfactants, adjuvants, ionic strength enhancers, isotonicity agents, preservatives, diluents, or any combination thereof) followed by filter sterilization.
  • sterile injectable solutions can be prepared as sterile lyophilized powders (eg, by vacuum drying or freeze-drying) for ease of storage and use.
  • Such sterile lyophilized powders can be dispersed in a suitable vehicle, eg, water for injection (WFI), bacteriostatic water for injection (BWFI), sodium chloride solution (eg, 0.9% (w/v) NaCl), Dextrose solutions (eg, 5% dextrose), surfactant-containing solutions (eg, 0.01% polysorbate 20), pH buffered solutions (eg, phosphate buffered solutions), Ringer's solution, and any combination thereof.
  • WFI water for injection
  • BWFI bacteriostatic water for injection
  • sodium chloride solution eg, 0.9% (w/v) NaCl
  • Dextrose solutions eg, 5% dextrose
  • surfactant-containing solutions eg, 0.01% polysorbate 20
  • pH buffered solutions eg, phosphate buffered solutions
  • Ringer's solution eg, Ringer's solution, and any combination thereof.
  • the antibodies or antigen-binding fragments thereof, bispecific or multispecific molecules, immunoconjugates, pharmaceutical compositions, chimeric antigen receptors, or host cells expressing said chimeric antigen receptors can be presented in a pharmaceutical composition in unit dosage form for ease of administration.
  • Antibodies or antigen-binding fragments thereof, bispecific or multispecific molecules, immunoconjugates, pharmaceutical compositions, chimeric antigen receptors, or host cells (eg, T cells) expressing said chimeric antigen receptors of the invention Administration may be by any suitable method known in the art, including, but not limited to, oral, buccal, sublingual, ocular, topical, parenteral, rectal, intrathecal, intracytoplasmic reticulum, inguinal, intravesical, Topical (eg, powder, ointment, or drops), or nasal route.
  • the preferred route/mode of administration is parenteral administration (eg, intravenous or bolus injection, subcutaneous injection, intraperitoneal injection, intramuscular injection).
  • the route and/or mode of administration will vary depending on the intended purpose.
  • the antibody or antigen-binding fragment thereof, bispecific or multispecific molecule, immunoconjugate, pharmaceutical composition, chimeric antigen receptor or expression thereof of the invention is of host cells (eg T cells) are administered by intravenous injection or bolus injection.
  • compositions of the present invention may include a "therapeutically effective amount” or “prophylactically effective amount” of an antibody or antigen-binding fragment thereof, bispecific or multispecific molecule, immunoconjugate, pharmaceutical composition, chimeric An antigen receptor or a host cell (eg, a T cell) expressing the chimeric antigen receptor.
  • a “prophylactically effective amount” refers to an amount sufficient to prevent, prevent, or delay the onset of a disease.
  • a “therapeutically effective amount” refers to an amount sufficient to cure or at least partially arrest the disease and its complications in a patient already suffering from the disease.
  • the therapeutically effective amount of the antibody or antigen-binding fragment thereof of the present invention may vary according to the following factors: the severity of the disease to be treated, the general state of the patient's own immune system, the general condition of the patient such as age, weight and sex, the drug's mode of administration, and other treatments administered concurrently, among others.
  • the dosing regimen can be adjusted to obtain the optimal response of interest (eg, a therapeutic or prophylactic response). For example, a single dose may be administered, multiple doses may be administered over a period of time, or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation.
  • the optimal response of interest eg, a therapeutic or prophylactic response.
  • a single dose may be administered, multiple doses may be administered over a period of time, or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation.
  • the subject may be a mammal, such as a human.
  • the antibody or antigen-binding fragment thereof of the present invention can specifically bind to CLDN6 and/or CLDN9, and thus can be used to detect the presence or level of CLDN6 and/or CLDN9 in a sample.
  • the present invention provides a kit comprising an antibody or antigen-binding fragment thereof of the present invention.
  • the antibodies or antigen-binding fragments thereof of the invention are detectably labeled.
  • the kit further comprises a second antibody that specifically recognizes the antibody or antigen-binding fragment thereof of the present invention.
  • the second antibody further comprises a detectable label.
  • the detectable label may be any substance detectable by fluorescent, spectroscopic, photochemical, biochemical, immunological, electrical, optical or chemical means. It is particularly preferred that such labels be suitable for use in immunological detection (eg, enzyme-linked immunoassays, radioimmunoassays, fluorescent immunoassays, chemiluminescence immunoassays, etc.).
  • immunological detection eg, enzyme-linked immunoassays, radioimmunoassays, fluorescent immunoassays, chemiluminescence immunoassays, etc.
  • Such labels include, but are not limited to, enzymes (eg, horseradish peroxidase, alkaline phosphatase, beta-galactosidase, urease, glucose oxidase, etc.), radionuclides ( For example, 3 H, 125 I, 35 S, 14 C, or 32 P), fluorescent dyes (eg, fluorescein isothiocyanate (FITC), fluorescein, tetramethylrhodamine isothiocyanate (TRITC), algae Hemoglobin (PE), Texas Red, Rhodamine, Quantum Dots or Cyanine Derivatives (e.g. Cy7, Alexa 750)), Luminescent Substances (e.g.
  • Chemiluminescent Substances such as Acridine Esters), Magnetic Beads (E.g, ), calorimetric labels such as colloidal gold or colored glass or plastic (eg, polystyrene, polypropylene, latex, etc.) beads, and modified avidins (eg, streptavidin) for binding to the aforementioned labels ) of biotin.
  • Patents teaching the use of this marker include, but are not limited to, US Patents 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149; and 4,366,241 (all incorporated herein by reference). Labels encompassed by the present invention can be detected by methods known in the art.
  • radiolabels can be detected using photographic film or a scintillation calculator, and fluorescent labels can be detected using a light detector to detect the emitted light.
  • Enzyme labels are generally detected by providing a substrate to the enzyme and detecting the reaction product produced by the action of the enzyme on the substrate, and calorimetric labels are detected by simply visualizing the colored label.
  • a detectable label as described above can be attached to an antibody or antigen-binding fragment thereof of the invention via linkers of varying lengths to reduce potential steric hindrance.
  • the present invention provides a method of detecting the presence or amount of CLDN6 and/or CLDN9 in a sample, comprising the steps of:
  • the formation of the complex indicates the presence of CLDN6 and/or CLDN9 or cells expressing CLDN6 and/or CLDN9.
  • the sample is a cellular sample, ie, a sample comprising cells (eg, tumor cells).
  • the complex is formed between the antibody, antigen-binding fragment or conjugate and CLDN6 and/or CLDN9 expressed by cells in the sample.
  • the antibody or antigen-binding fragment thereof of the invention is also detectably labeled.
  • a reagent with a detectable label is used to detect the antibody or antigen-binding fragment thereof of the present invention.
  • the method may be used for diagnostic purposes, or for non-diagnostic purposes (eg, the sample is a cell sample rather than a sample from a patient).
  • the CLDN6 and/or CLDN9 is human CLDN6 and/or CLDN9.
  • an antibody or antigen-binding fragment thereof of the present invention in the preparation of a kit for detecting the presence or amount of CLDN6 and/or CLDN9 in a sample.
  • the CLDN6 and/or CLDN9 is human CLDN6 and/or CLDN9.
  • the present invention provides a method for detecting whether a tumor can be treated by an anti-tumor therapy targeting CLDN6 and/or CLDN9, comprising the steps of:
  • the complex is formed between the antibody or antigen-binding fragment thereof and CLDN6 and/or CLDN9 expressed by tumor cells in the sample.
  • the sample is from a subject who has, is suspected of having, or is at risk of having a tumor.
  • the sample is from a tissue or organ in which cells do not substantially express CLDN6 and/or CLDN9 when the tissue or organ is not cancerous.
  • the tissue is selected from gastric tissue, lung tissue, esophageal tissue, pancreatic tissue, or breast tissue, and the tissue has optionally been diagnosed as being affected by cancer, eg, by treating the tissue Or organ cells are diagnosed by visual inspection or culture tests.
  • the tissue is tissue other than gastric tissue.
  • the tissue is lung tissue, esophageal tissue, pancreatic tissue, or breast tissue.
  • CLDN6 and/or CLDN9 or An increase in the amount of cells expressing CLDN6 and/or CLDN9 indicates that the subject is suitable for anti-tumor therapy targeting CLDN6 and/or CLDN9.
  • the antibody or antigen-binding fragment thereof of the invention is also detectably labeled.
  • a reagent with a detectable label is used to detect the antibody or antigen-binding fragment thereof of the present invention.
  • the CLDN6 and/or CLDN9 is human CLDN6 and/or CLDN9.
  • the tumor is selected from ovarian cancer, testicular cancer, gastric cancer, endometrial cancer, lung cancer, esophageal cancer, pancreatic cancer, bronchial cancer, breast cancer, ear nose and throat (ENT) cancer, colon cancer , liver cancer, head and neck cancer, gallbladder cancer and their metastases (eg, gastric cancer metastasis such as Krukenberg tumor, peritoneal metastasis or lymph node metastasis).
  • metastases eg, gastric cancer metastasis such as Krukenberg tumor, peritoneal metastasis or lymph node metastasis.
  • the antibody or antigen-binding fragment thereof is detectably labeled.
  • the CLDN6 and/or CLDN9 is human CLDN6 and/or CLDN9.
  • the tumor is selected from ovarian cancer, testicular cancer, gastric cancer, endometrial cancer, lung cancer, esophageal cancer, pancreatic cancer, bronchial cancer, breast cancer, ear nose and throat (ENT) cancer, colon cancer , liver cancer, head and neck cancer, gallbladder cancer and their metastases (eg, gastric cancer metastasis such as Krukenberg tumor, peritoneal metastasis or lymph node metastasis).
  • metastases eg, gastric cancer metastasis such as Krukenberg tumor, peritoneal metastasis or lymph node metastasis.
  • CLDN6 Claudin 6, Claudin 6
  • CLDN9 Claudin 9, Claudin 9
  • NCBI database accession number 095484 The sequence of CLDN9 is well known in the art and can be found in NCBI database accession number 095484.
  • antibody refers to an immunoglobulin molecule generally composed of two pairs of polypeptide chains, each pair having one light (LC) and one heavy (HC) chain.
  • Antibody light chains can be classified as kappa (kappa) and lambda (lambda) light chains.
  • Heavy chains can be classified as mu, delta, gamma, alpha, or epsilon, and define the antibody's isotype as IgM, IgD, IgG, IgA, and IgE, respectively.
  • the variable and constant regions are linked by a "J" region of about 12 or more amino acids, and the heavy chain also contains a "D" region of about 3 or more amino acids.
  • Each heavy chain consists of a heavy chain variable region (VH) and a heavy chain constant region (CH).
  • the heavy chain constant region consists of 3 domains (CH1, CH2 and CH3).
  • Each light chain consists of a light chain variable region (VL) and a light chain constant region (CL).
  • the light chain constant region consists of one domain, CL.
  • Constant domains are not directly involved in the binding of antibodies to antigens, but exhibit a variety of effector functions, such as mediating immunoglobulins with host tissues or factors, including various cells of the immune system (eg, effector cells) and classical complement Binding of the first component (C1q) of the system.
  • VH and VL regions can also be subdivided into regions of high variability called complementarity determining regions (CDRs) interspersed with more conserved regions called framework regions (FRs).
  • CDRs complementarity determining regions
  • FRs framework regions
  • Each VH and VL consists of 3 CDRs and 4 FRs arranged in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4 from amino terminus to carboxy terminus.
  • the assignment of amino acids to regions or domains can follow Kabat, Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, Md. (1987 and 1991)), or Chothia & Lesk (1987) J. Mol. Biol. 196:901- 917; definition by Chothia et al. (1989) Nature 342:878-883.
  • CDR complementarity determining region
  • the variable regions of the heavy and light chains each contain three CDRs, designated CDR1, CDR2 and CDR3.
  • CDR1, CDR2 and CDR3 The precise boundaries of these CDRs can be defined according to various numbering systems known in the art, for example according to the Kabat numbering system (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md., 1991), the Chothia numbering system (Chothia & Lesk (1987) J. Mol. Biol. 196:901-917; Chothia et al.
  • the CDRs contained in the antibody or antigen-binding fragment thereof of the present invention can be determined according to various numbering systems known in the art. In certain embodiments, the CDRs contained by an antibody or antigen-binding fragment thereof of the invention are preferably determined by the Kabat, Chothia or IMGT numbering systems. In certain embodiments, the CDRs contained by an antibody or antigen-binding fragment thereof of the invention are preferably determined by the IMGT numbering system.
  • framework region or "FR” residues refers to those amino acid residues in the variable region of an antibody other than the CDR residues as defined above.
  • antibody is not limited by any particular method of producing an antibody. For example, it includes recombinant antibodies, monoclonal antibodies and polyclonal antibodies. Antibodies can be of different isotypes, eg, IgG (eg, IgGl, IgG2, IgG3, or IgG4 subtype), IgAl, IgA2, IgD, IgE, or IgM antibodies.
  • IgG eg, IgGl, IgG2, IgG3, or IgG4 subtype
  • IgAl IgA2, IgD, IgE, or IgM antibodies.
  • antigen-binding fragment of an antibody refers to a polypeptide comprising a fragment of a full-length antibody that retains the ability to specifically bind to, and/or compete with, the same antigen to which the full-length antibody binds Specific binding to an antigen, which is also referred to as an "antigen binding moiety".
  • an antigen binding moiety which is also referred to as an "antigen binding moiety”.
  • Non-limiting examples of antigen-binding fragments include Fab, Fab', F(ab') 2 , Fd, Fv, complementarity determining region (CDR) fragments, scFv, diabody, single domain antibody, chimeric antibody, linear antibody, nanobody (technology from Domantis), , probody and polypeptides comprising sufficient to confer specificity to the polypeptide At least a portion of an antibody with antigen binding capacity.
  • Engineered antibody variants are reviewed in Holliger et al., 2005; Nat Biotechnol, 23: 1126-1136.
  • full-length antibody means an antibody consisting of two “full-length heavy chains” and two “full-length light chains”.
  • full-length heavy chain refers to a polypeptide chain consisting of a heavy chain variable region (VH), a heavy chain constant region CH1 domain, a hinge region (HR), a heavy chain A constant region CH2 domain, a heavy chain constant region CH3 domain; and, when the full-length antibody is of the IgE isotype, optionally a heavy chain constant region CH4 domain.
  • VH heavy chain variable region
  • CH1 domain heavy chain constant region
  • HR hinge region
  • CH2 domain heavy chain A constant region
  • CH3 domain a heavy chain constant region CH4 domain
  • a "full-length heavy chain” is a polypeptide chain consisting of VH, CH1, HR, CH2 and CH3 in the N-terminal to C-terminal direction.
  • a "full-length light chain” is a polypeptide chain consisting of a light chain variable region (VL) and a light chain constant region (CL) in the N-terminal to C-terminal direction.
  • the two pairs of full-length antibody chains are linked together by a disulfide bond between CL and CH1 and a disulfide bond between the HRs of the two full-length heavy chains.
  • the full-length antibody of the present invention can be from a single species, such as human; it can also be a chimeric antibody or a humanized antibody.
  • the full-length antibodies of the present invention comprise two antigen-binding sites formed by VH and VL pairs, respectively, which specifically recognize/bind to the same antigen.
  • Fd means an antibody fragment consisting of VH and CH1 domains
  • dAb fragment means an antibody fragment consisting of a VH domain (Ward et al., Nature 341:544 546 ( 1989))
  • Fab fragment means an antibody fragment consisting of VL, VH, CL and CH1 domains
  • F(ab') 2 fragment means an antibody fragment comprising two fragments linked by a disulfide bridge on the hinge region.
  • Fab'fragment means a fragment obtained by reducing the disulfide bond linking two heavy chain fragments in an F(ab') 2 fragment, consisting of an intact light chain and heavy chain Fd Fragments (consisting of VH and CH1 domains).
  • Fv means an antibody fragment consisting of the one-armed VL and VH domains of an antibody. Fv fragments are generally considered to be the smallest antibody fragments that can form a complete antigen-binding site. It is generally believed that the six CDRs confer antigen-binding specificity to an antibody. However, even a single variable region (eg, an Fd fragment, which contains only three CDRs specific for the antigen) is able to recognize and bind the antigen, albeit probably with lower affinity than the intact binding site.
  • Fc means that the second and third constant regions of the first heavy chain of an antibody are joined by disulfide bonds to the second and third constant regions of the second heavy chain.
  • Antibody Fragments The Fc fragment of an antibody has many different functions, but is not involved in antigen binding.
  • scFv refers to a single polypeptide chain comprising VL and VH domains, wherein the VL and VH are connected by a linker (see, eg, Bird et al., Science 242:423 -426 (1988); Huston et al., Proc. Natl. Acad. Sci. USA 85:5879-5883 (1988); and Pluckthun, The Pharmacology of Monoclonal Antibodies, Vol. 113, eds. Roseburg and Moore, Springer-Verlag, New York, pp. 269-315 (1994)).
  • Such scFv molecules may have the general structure: NH2 -VL-linker-VH-COOH or NH2 -VH-linker-VL-COOH.
  • Suitable prior art linkers consist of repeated GGGGS amino acid sequences or variants thereof.
  • GGGGS linker with the amino acid sequence
  • Other linkers useful in the present invention are described by Alfthan et al. (1995), Protein Eng. 8:725-731, Choi et al. (2001), Eur. J. Immunol. 31:94-106, Hu et al.
  • a disulfide bond may also exist between the VH and VL of the scFv.
  • the term "diabody” means that its VH and VL domains are expressed on a single polypeptide chain, but use linkers that are too short to allow pairing between the two domains of the same chain, This forces the domains to pair with the complementary domains of the other chain and create two antigen-binding sites (see, e.g., Holliger P. et al., Proc. Natl. Acad. Sci. USA 90:6444-6448 (1993), and Poljak R.J. et al, Structure 2:1121-1123 (1994)).
  • single-domain antibody has the meaning commonly understood by those of skill in the art, which refers to a combination of a single monomeric variable antibody domain (eg, a single heavy chain variable region), which retain the ability to specifically bind to the same antigen to which the full-length antibody binds.
  • Single domain antibodies are also known as nanobodies.
  • the term "probody” has the meaning commonly understood by those of skill in the art and refers to a masked antibody that remains inert in healthy tissue but is specifically activated in a disease setting (eg, via protease cleavage by proteases that are enriched or unique in the disease environment). Detailed teachings thereof can be found, for example, in Desnoyers et al., Sci. Transl. Med., 5:207ra144, 2013. Similar masking techniques can be used with any of the antibodies or antigen-binding portions thereof described herein.
  • Each of the aforementioned antibody fragments retains the ability to specifically bind to the same antigen bound by the full-length antibody, and/or compete with the full-length antibody for specific binding to the antigen.
  • Antigen-binding fragments of an antibody can be obtained from a given antibody (eg, an antibody provided herein) using conventional techniques known to those of skill in the art (eg, recombinant DNA techniques or enzymatic or chemical fragmentation methods). ), and the antibody is screened for specificity for antigen-binding fragments in the same manner as is used for intact antibodies.
  • antibody includes not only whole antibodies but also antigen-binding fragments of antibodies.
  • the terms "monoclonal antibody”, “monoclonal antibody”, “mAb” have the same meaning and are used interchangeably and interchangeably, and refer to one from a population of highly homologous antibody molecules An antibody or a fragment of an antibody, that is, a population of identical antibody molecules, except for natural mutations that may arise spontaneously.
  • Monoclonal antibodies are highly specific for a single epitope on an antigen.
  • Polyclonal antibodies are relative to monoclonal antibodies, which generally comprise at least two or more different antibodies that generally recognize different epitopes on an antigen.
  • the modifier "monoclonal” only indicates that the antibody is characterized as being obtained from a population of highly homologous antibodies and should not be construed as requiring any particular method to prepare said antibody.
  • Monoclonal antibodies of the invention can be prepared by a variety of techniques, such as hybridoma technology (see, eg, Kohler et al. Nature, 256:495, 1975), recombinant DNA technology (see, eg, US Patent Application 4,816,567), or bacteriophage Antibody library technology (see, eg, Clackson et al. Nature 352:624-628, 1991, or Marks et al. J. Mol. Biol. 222:581-597, 1991).
  • Antibodies can be purified by well-known techniques, such as affinity chromatography using protein A or protein G. Subsequently or alternatively, the specific antigen (the target molecule recognized by the antibody) or its epitope can be immobilized on a column and the immunospecific antibody purified by immunoaffinity chromatography.
  • immunoaffinity chromatography For the purification of immunoglobulin, refer to, for example, D. Wilkinson (The Engineer, published by The Engineer, Inc., Philadelphia Pa., Vol. 14, No. 8 (Apr. 17, 2000), pp. 25-28).
  • chimeric antibody refers to an antibody whose light chain or/and a portion of its heavy chain is derived from an antibody (which may be derived from a particular species or belong to a a particular antibody class or subclass), and another portion of the light chain or/and heavy chain is derived from another antibody (which may be derived from the same or a different species or of the same or different antibody class or subclass), but regardless of whether the However, it still retains binding activity to the target antigen (U.S.P 4,816,567 to Cabilly et al.; Morrison et al., Proc. Natl. Acad. Sci. USA, 81:6851 6855 (1984)).
  • chimeric antibody can include antibodies (eg, human-mouse chimeric antibodies) in which the heavy and light chain variable regions of the antibody are derived from a primary antibody (eg, a murine antibody) and the heavy and The light chain variable region is derived from a second antibody (eg, a human antibody).
  • a primary antibody eg, a murine antibody
  • a second antibody eg, a human antibody
  • humanized antibody refers to a genetically engineered non-human antibody whose amino acid sequence has been modified to increase homology to the sequence of a human antibody.
  • CDR regions of a humanized antibody are derived from a non-human antibody (donor antibody), and all or part of the non-CDR regions (eg, variable FR and/or constant regions) are derived from human Immunoglobulins (receptor antibodies).
  • Humanized antibodies generally retain the expected properties of the donor antibody, including, but not limited to, antigen specificity, affinity, reactivity, and the like.
  • the donor antibody can be a mouse, rat, rabbit, or non-human primate (eg, cynomolgus monkey) antibody with the desired properties (eg, antigen specificity, affinity, reactivity, etc.).
  • the expected properties of the antibodies of the invention include: (1) specific recognition/binding of CLDN6 and/or CLDN9 (especially human CLDN6 and/or human CLDN9); (2) mediation of CLDN6 internalization; (3) Induction of killing of human CLDN6 expressing cells by antibody-dependent cell-mediated cytotoxicity (ADCC); (4) induction of killing of human CLDN6-expressing cells by complement-dependent cytotoxicity (CDC); (5) prevention and/or treatment tumor capacity.
  • Antibodies of the present invention possess one or more of the expected properties described above.
  • the chimeric antibody or humanized antibody of the present invention can be prepared according to the sequence of the mouse monoclonal antibody prepared above.
  • DNA encoding the heavy and light chains can be obtained from target murine hybridomas and engineered to contain non-murine (eg, human) immunoglobulin sequences using standard molecular biology techniques.
  • murine immunoglobulin variable regions can be linked to human immunoglobulin constant regions using methods known in the art (see, eg, US Patent No. 4,816,567 to Cabilly et al.).
  • the VH-encoding DNA is operably linked to another DNA molecule encoding the heavy chain constant region to obtain a full-length heavy chain gene.
  • the sequences of human heavy chain constant region genes are known in the art (see, e.g., Kabat, E.A. et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242 ), DNA fragments containing these regions can be obtained by standard PCR amplification.
  • the heavy chain constant region may be an IgGl, IgG2, IgG3, IgG4, IgA, IgE, IgM or IgD constant region, but is generally preferably an IgGl or IgG4 constant region.
  • the DNA encoding VL is operably linked to another DNA molecule encoding the light chain constant region CL to obtain a full-length light chain gene (as well as a Fab light chain gene).
  • Sequences of human light chain constant region genes are known in the art (see, e.g., Kabat, E.A. et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242 ), DNA fragments containing these regions can be obtained by standard PCR amplification.
  • the light chain constant region may be a kappa or lambda constant region, but is generally preferably a kappa constant region.
  • murine CDR regions can be inserted into human framework sequences using methods known in the art (see US Patent Nos. 5,225,539 to Winter; US Patent Nos. 5,530,101 to Queen et al; 5,585,089; 5,693,762 and 6,180,370; and Lo, Benny, KC, editor, in Antibody Engineering: Methods and Protocols, volume 248, Humana Press, New Jersey, 2004).
  • transgenic animals that are capable of producing no endogenous immunoglobulins following immunization and capable of producing fully human antibody repertoires can also be utilized.
  • JH antibody heavy chain joining region
  • Non-limiting examples of such transgenic animals include, HuMAb mice (Medarex, Inc.), which contain human immunoglobulin gene miniatures encoding unrearranged human heavy (mu and gamma) and kappa light chain immunoglobulin sequences. loci (miniloci), plus targeted mutations that inactivate endogenous mu and kappa chain loci (see, eg, Lonberg et al. (1994) Nature 368(6474):856-859); or carrying a human heavy chain transgene and human "KM mouse TM " of the light chain transchromosome (see patent application WO02/43478).
  • Other methods for humanizing antibodies include phage display technology (Hoogenboom et al., 1991, J. Mol. Biol. 227:381; Marks et al., J. Mol. Biol. 1991, 222:581-597; Vaughan et al., 1996 , Nature Biotech 14:309).
  • germline antibody gene or “germline antibody gene segment” refers to sequences encoding immunoglobulins present in the genome of an organism , which have not undergone maturation processes that lead to genetic rearrangements and mutations that result in the expression of specific immunoglobulins.
  • the expression “heavy chain germline gene” refers to a germline antibody gene or gene fragment encoding an immunoglobulin heavy chain, which includes V gene (variable), D gene (diversity), and J gene (joining) and C gene (constant); similarly, the expression “light chain germline gene” refers to a germline antibody gene or gene fragment encoding an immunoglobulin light chain, which includes V gene (variable), J gene (joining) and C gene (constant).
  • the amino acid sequence encoded by the germline antibody gene or germline antibody gene fragment is also referred to as "germline sequence”. Germline antibody genes or germline antibody gene fragments and their corresponding germline sequences are well known to those skilled in the art and can be obtained or queried from specialized databases (eg, IMGT, UNSWIg, NCBI or VBASE2).
  • the term “specific binding” refers to a non-random binding reaction between two molecules, such as between an antibody and the antigen to which it is directed.
  • the strength or affinity of a specific binding interaction can be expressed in terms of the equilibrium dissociation constant ( KD ) for that interaction.
  • K D the equilibrium dissociation constant
  • K D refers to the dissociation equilibrium constant of a particular antibody-antigen interaction, which is used to describe the binding affinity between an antibody and an antigen. The smaller the equilibrium dissociation constant, the tighter the antibody-antigen binding and the higher the affinity between the antibody and the antigen.
  • an antibody that specifically binds to an antigen refers to an antibody with a concentration of less than about 10-9 M, such as less than about 10-9 M, 10-10 M, Binds the antigen with an affinity (K D ) of 10 ⁇ 11 M or 10 ⁇ 12 M or less.
  • K D surface plasmon resonance
  • cytotoxic agent includes any agent that is detrimental to (eg, kills) cells, such as chemotherapeutic drugs, bacterial toxins, plant toxins, or radioisotopes, and the like.
  • the term "vector” refers to a nucleic acid delivery vehicle into which a polynucleotide can be inserted.
  • the vector can express the protein encoded by the inserted polynucleotide, the vector is called an expression vector.
  • the vector can be introduced into a host cell by transformation, transduction or transfection, so that the genetic material elements carried by it can be expressed in the host cell.
  • Vectors are well known to those skilled in the art and include, but are not limited to: plasmids; phagemids; cosmids; artificial chromosomes, such as yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs) or P1 derived artificial chromosomes (PACs) ; Phage such as ⁇ phage or M13 phage and animal viruses.
  • YACs yeast artificial chromosomes
  • BACs bacterial artificial chromosomes
  • PACs P1 derived artificial chromosomes
  • Animal viruses that can be used as vectors include, but are not limited to, retroviruses (including lentiviruses), adenoviruses, adeno-associated viruses, herpesviruses (eg, herpes simplex virus), poxviruses, baculoviruses, papillomaviruses, papillomaviruses Polyoma vacuolar virus (eg SV40).
  • retroviruses including lentiviruses
  • adenoviruses eg, adeno-associated viruses
  • herpesviruses eg, herpes simplex virus
  • poxviruses baculoviruses
  • papillomaviruses papillomaviruses
  • Polyoma vacuolar virus eg SV40
  • a vector may contain a variety of elements that control expression, including, but not limited to, promoter sequences, transcription initiation sequences, enhancer sequences, selection elements, and
  • the term "host cell” refers to a cell that can be used to introduce a vector, including, but not limited to, prokaryotic cells such as E. coli or Bacillus subtilis, fungal cells such as yeast cells or Aspergillus, etc., Insect cells such as S2 Drosophila cells or Sf9, or animal cells such as fibroblasts, CHO cells, COS cells, NSO cells, HeLa cells, BHK cells, HEK 293 cells or human cells.
  • prokaryotic cells such as E. coli or Bacillus subtilis
  • fungal cells such as yeast cells or Aspergillus, etc.
  • Insect cells such as S2 Drosophila cells or Sf9
  • animal cells such as fibroblasts, CHO cells, COS cells, NSO cells, HeLa cells, BHK cells, HEK 293 cells or human cells.
  • identity is used to refer to the match of sequences between two polypeptides or between two nucleic acids.
  • a position in both sequences being compared is occupied by the same base or amino acid monomer subunit (e.g., a position in each of two DNA molecules is occupied by an adenine, or both A position in each of the polypeptides is occupied by a lysine)
  • the molecules are identical at that position.
  • the "percent identity” between two sequences is a function of the number of matched positions shared by the two sequences divided by the number of positions compared x 100. For example, two sequences are 60% identical if 6 out of 10 positions match.
  • the DNA sequences CTGACT and CAGGTT share 50% identity (matching at 3 positions out of a total of 6).
  • comparisons are made when two sequences are aligned for maximum identity.
  • Such alignment can be accomplished using, for example, the method of Needleman et al. (1970) J. Mol. Biol. 48:443-453, which can be conveniently performed by a computer program such as the Align program (DNAstar, Inc.). It is also possible to use the algorithm of E. Meyers and W. Miller (Comput.
  • conservative substitutions means amino acid substitutions that do not adversely affect or alter the intended properties of the protein/polypeptide comprising the amino acid sequence.
  • conservative substitutions can be introduced by standard techniques known in the art such as site-directed mutagenesis and PCR-mediated mutagenesis.
  • Conservative amino acid substitutions include substitutions of amino acid residues with amino acid residues that have similar side chains, e.g., that are physically or functionally similar to the corresponding amino acid residues (e.g., have similar size, shape, charge, chemical properties, including the ability to form covalent bonds or hydrogen bonds, etc.) Families of amino acid residues with similar side chains have been defined in the art.
  • These families include those with basic side chains (eg, lysine, arginine, and histidine), acidic side chains (eg, aspartic acid, glutamic acid), uncharged polar side chains (eg, glycine) , asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), non-polar side chains (e.g.
  • alanine, valine, leucine, isoleucine amino acid, proline, phenylalanine, methionine), beta branched side chains (eg, threonine, valine, isoleucine), and aromatic side chains (eg, tyrosine, phenylalanine, tryptophan, histidine). Therefore, it is preferred to replace the corresponding amino acid residue with another amino acid residue from the same side chain family.
  • Methods for identifying conservative substitutions of amino acids are well known in the art (see, eg, Brummell et al., Biochem. 32:1180-1187 (1993); Kobayashi et al. Protein Eng. 12(10):879-884 (1999) and Burks et al. Proc. Natl Acad. Set USA 94:412-417 (1997), which is incorporated herein by reference).
  • amino acids are generally represented by one-letter and three-letter abbreviations well known in the art.
  • alanine can be represented by A or Ala.
  • chimeric antigen receptor refers to an extracellular antibody-derived targeting domain (e.g., scFv) engineered T cell receptors.
  • the term “chimeric antigen receptor T cell” is a T cell that expresses a CAR and has an antigen specificity determined by the targeting domain of the CAR.
  • Methods of making CARs are known in the art, see, eg, Park et al., Trends Biotechnol., 29:550-557, 2011; Grupp et al., NEnglJMed., 368:1509-1518 , 2013; Han et al., J. Hematol Oncol., 6:47, 2013; PCT Patent Publications WO2012/079000, WO2013/059593; and US Patent Publication 2012/0213783, all of which are incorporated herein by reference in their entirety.
  • the term "pharmaceutically acceptable carrier and/or excipient” refers to a carrier and/or excipient that is pharmacologically and/or physiologically compatible with the subject and the active ingredient, It is well known in the art (see e.g. Remington's Pharmaceutical Sciences. Edited by Gennaro AR, 19th ed. Pennsylvania: Mack Publishing Company, 1995) and includes, but is not limited to: pH adjusters, surfactants, adjuvants, ionic strength enhancers Agents, diluents, agents to maintain osmotic pressure, agents to delay absorption, preservatives.
  • pH adjusting agents include, but are not limited to, phosphate buffers.
  • Surfactants include, but are not limited to, cationic, anionic or nonionic surfactants, such as Tween-80.
  • Ionic strength enhancers include, but are not limited to, sodium chloride.
  • Preservatives include, but are not limited to, various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, sorbic acid, and the like.
  • Agents for maintaining osmotic pressure include, but are not limited to, sugars, NaCl, and the like.
  • Agents that delay absorption include, but are not limited to, monostearate salts and gelatin.
  • Diluents include, but are not limited to, water, aqueous buffers (eg, buffered saline), alcohols and polyols (eg, glycerol), and the like.
  • Preservatives include, but are not limited to, various antibacterial and antifungal agents, such as thimerosal, 2-phenoxyethanol, parabens, chlorobutanol, phenol, sorbic acid, and the like.
  • Stabilizers have the meaning commonly understood by those skilled in the art, which are capable of stabilizing the desired activity of the active ingredient in the drug, including but not limited to sodium glutamate, gelatin, SPGA, sugars (such as sorbitol, mannitol, starch, sucrose , lactose, glucan, or glucose), amino acids (such as glutamic acid, glycine), proteins (such as dry whey, albumin or casein) or their degradation products (such as lactalbumin hydrolyzate) and the like.
  • the pharmaceutically acceptable carrier or excipient includes sterile injectable liquids (eg, aqueous or non-aqueous suspensions or solutions).
  • such sterile injectable liquids are selected from the group consisting of water for injection (WFI), bacteriostatic water for injection (BWFI), sodium chloride solution (eg, 0.9% (w/v) NaCl), dextrose Solutions (eg, 5% dextrose), surfactant-containing solutions (eg, 0.01% polysorbate 20), pH buffered solutions (eg, phosphate buffered solution), Ringer's solution, and any combination thereof.
  • WFI water for injection
  • BWFI bacteriostatic water for injection
  • sodium chloride solution eg, 0.9% (w/v) NaCl
  • dextrose Solutions eg, 5% dextrose
  • surfactant-containing solutions eg, 0.01% polysorbate 20
  • pH buffered solutions eg, phosphate buffered solution
  • Ringer's solution e.g, Ringer's solution, and any combination thereof.
  • prevention refers to a method performed to prevent or delay the occurrence of a disease or disorder or symptom (eg, tumor) in a subject.
  • treatment refers to a method performed to obtain a beneficial or desired clinical result.
  • a beneficial or desired clinical outcome includes, but is not limited to, alleviation of symptoms, reduction in the extent of the disease, stabilization (ie, not worsening) of the disease state, delaying or slowing the progression of the disease, amelioration or alleviation of the disease status, and relief of symptoms (whether in part or in full), whether detectable or undetectable.
  • treatment can also mean prolonging survival as compared to expected survival if not receiving treatment.
  • the term "subject” refers to a mammal, such as a primate, such as a human.
  • the subject eg, a human
  • has a tumor eg, a tumor expressing CLDN6 and/or CLDN9, or is at risk of having the aforementioned diseases.
  • the term "effective amount" refers to an amount sufficient to obtain, or at least partially obtain, the desired effect.
  • a disease-prophylactically effective amount refers to an amount sufficient to prevent, arrest, or delay the onset of a disease (eg, a tumor);
  • a disease-treatment effective amount refers to an amount sufficient to cure or at least partially prevent an existing disease
  • an amount effective for therapeutic use will depend on the severity of the disease to be treated, the general state of the patient's own immune system, the patient's general condition such as age, weight and sex, the mode of administration of the drug, and other concurrently administered treatments and many more.
  • immune effector cells includes cells of hematopoietic origin and that play a role in immune responses, such as lymphocytes, such as B cells and T cells; natural killer cells; myeloid cells, such as monocytes cells, macrophages, eosinophils, mast cells, basophils and granulocytes.
  • lymphocytes such as B cells and T cells
  • natural killer cells such as myeloid cells, such as monocytes cells, macrophages, eosinophils, mast cells, basophils and granulocytes.
  • myeloid cells such as monocytes cells, macrophages, eosinophils, mast cells, basophils and granulocytes.
  • the immune effector cells are T cells.
  • metastasis refers to the spread of cancer cells from their original site to other parts of the body.
  • the formation of metastases is a very complex process and depends on the detachment of malignant cells from the primary tumor, invasion of the extracellular matrix, penetration of the endothelial basement membrane to enter body cavities and blood vessels, and subsequent infiltration of target organs after transport by the blood.
  • new tumors ie, secondary tumors or metastatic tumors
  • Tumor metastasis often occurs even after resection of the primary tumor, as tumor cells or components may remain and develop metastatic potential.
  • the term “metastasis” relates to "distant metastasis", which involves metastasis away from the primary tumor and the regional lymph node system.
  • the cells of a secondary or metastatic tumor resemble those in the original tumor. This means that for example if ovarian cancer metastasizes to the liver, the secondary tumor consists of abnormal ovarian cells (rather than abnormal liver cells). The tumor in the liver is then called metastatic ovarian cancer (rather than liver cancer).
  • the antibodies of the present invention can specifically recognize/bind to CLDN6 and/or CLDN9, and can induce killing of CLDN6-expressing cells (eg, tumor cells) through ADCC and/or CDC. Therefore, the antibodies of the present invention have potential for use in the prevention and/or treatment of tumors (especially expressing CLDN6).
  • the humanized antibody of the present invention not only retains the functions and properties of the parent antibody, but also has a high degree of humanization, so that it can be safely administered to a human subject without eliciting an immunogenic response.
  • the antibodies of the present invention hardly bind to other proteins in the CLDN family (eg, CLDN3 and CLDN4). Therefore, the antibodies (especially humanized antibodies) of the present invention have great clinical value.
  • Figures 1A-1D show the results of measuring the binding activity of the anti-CLDN6 murine antibody 15H2 to different cell surface CLDN proteins, respectively.
  • Figure 1A CHOS-hCLDN6
  • Figure 1B CHOS-CLDN3
  • Figure 1C CHOS-CLDN4
  • Figure ID CHOS-CLDN9.
  • Figures 2A-2D show the assay results of the binding activity of the anti-CLDN6 murine antibody 9H3 to different cell surface CLDN proteins, respectively.
  • Figure 2A CHOS-hCLDN6
  • Figure 2B CHOS-CLDN3
  • Figure 2C CHOS-CLDN4
  • Figure 2D CHOS-CLDN9.
  • Figures 3A-3D show the binding results of humanized antibodies 7008-01 and 7008-03 to four tumor cells naturally expressing human CLDN6, respectively.
  • Figure 3A OV90
  • Figure 3B NEC8
  • Figure 3C NTERA2
  • Figure 3D Bewo.
  • Figures 4A-4D show the results of antibody-dependent cytotoxicity of effector cells induced by humanized antibodies 7008-01 and 7008-03 on four tumor cells naturally expressing human CLDN6, respectively.
  • Figure 4A OV90
  • Figure 4B NEC8
  • Figure 4C NTERA2
  • Figure 4D Bewo.
  • Figure 5 shows the results of complement-dependent killing of NTERA2 tumor cells naturally expressing human CLDN6 by humanized antibodies 7008-01 and 7008-03 induced by complement.
  • Figures 6A-6D show the binding results of hotspot mutant antibodies to different CLDN6 expressing tumor cells, respectively.
  • Figure 6A Binding result of 15H2 antibody and NEC8
  • Figure 6B Binding result of 15H2 antibody and Bewo
  • Figure 6C Binding result of 9H3 antibody and NEC8
  • Figure 6D Binding result of 9H3 antibody and Bewo.
  • the molecular biology experimental methods and immunoassay methods used in the present invention basically refer to J. Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory Press, 1989, and F.M. Ausubel et al., Refined Molecular Biology Laboratory Manual, 3rd Edition, John Wiley & Sons, Inc., 1995, was performed as described; restriction enzymes were used according to the conditions recommended by the product manufacturer.
  • restriction enzymes were used according to the conditions recommended by the product manufacturer.
  • the constructed CHOS-hCLDN6 cells overexpressing human CLDN6 were used to immunize Balb/c mice (Beijing Weitong Lihua Laboratory Animal Technology Co., Ltd., strain code 216); the primary adjuvant was complete CFA (InvivoGen, product number vac-cfa-60) was used as adjuvant, and IFA (InvivoGen company, product number vac-ifa-60) was used as an immune adjuvant; the immunization route was subcutaneous multiple points.
  • CFA InvivoGen, product number vac-cfa-60
  • IFA InvivoGen company, product number vac-ifa-60
  • the spleen cells of the immunized mice were fused with mouse myeloma cells SP2/0 using the polyethylene glycol method to obtain B cells that could express antibodies and proliferate indefinitely in vitro, and were selected and cultured in HAT. cultured in the base.
  • the fused hybridoma cells were plated in a 96-well cell culture plate, and by detecting the ability of the antibody in the supernatant to bind CLDN3/4/6/9 at the cellular level, the target positive clones (only binding to CLDN6, not binding to CLDN6) were screened out.
  • Antibodies to CLDN3/4/9; antibodies that simultaneously bind CLDN6/9, but not CLDN3/4) were subjected to 2-3 rounds of subcloning.
  • High-throughput screening of murine anti-binding cell level In the screening, cells expressing human CLDN3/4/6/9 (CHOS-hCLDN6, CHOS-CLDN3, CHOS-CLDN4, CHOS-CLDN9) were plated separately. Dilute 10,000 cells in 100 ⁇ L of complete medium, use a flat-bottom 96-well plate, allow cells to adhere or settle to the bottom of the well overnight, and remove the supernatant the next day. 100 ⁇ L of the hybridoma supernatant to be screened was added to the cell plate and incubated at room temperature for 1 hour.
  • the image obtained by the fluorescence channel counts the cells bound by the antibody according to the parameters set by the fluorescently labeled cell morphology and fluorescence intensity, and the image obtained by the brightfield channel counts the adherent cells according to the parameters set by the cell shape.
  • the percentage of cells showing fluorescence bound to the antibody was obtained by dividing the total number of cells. Based on this ratio, the binding effect of the antibody in the supernatant of the fusion tumor to the cells expressing CLDN3/4/6/9 was determined.
  • CLDN6 expressing cells (CHOS-hCLDN6, CHOS-CLDN3, CHOS-CLDN4, CHOS-CLDN9) were placed in FACS buffer (PBS + 2% FBS) )/well, incubate at 4°C for 1 hour after adding the mouse antibody to be tested. The supernatant was removed by centrifugation, washed twice with FACS buffer, and a secondary antibody (DyLight488 goat anti-mouse IgG, Abcam catalog number ab97015) was added and incubated at 4 degrees Celsius for 0.5 hours.
  • FACS buffer PBS + 2% FBS
  • FIG. 1A-1D The binding of mouse antibody 15H2 to CHOS-hCLDN6, CHOS-CLDN3, CHOS-CLDN4, and CHOS-CLDN9 is shown in Figures 1A-1D.
  • the isotype control antibody ISO (Beyotime, CatA7028) does not bind to CHOS-hCLDN6 , CHOS-CLDN3, CHOS-CLDN4, CHOS-CLDN9 cells bind
  • antibody 15H2 can bind to CHOS-hCLDN6 cells, but hardly bind to CHOS-CLDN3, CHOS-CLDN4 and CHOS-CLDN9 cells
  • murine antibody 9H3 binds to CHOS-
  • FIG. 2A-2D The binding of hCLDN6, CHOS-CLDN3, CHOS-CLDN4, and CHOS-CLDN9 is shown in Figures 2A-2D.
  • the isotype control antibody ISO does not bind to CHOS-hCLDN6, CHOS-CLDN3, CHOS-CLDN4, and CHOS-CLDN9.
  • Cell binding, antibody 9H3 was able to bind to CHOS-hCLDN6 and CHOS-CLDN9 cells, but hardly to CHOS-CLDN3 and CHOS-CLDN4 cells.
  • Hybridoma cells were collected by centrifugation, 1 ml of TRIzol and 0.2 ml of chloroform were added to each 5-10 ⁇ 10 6 cells, vigorously shaken for 15 seconds, and left at room temperature for 3 minutes. The RNA was obtained after washing with ethanol and drying. Add template RNA and primers to the ice-bath centrifuge tube to make the primers and templates correctly paired, then perform reverse transcription, and then perform PCR amplification. 2.5 ⁇ l of dNTP/ddNTP mixture was added to each of the 4 microcentrifuge tubes, and the mixture was incubated at 37°C for 5 min for later use.
  • VH and VL sequences of the two strains of murine antibodies are shown in Table 1. Further, the CDR sequences of the two mouse monoclonal antibodies were determined by the IMGT numbering system.
  • variable region of the mouse antibody is linked to the constant region of the human antibody (human IgG1), and the expression plasmid containing the antibody gene is transfected into mammalian cells.
  • Flask-grown mammalian cell supernatants containing antibody clones were harvested, purified using a protein A column, and the antibody protein was eluted using 100 mM acetic acid pH 3.0. The purified antibody protein was then loaded onto a size exclusion chromatography column for further separation and purification.
  • Antibody proteins corresponding to monomers were formulated in PBS buffer supplemented with 20% glycerol.
  • the murine antibody provided in the above example can be designed and prepared by humanization, using methods known in the art to Human framework sequences were inserted into the murine CDR regions (see U.S. Patent No. 5,225,539 to Winter; U.S. Patent Nos. 5,530,101 to Queen et al.; 5,585,089; 5,693,762 and 6,180,370; , volume 248, Humana Press, New Jersey, 2004).
  • the heavy chain and light chain CDR regions of murine antibodies 15H2 and 9H3 were constructed on the FR framework of the corresponding humanized template, respectively, and a series of amino acid residues in the FR region of the humanized template were analyzed. Back-mutation is performed so that the humanized antibody retains the antigen-binding ability of the murine antibody as much as possible.
  • PTM hotspot Post-Translation Modification hotspot
  • the possible post-translational modification hotspots in the CDR regions of murine antibodies are considered (Post-Translation Modification hotspot, PTM hotspot), such as the aspartate isomerization hotspot DG in 15H2 HCDR2, and the aspartate isomerization hotspot in 9H3 HCDR2.
  • DG, deamination hotspots NG in 9H3 LCDR1 these hotspots were mutated using methods known in the art.
  • mutating D in aspartate isomerization hot spot DG to E/S/G, etc., or mutating G in DG to A/S/D, etc., or mutating N in deamination hot spot NG into Q/S/A, etc., or mutate G in NG to A/S/D, etc. after experimental verification, most of the above-mentioned mutations do not change the ability of the antibody to bind to CLDN6 expressing cells (such as 15H2 HCDR2 DG mutated to EG/SG/GG; 9H3 LCDR1 NG is mutated to QG/NA/SG; 9H3 LCDR1 NG is mutated to QG and its HCDR2 DG is mutated to DA) or within three-fold (9H3 LCDR1 NG is mutated to NA and its HCDR2 DG is also mutated to DA) mutated to DA; 9H3 LCDR1 NG was mutated to SG and its
  • Figures 6A and 6B show the binding of a partial hotspot mutant antibody of 15H2 to CLDN6 expressing tumor cells NEC8/Bewo
  • Figures 6C and 6D show the binding of a partial hotspot mutant antibody of 9H3 to CLDN6 expressing tumor cells NEC8/Bewo.
  • each murine antibody should correspond to humanized and One hot spot mutant antibody, respectively named 7008-01 (its heavy chain variable region and light chain variable region are shown in SEQ ID NOs: 19 and 20, respectively) and 7008-03 (its heavy chain variable region and light chain variable region are shown in SEQ ID NO: 19 and 20, respectively)
  • the chain variable regions are shown in SEQ ID NOs: 9 and 10, respectively).
  • the heavy chain constant region of each antibody is SEQ ID NO:21, and the light chain constant region is SEQ ID NO:22.
  • the target cells use CLDN6 naturally expressing tumor cells (OV90, ATCC; NEC8, JCRB; NTERA2, Nanjing Kebai Bio; Bewo, Nanjing Kebai Bio), and the effector cells use the in-house constructed stably transfected CD16 receptor and NFAT ( Nuclear Factor of Activated T-cells) reaction element Jurkat-NFAT-Luc-CD16 cell line, experiments were performed in 96-well flat-bottom cell plates (Corning 3903). The serially diluted antibodies were added to the target cells and incubated at 37°C for 30 minutes. Add 60,000 effector cells per 10,000 target cells, and carry out the reaction at 37°C for 4-6 hours.
  • One-GloTM reagent (Promega, E6110) was added for fluorescence color development, and the cell plate was measured with a Tecan Spark10 microplate reader. .
  • GraphPad was used for data analysis, the abscissa used the logarithm of the antibody concentration, and the ordinate used the luminescence reading of the corresponding well, and the EC50 of the antibody-dependent cytotoxicity of the anti-CLDN6 antibody was fitted according to the curve.
  • Humanized antibodies 7008-01 and 7008-03 induced antibody-dependent cytotoxicity of effector cells to four tumor cells naturally expressing human CLDN6 (OV90/NEC8/NTERA2/Bewo) as shown in Figures 4A-4D, respectively.
  • Table 3 lists the EC50 and maximum (Top Lum) of ADCC of the two antibodies in different tumor cells. The results showed that both humanized antibodies 7008-01 and 7008-03 could effectively induce effector cells to kill CLDN6-expressing tumor cells.
  • Target cells naturally express tumor cell NTERA2 using CLDN6.
  • the target cells were pre-mixed with the BATDA fluorescence-enhancing ligand reagent (PerkinElmer, AD0116) in the EuTDA cytotoxicity detection kit at a ratio of 1 ⁇ 10 6 cells per milliliter of 2 microliters, and incubated at 37 °C for 20 minutes; Cells (5 ⁇ 10 3 ) were mixed with various concentrations of antibodies and human serum as a source of complement (TPCS, A515) at a ratio of 1:8 and incubated in a 96-well round bottom plate (Coring, GLS3799) at 37°C for 3 Hour.
  • TPCS human serum as a source of complement
  • the supernatant in the 96-well round bottom plate was transferred to a 96-well flat-bottom plate (Coring, Cat. No. 3903) supplemented with Europium solution (PerkinElmer, AD0116) for further incubation at room temperature for 15 min.
  • the fluorescence donor released into the supernatant after cell death in each well was excited and the emission light emitted by the acceptor after energy was transferred to the acceptor (excitation: 320/340 nm, emission: 615 nm).
  • This example tested anti-CLDN6 antibody-mediated internalization of CLDN6 by flow cytometry.
  • CLDN6 natively expressing tumor cells OV90/Bewo
  • 10 ⁇ g/mL antibody was incubated with 10 ⁇ g/mL antibody at 37°C/4°C for various times.
  • PBS containing 2% FBS 10 ⁇ g/mL secondary antibody was added for staining at 4° C. for 30 minutes, and then the cells were analyzed for CLDN6 expression by flow cytometry.
  • MFI37 is the MFI of the sample incubated at 37°C
  • MFI4 is the MFI of the sample incubated at 4°C, where only binding occurs without endocytosis, and the MFI background is the MFI of the secondary antibody only, antibody-mediated
  • the percentage of cell surface CLDN6 endocytosis was calculated by the following formula:

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)

Abstract

提供抗CLDN6的抗体或其抗原结合片段，编码其的核酸分子，包含其的免疫缀合物、双特异性分子、嵌合抗原受体及药物组合物，以及它们用于预防和/或治疗肿瘤的用途。

Description

抗CLDN6抗体及其用途 技术领域
本发明涉及疾病治疗及免疫学领域，具体而言，本发明涉及抗CLDN6的抗体或其抗原结合片段，编码其的核酸分子，包含其的免疫缀合物、双特异性分子、嵌合抗原受体及药物组合物，以及它们用于预防和/或治疗肿瘤的用途。
背景技术
卵巢癌(Ovarian Cancer，OC)是常见的妇科恶性肿瘤，属于高度异质性的上皮肿瘤，具有不同的组织学亚型以及遗传和生物学特征，包括浆液性癌，子宫内膜样癌，透明细胞癌和粘液性癌。卵巢癌全球每年新发病例31万，死亡超过20万例(5)。75％的卵巢癌为浆液性癌，五年生存率35％，是恶质性极强的一类癌症，通常被诊断时已经是晚期。这一类肿瘤表现出非凡的侵略性，在靶向药物方面，除了抗血管生成疗法已被临床证明能改善III-IV期浆液性卵巢癌患者的无进展生存期外，晚期浆液性卵巢癌最初对铂类化学疗法敏感，但在初始反应后不久会复发，大约70–80％的病例的主要治疗手段是外科手术。近年针对卵巢癌发病机理和分子特征的研究为靶向治疗卵巢癌提供了更多的科学依据和科学见解。90％的卵巢与TP53的自发体细胞突变相关，更为重要的相关是BRCA1和BRCA2突变，这些突变导致遗传不稳定和同源DNA修复的纯合缺陷是细胞恶质性转化的主要原因。这些研究为靶向聚ADP核糖聚合酶(Poly ADP-ribose Polymerase，PARP)药物治疗卵巢癌提供了依据，其实际效果有待临床证明。
密蛋白(Claudin，CLDN)属于跨膜蛋白，是位于上皮细胞和内皮细胞紧密连接处的膜蛋白。CLDN家族蛋白分布具有组织器官特异性，功能主要为细胞间黏附、维持细胞极性、调节细胞旁通透性及参与细胞增殖、分化的调节。近年研究表明CLDN家族部分成员在癌变过程表达上调，并在非其正常分布的组织中出现癌变情况下的异位激活，这一性质使得科学家们进一步考虑CLDN蛋白作为肿瘤靶点的可能性。2016年美国临床肿瘤学会(ASCO)上对靶向CLDN18.2的单克隆抗体药物zolbetuximab的二期临床研究进行了报道，zolbetuimab合用化药显著增加胃癌/胃食管交界腺癌病人的总体生存期和无进展生存，目前该药物在进行胃癌三期临床和胰腺癌二期临床。靶向CLDN18.2药物的成功进一步增强了科学家对于CLDN家族成员作为肿瘤靶点的信心。
TCGA中大量研究数据显示卵巢癌患者的CLDN6水平相比正常卵巢组织显著上调，正 常卵巢组织中CLDN6水平为0TPM(transcripts per million，n＝88),而在卵巢肿瘤中CLDN6水平为31.4TPM(n＝426)。并且CLDN6仅在胚胎发育期间高表达，在正常成人组织中不表达。CLDN6在正常成人组织中表达最高的是睾丸，表达水平也仅为0.83TPM。除了在卵巢癌中的高表达，CLDN6还在睾丸癌(159.9TPM,n＝137),子宫肉瘤(8.4TPM,n＝57)，和部分子宫内膜癌，胃癌，肺癌高表达。研究表明，子宫内膜癌中CLDN6的高表达与多种临床病理因素有关，并且是独立的预后因素。Kaplan-Meier分析显示了CLDN6高表达组和低表达组的总体生存率和无复发生存率存在显著差异，高CLDN6表达组的5年生存率约30％，而低表达组的5年生存率为89％。除了子宫内膜癌，CLDN6的高表达还和胃癌，尿路上皮癌的预后负相关。正常组织的不表达，肿瘤组织高表达，和肿瘤预后负相关使得CLDN6成为一个理想的肿瘤靶点。
CLDN6蛋白是四次跨膜蛋白，具有四个跨膜疏水区和两个胞外环，其重组蛋白极难表达，因而无合适蛋白抗原进行免疫，给针对CLDN6的抗体的免疫和筛选带来难度。另外CLDN家族蛋白同源性较高，靶向CLDN6的同时需要注意避免和在正常组织上表达较为广泛的并且和CLDN6同源性较高的CLDN3和CLDN4的结合，以避免交叉结合可能带来的毒性问题。以上是抗CLDN6抗体的研发中的两大难点。
CLDN9是CLDN家族中与CLDN6同源性最高的蛋白。TCGA数据显示CLDN9在胰腺上低表达(4.23TPM,n＝4)，在肾脏上低表达(1.99TPM,n＝25),在其他正常组织表达水平中几乎不表达(表达最高的胆管中表达水平为0.82TPM,n＝9)。同时CLDN9在卵巢癌中表达上调(5.68TPM,n＝426),在胆管癌中表达上调(8.44TPM,n＝36)。
因此，发展具有更高的特异性、更低的毒副作用的抗CLDN6抗体以及抗CLDN6和/或抗CLDN9抗体是迫切而必要的，这将给癌症患者提供更多的用药选择。
发明内容
本发明的抗体能够特异性识别/结合人CLDN6和/或CLDN9，并且能够通过ADCC和/或CDC来诱导杀伤表达CLDN6的细胞(例如，肿瘤细胞)。因此，本发明的抗体具有用于预防和/或治疗肿瘤的潜力，具有重大的临床价值。
本发明的抗体
因此，在一个方面，本发明提供了能够特异性结合CLDN6的抗体或其抗原结合片段，所述抗体或其抗原结合片段包含：
(a)包含下述3个互补决定区(CDR)的重链可变区(VH)：
(i)VH CDR1，其由下述序列组成：SEQ ID NO:3，或与其相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列，
(ii)VH CDR2，其由下述序列组成：SEQ ID NO:4或33，或与其相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列，和
(iii)VH CDR3，其由下述序列组成：SEQ ID NO:5，或与其相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列；
和/或
(b)包含下述3个互补决定区(CDR)的轻链可变区(VL)：
(iv)VL CDR1，其由下述序列组成：SEQ ID NO:6，或与其相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列，
(v)VL CDR2，其由下述序列组成：SEQ ID NO:7，或与其相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列，和(vi)VL CDR3，其由下述序列组成：SEQ ID NO:8，或与其相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列。
在某些优选的实施方案中，(i)-(vi)任一项中所述的置换为保守置换。
在某些优选的实施方案中，(i)-(vi)任一项中所述的CDR根据Kabat、IMGT或Chothia编号系统定义。
在某些优选的实施方案中，(i)-(vi)任一项中所述的CDR根据IMGT编号系统定义。
在某些优选的实施方案中，所述抗体或其抗原结合片段，其包含：如下3个重链CDRs：序列为SEQ ID NO：3的VH CDR1，序列为SEQ ID NO：4的VH CDR2，序列为SEQ ID NO：5的VH CDR3；和/或，如下3个轻链CDRs：序列为SEQ ID NO：6的VL CDR1，序列为SEQ ID NO：7的VL CDR2，序列为SEQ ID NO：8的VL CDR3；或者，
所述抗体或其抗原结合片段，其包含：如下3个重链CDRs：序列为SEQ ID NO：3的VH CDR1，序列为SEQ ID NO：33的VH CDR2，序列为SEQ ID NO：5的VH CDR3；和/或，如下3个轻链CDRs：序列为SEQ ID NO：6的VL CDR1，序列为SEQ ID NO：7的VL CDR2，序列为SEQ ID NO：8的VL CDR3。
在某些优选的实施方案中，所述抗体或其抗原结合片段，其进一步包含来源于人的框架区序列(例如，人免疫球蛋白)。
在某些优选的实施方案中，所述人免疫球蛋选自人重排抗体序列或人胚系抗体序列。
在某些优选的实施方案中，本发明提供了能够特异性结合CLDN6的抗体或其抗原结合片段，所述抗体或其抗原结合片段包含：
(a)包含下述3个互补决定区(CDR)的重链可变区(VH)：
(i)VH CDR1，其由下述序列组成：SEQ ID NO:3，或与其相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列，
(ii)VH CDR2，其由下述序列组成：SEQ ID NO:4，或与其相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列，和
(iii)VH CDR3，其由下述序列组成：SEQ ID NO:5，或与其相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列；
和/或
(b)包含下述3个互补决定区(CDR)的轻链可变区(VL)：
(iv)VL CDR1，其由下述序列组成：SEQ ID NO:6，或与其相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列，
(v)VL CDR2，其由下述序列组成：SEQ ID NO:7，或与其相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列，和
(vi)VL CDR3，其由下述序列组成：SEQ ID NO:8，或与其相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列。
在某些优选的实施方案中，(i)-(vi)任一项中所述的置换为保守置换。
在某些优选的实施方案中，(i)-(vi)任一项中所述的CDR根据Kabat、IMGT或Chothia编号系统定义。
在某些优选的实施方案中，(i)-(vi)任一项中所述的CDR根据IMGT编号系统定义。
在某些优选的实施方案中，所述抗体或其抗原结合片段，其包含：如下3个重链CDRs：序列为SEQ ID NO：3的VH CDR1，序列为SEQ ID NO：4的VH CDR2，序列为SEQ ID NO：5的VH CDR3；和/或，如下3个轻链CDRs：序列为SEQ ID NO：6的VL CDR1，序列为SEQ ID NO：7的VL CDR2，序列为SEQ ID NO：8的VL CDR3。
在某些优选的实施方案中，所述抗体或其抗原结合片段，其进一步包含来源于人的框架区序列(例如，人免疫球蛋白)。
在某些优选的实施方案中，所述人免疫球蛋选自人重排抗体序列或人胚系抗体序列。
在某些优选的实施方案中，所述抗体或其抗原结合片段具备以下生物学功能中的一项或多项：
(a)以5μg/ml或更小(例如3μg/ml或更小)的EC50结合人CLDN6；
(b)不结合人CLDN3、CLDN4和CLDN9；
(c)通过抗体依赖性细胞介导的细胞毒性(ADCC)来诱导杀伤表达人CLDN6的细胞(例如肿瘤细胞，如表达CLDN6的肿瘤细胞)；
(d)通过补体依赖的细胞毒性(CDC)来诱导杀伤表达人CLDN6的细胞(例如肿瘤细胞，如表达CLDN6的肿瘤细胞)；
(e)在受试者中预防和/治疗肿瘤(例如，表达CLDN6的肿瘤)。
在一个示例性实施方案中，所述抗体或其抗原结合片段包含：
(a)重链可变区(VH)，其包含选自下列的氨基酸序列：
(i)SEQ ID NO:1所示的序列；
(ii)与SEQ ID NO:1所示的序列相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个，3个，4个或5个氨基酸的置换、缺失或添加)的序列；或
(iii)与SEQ ID NO:1所示的序列具有至少80％、至少85％、至少90％、至少91％、至少92％、至少93％、至少94％、至少95％、至少96％、至少97％、至少98％、至少99％、或100％的序列同一性的序列；
和/或，
(b)轻链可变区(VL)，其包含选自下列的氨基酸序列：
(iv)SEQ ID NO:2所示的序列；
(v)与SEQ ID NO:2所示的序列相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个，3个，4个或5个氨基酸的置换、缺失或添加)的序列；或
(vi)与SEQ ID NO:2所示的序列具有至少80％、至少85％、至少90％、至少91％、至少92％、至少93％、至少94％、至少95％、至少96％、至少97％、至少98％、至少99％、或100％的序列同一性的序列。
在某些优选的实施方案中，(ii)或(v)中所述的置换是保守置换。
在某些优选的实施方案中，所述抗体或其抗原结合片段包含：具有如SEQ ID NO:1所示的序列的VH和具有如SEQ ID NO:2所示的序列的VL。
在某些优选的实施方案中，本发明提供了能够特异性结合CLDN6的抗体或其抗原结合片段，所述抗体或其抗原结合片段包含：
(a)包含下述3个互补决定区(CDR)的重链可变区(VH)：
(i)VH CDR1，其由下述序列组成：SEQ ID NO:3，或与其相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列，
(ii)VH CDR2，其由下述序列组成：SEQ ID NO:33，或与其相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列，和
(iii)VH CDR3，其由下述序列组成：SEQ ID NO:5，或与其相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列；
和/或
(b)包含下述3个互补决定区(CDR)的轻链可变区(VL)：
(iv)VL CDR1，其由下述序列组成：SEQ ID NO:6，或与其相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列，
(v)VL CDR2，其由下述序列组成：SEQ ID NO:7，或与其相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列，和
(vi)VL CDR3，其由下述序列组成：SEQ ID NO:8，或与其相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列。
在某些优选的实施方案中，(i)-(vi)任一项中所述的置换为保守置换。
在某些优选的实施方案中，(i)-(vi)任一项中所述的CDR根据Kabat、IMGT或Chothia编号系统定义。
在某些优选的实施方案中，(i)-(vi)任一项中所述的CDR根据IMGT编号系统定义。
在某些优选的实施方案中，所述抗体或其抗原结合片段，其包含：如下3个重链CDRs：序列为SEQ ID NO：3的VH CDR1，序列为SEQ ID NO：33的VH CDR2，序列为SEQ ID NO：5的VH CDR3；和/或，如下3个轻链CDRs：序列为SEQ ID NO：6的VL CDR1，序列为SEQ ID NO：7的VL CDR2，序列为SEQ ID NO：8的VL CDR3。
在某些优选的实施方案中，所述抗体或其抗原结合片段，其进一步包含来源于人的框架区序列(例如，人免疫球蛋白)。
在某些优选的实施方案中，所述人免疫球蛋选自人重排抗体序列或人胚系抗体序列。
在一个示例性实施方案中，所述抗体或其抗原结合片段包含：
(a)重链可变区(VH)，其包含选自下列的氨基酸序列：
(i)SEQ ID NO:19所示的序列；
(ii)与SEQ ID NO:19所示的序列相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个，3个，4个或5个氨基酸的置换、缺失或添加)的序列；或
(iii)与SEQ ID NO:19所示的序列具有至少80％、至少85％、至少90％、至少91％、至少92％、至少93％、至少94％、至少95％、至少96％、至少97％、至少98％、至少99％、或100％的序列同一性的序列；
和/或，
(b)轻链可变区(VL)，其包含选自下列的氨基酸序列：
(iv)SEQ ID NO:20所示的序列；
(v)与SEQ ID NO:20所示的序列相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个，3个，4个或5个氨基酸的置换、缺失或添加)的序列；或
(vi)与SEQ ID NO:20所示的序列具有至少80％、至少85％、至少90％、至少91％、至少92％、至少93％、至少94％、至少95％、至少96％、至少97％、至少98％、至少99％、或100％的序列同一性的序列。
在某些优选的实施方案中，(ii)或(v)中所述的置换是保守置换。
在某些优选的实施方案中，所述抗体或其抗原结合片段包含：具有如SEQ ID NO:19所示的序列的VH和具有如SEQ ID NO:20所示的序列的VL。
在另一个方面，本发明提供了能够特异性结合CLDN6和/或CLDN9的抗体或其抗原结合片段，所述抗体或其抗原结合片段包含：
(a)包含下述3个互补决定区(CDR)的重链可变区(VH)：
(i)VH CDR1，其由下述序列组成：SEQ ID NO:13，或与其相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列，
(ii)VH CDR2，其由下述序列组成：SEQ ID NO:14或23，或与其相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列，和
(iii)VH CDR3，其由下述序列组成：SEQ ID NO:15，或与其相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列；
和/或
(b)包含下述3个互补决定区(CDR)的轻链可变区(VL)：
(iv)VL CDR1，其由下述序列组成：SEQ ID NO:16或24，或与其相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列，
(v)VL CDR2，其由下述序列组成：SEQ ID NO:17，或与其相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列，和
(vi)VL CDR3，其由下述序列组成：SEQ ID NO:18，或与其相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列。
在某些优选的实施方案中，(i)-(vi)任一项中所述的置换为保守置换。
在某些优选的实施方案中，(i)-(vi)任一项中所述的CDR根据Kabat、IMGT或Chothia编号系统定义。
在某些优选的实施方案中，(i)-(vi)任一项中所述的CDR根据IMGT编号系统定义。
在某些优选的实施方案中，所述抗体或其抗原结合片段，其包含：如下3个重链CDRs：序列为SEQ ID NO：13的VH CDR1，序列为SEQ ID NO：14的VH CDR2，序列为SEQ ID NO：15的VH CDR3；和/或，如下3个轻链CDRs：序列为SEQ ID NO：16的VL CDR1，序列为SEQ ID NO：17的VL CDR2，序列为SEQ ID NO：18的VL CDR3；或者，
所述抗体或其抗原结合片段，其包含：如下3个重链CDRs：序列为SEQ ID NO：13的VH CDR1，序列为SEQ ID NO：23的VH CDR2，序列为SEQ ID NO：15的VH CDR3；和/或，如下3个轻链CDRs：序列为SEQ ID NO：24的VL CDR1，序列为SEQ ID NO：17的VL CDR2，序列为SEQ ID NO：18的VL CDR3。
在某些优选的实施方案中，所述抗体或其抗原结合片段，其进一步包含来源于人的框架区序列(例如，人免疫球蛋白)。
在某些优选的实施方案中，所述人免疫球蛋选自人重排抗体序列或人胚系抗体序列。
在某些优选的实施方案中，本发明提供了能够特异性结合CLDN6和/或CLDN9的抗体或其抗原结合片段，所述抗体或其抗原结合片段包含：
(a)包含下述3个互补决定区(CDR)的重链可变区(VH)：
(i)VH CDR1，其由下述序列组成：SEQ ID NO:13，或与其相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列，
(ii)VH CDR2，其由下述序列组成：SEQ ID NO:14，或与其相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列，和
(iii)VH CDR3，其由下述序列组成：SEQ ID NO:15，或与其相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列；
和/或
(b)包含下述3个互补决定区(CDR)的轻链可变区(VL)：
(iv)VL CDR1，其由下述序列组成：SEQ ID NO:16，或与其相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列，
(v)VL CDR2，其由下述序列组成：SEQ ID NO:17，或与其相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列，和
(vi)VL CDR3，其由下述序列组成：SEQ ID NO:18，或与其相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列。
在某些优选的实施方案中，(i)-(vi)任一项中所述的置换为保守置换。
在某些优选的实施方案中，(i)-(vi)任一项中所述的CDR根据Kabat、IMGT或Chothia编号系统定义。
在某些优选的实施方案中，(i)-(vi)任一项中所述的CDR根据IMGT编号系统定义。
在某些优选的实施方案中，所述抗体或其抗原结合片段，其包含：如下3个重链CDRs：序列为SEQ ID NO：13的VH CDR1，序列为SEQ ID NO：14的VH CDR2，序列为SEQ ID NO：15的VH CDR3；和/或，如下3个轻链CDRs：序列为SEQ ID NO：16的VL CDR1，序列为SEQ ID NO：17的VL CDR2，序列为SEQ ID NO：18的VL CDR3。
在某些优选的实施方案中，所述抗体或其抗原结合片段，其进一步包含来源于人的框架区序列(例如，人免疫球蛋白)。
在某些优选的实施方案中，所述人免疫球蛋选自人重排抗体序列或人胚系抗体序列。
在某些优选的实施方案中，所述抗体或其抗原结合片段具备以下生物学功能中的一项或多项：
(a)以5μg/ml或更小(例如3μg/ml或更小)的EC50结合人CLDN6；
(b)不结合人CLDN3和CLDN4；
(c)通过抗体依赖性细胞介导的细胞毒性(ADCC)来诱导杀伤表达人CLDN6的细胞 (例如肿瘤细胞，如表达CLDN6的肿瘤细胞)；
(d)通过补体依赖的细胞毒性(CDC)来诱导杀伤表达人CLDN6的细胞(例如肿瘤细胞，如表达CLDN6的肿瘤细胞)；
(e)在受试者中预防和/治疗肿瘤(例如，表达CLDN6的肿瘤)。
在一个示例性实施方案中，所述抗体或其抗原结合片段包含：
(a)重链可变区(VH)，其包含选自下列的氨基酸序列：
(i)SEQ ID NO:11所示的序列；
(ii)与SEQ ID NO:11所示的序列相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个，3个，4个或5个氨基酸的置换、缺失或添加)的序列；或
(iii)与SEQ ID NO:11所示的序列具有至少80％、至少85％、至少90％、至少91％、至少92％、至少93％、至少94％、至少95％、至少96％、至少97％、至少98％、至少99％、或100％的序列同一性的序列；
和/或，
(b)轻链可变区(VL)，其包含选自下列的氨基酸序列：
(iv)SEQ ID NO:12所示的序列；
(v)与SEQ ID NO:12所示的序列相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个，3个，4个或5个氨基酸的置换、缺失或添加)的序列；或
(vi)与SEQ ID NO:12所示的序列具有至少80％、至少85％、至少90％、至少91％、至少92％、至少93％、至少94％、至少95％、至少96％、至少97％、至少98％、至少99％、或100％的序列同一性的序列。
在某些优选的实施方案中，(ii)或(v)中所述的置换是保守置换。
在某些优选的实施方案中，所述抗体或其抗原结合片段包含：具有如SEQ ID NO:11所示的序列的VH和具有如SEQ ID NO:12所示的序列的VL。
在某些优选的实施方案中，本发明提供了能够特异性结合CLDN6和/或CLDN9的抗体或其抗原结合片段，所述抗体或其抗原结合片段包含：
(a)包含下述3个互补决定区(CDR)的重链可变区(VH)：
(i)VH CDR1，其由下述序列组成：SEQ ID NO:13，或与其相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列，
(ii)VH CDR2，其由下述序列组成：SEQ ID NO:23，或与其相比具有一个或几个氨 基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列，和
(iii)VH CDR3，其由下述序列组成：SEQ ID NO:15，或与其相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列；
和/或
(b)包含下述3个互补决定区(CDR)的轻链可变区(VL)：
(iv)VL CDR1，其由下述序列组成：SEQ ID NO:24，或与其相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列，
(v)VL CDR2，其由下述序列组成：SEQ ID NO:17，或与其相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列，和
(vi)VL CDR3，其由下述序列组成：SEQ ID NO:18，或与其相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列。
在某些优选的实施方案中，(i)-(vi)任一项中所述的置换为保守置换。
在某些优选的实施方案中，(i)-(vi)任一项中所述的CDR根据Kabat、IMGT或Chothia编号系统定义。
在某些优选的实施方案中，(i)-(vi)任一项中所述的CDR根据IMGT编号系统定义。
在某些优选的实施方案中，所述抗体或其抗原结合片段，其包含：如下3个重链CDRs：序列为SEQ ID NO：13的VH CDR1，序列为SEQ ID NO：23的VH CDR2，序列为SEQ ID NO：15的VH CDR3；和/或，如下3个轻链CDRs：序列为SEQ ID NO：24的VL CDR1，序列为SEQ ID NO：17的VL CDR2，序列为SEQ ID NO：18的VL CDR3。
在某些优选的实施方案中，所述抗体或其抗原结合片段，其进一步包含来源于人的框架区序列(例如，人免疫球蛋白)。
在某些优选的实施方案中，所述人免疫球蛋选自人重排抗体序列或人胚系抗体序列。
在某些优选的实施方案中，所述抗体或其抗原结合片段具备以下生物学功能中的一项或多项：
(a)以5μg/ml或更小(例如3μg/ml或更小)的EC50结合人CLDN6；
(b)不结合人CLDN3和CLDN4；
(c)通过抗体依赖性细胞介导的细胞毒性(ADCC)来诱导杀伤表达人CLDN6的细胞(例如肿瘤细胞，如表达CLDN6的肿瘤细胞)；
(d)通过补体依赖的细胞毒性(CDC)来诱导杀伤表达人CLDN6的细胞(例如肿瘤细胞，如表达CLDN6的肿瘤细胞)；
(e)在受试者中预防和/治疗肿瘤(例如，表达CLDN6的肿瘤)。
在一个示例性实施方案中，所述抗体或其抗原结合片段包含：
(a)重链可变区(VH)，其包含选自下列的氨基酸序列：
(i)SEQ ID NO:9所示的序列；
(ii)与SEQ ID NO:9所示的序列相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个，3个，4个或5个氨基酸的置换、缺失或添加)的序列；或
(iii)与SEQ ID NO:9所示的序列具有至少80％、至少85％、至少90％、至少91％、至少92％、至少93％、至少94％、至少95％、至少96％、至少97％、至少98％、至少99％、或100％的序列同一性的序列；
和/或，
(b)轻链可变区(VL)，其包含选自下列的氨基酸序列：
(iv)SEQ ID NO:10所示的序列；
(v)与SEQ ID NO:10所示的序列相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个，3个，4个或5个氨基酸的置换、缺失或添加)的序列；或
(vi)与SEQ ID NO:10所示的序列具有至少80％、至少85％、至少90％、至少91％、至少92％、至少93％、至少94％、至少95％、至少96％、至少97％、至少98％、至少99％、或100％的序列同一性的序列。
在某些优选的实施方案中，(ii)或(v)中所述的置换是保守置换。
在某些优选的实施方案中，所述抗体或其抗原结合片段包含：具有如SEQ ID NO:9所示的序列的VH和具有如SEQ ID NO:10所示的序列的VL。
在某些优选的实施方案中，所述抗体或其抗原结合片段是人源化的。
在某些优选的实施方案中，所述抗体或其抗原结合片段的VH包含来源于人免疫球蛋白的重链可变区(VH)构架区(FR)，和/或所述抗体或其抗原结合片段的VL包含来源于人免疫球蛋白的轻链可变区(VL)构架区(FR)。在此类实施方案中，所述抗体或其抗原结合片段的重链可变区FR和/或轻链可变区FR可以包含一个或多个非人源(例如，鼠源)氨基酸残基，例如所述重链构架区FR和/或轻链构架区FR可以包含一或多个氨基酸回复突变，在这些回复突变中有相应的鼠源氨基酸残基。
在某些优选的实施方案中，所述抗体或其抗原结合片段进一步包含：
(a)人免疫球蛋白的重链恒定区(CH)或其变体，所述变体与其所源自的野生型序列相比具有一个或多个氨基酸的置换、缺失或添加(例如，至多20个、至多15个、至多10个、或至多5个氨基酸的置换、缺失或添加；例如1个，2个，3个，4个或5个氨基酸的置换、缺失或添加)；和
(b)人免疫球蛋白的轻链恒定区(CL)或其变体，所述变体与其所源自的野生型序列相比具有至多20个氨基酸的保守置换(例如至多15个、至多10个、或至多5个氨基酸的保守置换；例如1个，2个，3个，4个或5个氨基酸的保守置换)。
在某些优选的实施方案中，所述重链恒定区是IgG重链恒定区，例如IgG1、IgG2、IgG3或IgG4重链恒定区。
在某些优选的实施方案中，所述抗体或其抗原结合片段包含SEQ ID NO:21所示的重链恒定区(CH)。
在某些优选的实施方案中，所述轻链恒定区是κ或λ轻链恒定区。
在某些优选的实施方案中，所述抗体或其抗原结合片段包含SEQ ID NO:22所示的轻链恒定区(CL)。
在某些优选的实施方案中，所述抗原结合片段选自Fab、Fab’、(Fab’) 2、Fv、二硫键连接的Fv、scFv、双抗体(diabody)和单域抗体(sdAb)；和/或，所述抗体为鼠源抗体、嵌合抗体、人源化抗体、双特异性抗体或多特异性抗体。
在本发明中，本发明的抗体或其抗原结合片段可以包括这样的变体，所述变体与其所源自的抗体或其抗原结合片段相比差异仅在于一个或多个(例如，至多20个、至多15个、至多10个、或至多5个氨基酸的保守置换)氨基酸残基的保守置换，或者与其所源自的抗体或其抗原结合片段具有至少85％、至少90％、至少95％、至少96％、至少97％、至少98％、至少99％、或100％的序列同一性，且基本保留了其所源自的抗体或其抗原结合片段的上述生物学功能。
抗体的制备
本发明的抗体可以本领域已知的各种方法来制备，例如通过基因工程重组技术来获得。例如，通过化学合成或PCR扩增获得编码本发明抗体的重链和轻链基因的DNA分子。将所得DNA分子插入表达载体内，然后转染宿主细胞。然后，在特定条件下培养转染后的宿主细胞，并表达本发明的抗体。
本发明的抗原结合片段可以通过水解完整的抗体分子获得(参见Morimoto et al.,J.Biochem.Biophys.Methods 24:107-117(1992)and Brennan et al.,Science 229:81(1985))。另外，这些抗原结合片段也可以直接由重组宿主细胞产生(reviewed in Hudson,Curr.Opin.Immunol.11:548-557(1999)；Little et al.,Immunol.Today,21:364-370(2000))。比如，Fab’片段可以直接从宿主细胞中获得；可以将Fab’片段化学偶联形成F(ab’) 2片段(Carter et al.,Bio/Technology,10:163-167(1992))。另外，Fv、Fab或F(ab’) 2片段也可以直接从重组宿主细胞培养液中直接分离得到。本领域的普通技术人员完全知晓制备这些抗原结合片段的其它技术。
因此，在另一个方面，本发明提供了一种分离的核酸分子，其包含编码本发明的抗体或其抗原结合片段，或其重链可变区和/或轻链可变区的核苷酸序列。在某些优选的实施方案中，所述分离的核酸分子编码本发明的抗体或其抗原结合片段，或其重链可变区和/或轻链可变区。
在另一个方面，本发明提供了一种载体(例如克隆载体或表达载体)，其包含本发明的分离的核酸分子。在某些优选的实施方案中，本发明的载体是例如质粒，粘粒，噬菌体等。在某些优选的实施方案中，所述载体能够在受试者(例如哺乳动物，例如人)体内表达本发明的抗体或其抗原结合片段。
在另一个方面，本发明提供了一种宿主细胞，其包含本发明的分离的核酸分子或本发明的载体。此类宿主细胞包括但不限于，原核细胞例如大肠杆菌细胞，以及真核细胞例如酵母细胞，昆虫细胞，植物细胞和动物细胞(如哺乳动物细胞，例如小鼠细胞、人细胞等)。在某些优选的实施方案中，本发明的宿主细胞是哺乳动物细胞，例如CHO(例如CHO-K1、CHO-S、CHO DG44)。
在另一个方面，提供了制备本发明的抗体或其抗原结合片段的方法，其包括，在允许所述抗体或其抗原结合片段表达的条件下，培养本发明的宿主细胞，和从培养的宿主细胞培养物中回收所述抗体或其抗原结合片段。
衍生的抗体
本发明的抗体或其抗原结合片段可进行衍生化，例如被连接至另一个分子(例如另一个多肽或蛋白)。通常，抗体或其抗原结合片段的衍生化(例如，标记)不会不利影响其对CLDN6和/或CLDN9(特别是人CLDN6和/或人CLDN9)的结合。因此，本发明的抗体或其抗原结合片段还意欲包括此类衍生化的形式。例如，可以将本发明的抗体或其抗原 结合片段功能性连接(通过化学偶合、基因融合、非共价连接或其它方式)于一个或多个其它分子基团，例如另一个抗体(例如，形成双特异性抗体)，检测试剂，药用试剂，和/或能够介导抗体或抗原结合片段与另一个分子结合的蛋白或多肽(例如，抗生物素蛋白或多组氨酸标签)。此外，本发明的抗体或其抗原结合片段还可以用化学基团进行衍生，例如聚乙二醇(PEG)，甲基或乙基，或者糖基。这些基团可用于改善抗体的生物学特性，例如增加血清半衰期。
因此，在某些优选的实施方案中，本发明的抗体或其抗原结合片段带有标记。在某些优选的实施方案中，本发明的抗体或其抗原结合片段带有可检测的标记，例如酶、放射性核素、荧光染料、发光物质(如化学发光物质)或生物素。本发明所述的可检测的标记可以是可通过荧光、光谱、光化学、生物化学、免疫学、电学、光学或化学手段检测的任何物质。这类标记是本领域熟知的，其实例包括但不限于，酶(例如，辣根过氧化物酶、碱性磷酸酶、β-半乳糖苷酶、脲酶、葡萄糖氧化酶，等)、放射性核素(例如， 3H、 125I、 35S、 14C或 32P)、荧光染料(例如，异硫氰酸荧光素(FITC)、荧光素、异硫氰酸四甲基罗丹明(TRITC)、藻红蛋白(PE)、德克萨斯红、罗丹明、量子点或花菁染料衍生物(例如Cy7、Alexa 750))、发光物质(例如化学发光物质，如吖啶酯类化合物)、磁珠(例如，
Figure PCTCN2021079380-appb-000001
)、测热标记物例如胶体金或有色玻璃或塑料(例如，聚苯乙烯、聚丙烯、乳胶，等)珠、以及用于结合上述标记物修饰的亲和素(例如，链霉亲和素)的生物素。教导该标记物的使用的专利包括，但不限于，美国专利3,817,837；3,850,752；3,939,350；3,996,345；4,277,437；4,275,149；及4,366,241(全部通过引用并入本文)。如上所述的可检测的标记可通过本领域已知的方法检测。例如，放射性标记可使用摄影胶片或闪烁计算器检测，荧光标记物可使用光检测器检测，以检测发射的光。酶标记物一般通过给酶提供底物及检测通过酶对底物的作用产生的反应产物来检测，及测热标记物通过简单可视化着色标记物来检测。在某些实施方案中，此类标记能够适用于免疫学检测(例如，酶联免疫测定法、放射免疫测定法、荧光免疫测定法、化学发光免疫测定法等)。在某些实施方案中，可通过不同长度的接头(linker)将如上所述的可检测的标记连接至本发明的抗体或其抗原结合片段，以降低潜在的位阻。
双特异性或多特异性分子
本发明的抗体或其抗原结合片段可用于形成双特异性或多特异性分子。本发明的抗体或其抗原结合片段可以是双特异性或多特异性分子的一部分，所述双特异性或多 特异性分子包含具有不同于本发明的抗体或其抗原结合片段的结合特异性的第二功能模块(例如第二抗体)，从而能够结合至少两个不同的结合位点和/或靶分子。例如，本发明的抗体或其抗原结合片段可连接至能够特异性结合可用作联合治疗的潜在靶标的任何蛋白质的第二抗体或其抗原结合片段。为产生所述双特异性或多特异性分子，可以将本发明的抗体或其抗原结合片段连接(例如通过化学偶联、基因融合、非共价缔合或其他方式)至一个或多个其他结合分子(例如另外的抗体、抗体片段、肽或结合模拟物)。
因此，在另一个方面，本发明提供了一种双特异性或多特异性分子，其包含本发明的抗体或其抗原结合片段。
在某些优选的实施方案中，所述双特异性或多特异性分子特异性结合CLDN6，并且额外地特异性结合一个或多个其他靶标。
在某些优选的实施方案中，所述双特异性或多特异性分子还包含至少一种具有针对第二靶标的第二结合特异性的分子(例如第二抗体)。
免疫缀合物
本发明的抗体或其抗原结合片段可以与治疗剂连接以形成免疫缀合物。由于免疫缀合物具有选择性递送一种或多种治疗剂至靶组织(例如与肿瘤相关的抗原，如表达CLDN6和/或CLDN9的肿瘤)的能力，因此，免疫缀合物可以提高本发明的抗体或其抗原结合片段在治疗疾病(例如癌症)中的治疗效力。
因此，在另一个方面，本发明提供了免疫缀合物，其包含本发明的抗体或其抗原结合片段以及连接于所述抗体或其抗原结合片段的治疗剂。
在某些优选的实施方案中，所述免疫缀合物是抗体-药物偶联物(ADC)。
在某些优选的实施方案中，所述治疗剂是细胞毒剂。在本发明中，所述细胞毒剂包括对细胞有害(例如杀伤细胞)的任何试剂。
在某些优选的实施方案中，所述治疗剂选自烷化剂、有丝分裂抑制剂、抗肿瘤抗生素、抗代谢物、拓扑异构酶抑制剂、酪氨酸激酶抑制剂、放射性核素剂，及其任意组合。
可用于本发明的免疫缀合物的烷化剂的实例包括但不限于氮芥类(如双氯乙基甲胺、苯丁酸氮芥、美法仑、环磷酰胺等)、乙烯亚胺类(如塞替哌等)、硫酸酯及多元醇类(如白消安、二溴甘露醇)、亚硝基脲类(如卡莫司汀、洛莫司汀等)、铂类抗肿瘤剂(如顺铂、奥沙利铂、卡铂等)等。
可用于本发明的免疫缀合物的有丝分裂抑制剂的实例包括但不限于美登素类(例如美登素、美登醇、美登醇的C-3酯等)、紫杉烷类(例如多西他赛、紫杉醇或纳米颗粒紫杉醇等)、长春花生物碱类(例如硫酸长春地辛、长春新碱、长春花碱或长春瑞滨等)
可用于本发明的免疫缀合物的抗肿瘤抗生素的实例包括但不限于放线菌素、蒽环类抗生素(例如柔红霉素、阿霉素、表柔比星、伊达比星等)、卡利奇霉素、倍癌霉素等。
可用于本发明的免疫缀合物的抗代谢物的实例包括但不限于叶酸拮抗剂(例如甲氨蝶呤等)、嘧啶拮抗剂(例如5-氟尿嘧啶、氟尿苷、阿糖胞苷、卡培他滨、吉西他滨等)、嘌呤拮抗剂(例如6-巯基嘌呤、6-硫鸟嘌呤等)、腺苷脱氨酶抑制剂(例如克拉屈滨、氟达拉滨、奈拉滨、喷司他丁等)。
可用于本发明的免疫缀合物的拓扑异构酶抑制剂的实例包括但不限于(喜树碱类及其衍生物(例如伊立替康、托泊替康等)、安吖啶、道诺霉素、阿霉素、表鬼臼毒素类、玫瑰树碱类、表柔比星、依托泊苷、丙亚胺、替尼泊苷等。
可用于本发明的免疫缀合物的酪氨酸激酶抑制剂的实例包括但不限于阿西替尼、博舒替尼、西地尼布、达沙替尼、厄洛替尼、吉非替尼、伊马替尼、拉帕替尼、来妥替尼、尼洛替尼、司马沙尼、舒尼替尼、凡德他尼等。
可用于本发明的免疫缀合物的放射性核素剂的实例包括但不限于于I 131、In 111、Y 90、Lu 177等。
在某些实例性实施方案中，所述治疗剂选自铂类抗肿瘤剂、蒽环类抗生素、紫杉烷类化合物、核苷类似物、喜树碱类化合物，及其类似物或同系物，及其任意组合。
在某些优选的实施方案中，本发明的抗体或其抗原结合片段任选地通过接头与所述治疗剂缀合。
在本发明中，使用本领域现有的接头技术可以将细胞毒剂偶联至本发明的抗体或其抗原结合片段。已经用于将细胞毒剂偶联至抗体的接头类型的实例包括但不限于腙、硫醚、酯、二硫化物和含肽的接头。可以选择例如易于在溶酶体隔室内被低pH切割或易于被蛋白酶(例如优先在肿瘤组织中表达的蛋白酶，如组织蛋白酶，诸如组织蛋白酶B、C、D)切割的接头。
关于细胞毒剂的类型、接头及将治疗剂偶联至抗体的方法的进一步讨论还可参见Sai to，G.等人(2003)Adv.Drug Deliv.Rev.55：199-215；Trail，P.A.等人(2003)Cancer I mmunol.Immunother.52：328-337；Payne，G.(2003)Cancer Cell 3：207-212；Allen，T.M.(2002)Nat.Rev.Cancer 2：750-763；Pastan，I.and Kreitman，R.J.(2002)Curr.O  pin.Investig.Drugs 3：1089-1091；Senter，P.D.and Springer，C.J.(2001)Adv.Drug Deliv.Rev.53：247-264。
嵌合抗原受体
本发明的抗体或其抗原结合片段可用于构建嵌合抗原受体(CAR)，所述CAR包含特异性结合CLDN6和/或CLDN9的、与跨膜结构域连接的、与一个或多个细胞内T细胞信号结构域连接的细胞外抗原结合结构域(例如，scFv)。所述细胞内T细胞信号结构域可包括，例如T细胞受体信号结构域、T细胞共刺激信号结构域或其组合。T细胞受体信号结构域是指CAR中包含T细胞受体的细胞内结构域(例如CD3ζ蛋白的细胞内部分)的部分。共刺激信号结构域是指CAR中包含共刺激分子的细胞内结构域的部分，所述共刺激分子是除了淋巴细胞对抗原的高效应答所需的抗原受体或其配体以外的细胞表面分子。
本发明的CAR的特征包括其以非MHC限制的方式将T-细胞特异性和反应性指向表达CLDN6和/或CLDN9的细胞(例如肿瘤细胞)的能力。非MHC限制的CLDN6和/或CLDN9识别能力赋予表达本发明的CAR的T细胞独立于抗原加工而识别抗原的能力。
因此，在另一个方面，本发明提供了一种嵌合抗原受体(CAR)，其包含本发明的抗体或其抗原结合片段的抗原结合结构域。
在某些优选的实施方案中，所述抗原结合结构域包含本发明的抗体或其抗原结合片段的重链可变区和轻链可变区。
在某些优选的实施方案中，所述抗原结合结构域是scFv。
在某些优选的实施方案中，所述抗原结合受体包含本发明抗体的抗原结合片段(例如scFv)。
在某些优选的实施方案中，所述抗原结合受体由免疫效应细胞(例如T细胞)所表达。
在某些优选的实施方案中，在所述CAR的抗原结合结构域与跨膜结构域之间，可存在包含多肽序列的间隔结构域。所述间隔结构域可包含多达300个氨基酸，优选10至100个氨基酸，并且最优选25至50个氨基酸。在一些实施方案中，所述间隔结构域可包含免疫球蛋白结构域，例如人免疫球蛋白序列。在某些示例性实施方案中，所述免疫球蛋白结构域包含免疫球蛋白CH2和CH3结构域序列。在此类实施方案中，不受特定理论的约束，认为CH2和CH3结构域使所述CAR的抗原结合结构域从表达CAR的细胞的膜延伸出去，并且可更精确地模拟天然TCR的大小和结构域结构。
在某些优选的实施方案中，所述跨膜结构域可衍生自天然来源或合成来源。在此类实施方案中，所述结构域可衍生自任何膜结合的或跨膜的蛋白质。可用于本发明的CAR中的示例性跨膜结构域可包含至少T细胞受体的α、β或ζ链的跨膜区，所述T细胞受体可以选自CD28、CD3ε、CD45、CD4、CD5、CDS、CD9、CD16、CD22、CD33、CD37、CD64、CD80、CD86、CD134、CD137、CD154。或者，所述跨膜结构域可为合成的，在这种情况下，其将主要包含疏水残基例如亮氨酸和缬氨酸。
在某些示例性实施方案中，所述跨膜结构域包含T细胞受体的跨膜结构域，例如CD8跨膜结构域。
在某些示例性实施方案中，所述跨膜结构域包含T细胞共刺激分子(例如CD137或CD28)的跨膜结构域。
在某些优选的实施方案中，可用于在所述CAR中使用的细胞内T细胞结构域的实例包括T细胞受体(TCR)的胞质序列和共刺激分子，所述T细胞受体(TCR)的胞质序列和共刺激分子在抗原受体接合后协力启动信号转导，以及这些序列和任何具有相同功能性能力的合成序列的任何衍生物或变体。
在某些优选的实施方案中，所述CAR的细胞内区可包含以刺激的方式起作用的初级胞质信号序列，其可包含被称为基于免疫受体酪氨酸的活化基序或ITAM的信号基序。可包含于所述CAR中的包含初级胞质信号序列的ITAM的实例包括来自CD3ζ、FcRγ、FcRβ、CD3γ、CD3δ、CD3ε、CDS、CD22、CD79a、CD79b、和CD66d蛋白的那些。
在某些优选的实施方案中，所述CAR的细胞内区可包含含有初级胞质信号结构域(例如CD3ζ)本身或与可用于CAR的环境中的任何其他期望的胞质结构域组合的ITAM。例如，所述CAR的胞质结构域包含CD3ζ链部分和细胞内共刺激信号结构域。所述共刺激信号结构域是指所述CAR的包含共刺激分子的细胞内结构域的部分。共刺激分子是除了淋巴细胞对抗原的高效应答所需的抗原受体或其配体以外的细胞表面分子。这样的分子的实例包括CD27、CD28、4-1BB(CD137)、OX40(CD134)、CD30、CD40、PD-1、ICOS、淋巴细胞功能相关抗原1(LFA-1)、CD2、CD7、LIGHT、NKG2C和B7-H3。
在某些优选的实施方案中，所述CAR可包含CD3ζ信号结构域、CD8信号结构域、CD28信号结构域、CD137信号结构域或其任意组合。所述一个或多个T细胞信号结构域在CAR上的顺序可由本领域技术人员根据需要而改变。
生成嵌合抗原受体、包含这样的受体的T细胞的方法以及它们的用途(例如，用于治 疗癌症)是本领域已知的，其详细描述可参见，例如，Brentjens等人,2010,Molecular Therapy,18:4,666-668；Morgan等人,2010,Molecular Therapy,published online February 23,2010,第1-9页；Till等人,2008,Blood,112:2261-2271；Park等人,Trends Biotechnol.,29:550-557,2011；Grupp等人,NEnglJMed.,368:1509-1518,2013；Han等人,J.Hematol Oncol.,6:47,2013；PCT专利公开文本WO2012/079000、WO2013/126726；和U.S.专利公开文本2012/0213783，其全部通过引用整体并入本文)。例如，可将编码本发明的嵌合抗原结合受体的核酸分子包含于用于在宿主细胞例如T细胞中表达的表达载体(例如，慢病毒载体)中，以制造所述CAR。在某些实例性实施方案中，使用所述嵌合抗原受体的方法包括从受试者分离T细胞，采用编码嵌合抗原受体的表达载体(例如慢病毒载体)转化T细胞，以及将表达所述嵌合抗原受体的工程化的T细胞施用至所述受试者以进行治疗，例如用于治疗所述受试者中的肿瘤。
因此，在另一个方面，本发明提供了一种分离的核酸分子，其包含编码本发明的嵌合抗原受体的核苷酸序列。在某些优选的实施方案中，所述分离的核酸分子编码本发明的嵌合抗原受体。
在另一个方面，本发明提供了一种载体(例如克隆载体或表达载体)，其包含如上所述的分离的核酸分子。在某些优选的实施方案中，本发明的载体例如是质粒。
在另一个方面，本发明提供了一种宿主细胞，其包含如上所述的分离的核酸分子或载体。在某些优选的实施方案中，所述宿主细胞是T细胞。在某些优选的实施方案中，所述宿主细胞是嵌合抗原受体T细胞(CAR-T)。
治疗方法和药物组合物
本发明的抗体或其抗原结合片段可通过结合CLDN6和/或CLDN9诱导ADCC和/或CDC从而杀伤细胞，从而能够用于预防和/或治疗肿瘤。
因此，在另一个方面，本发明提供了一种药物组合物，其含有本发明的抗体或其抗原结合片段、双特异性或多特异性分子、或免疫缀合物，以及药学上可接受的载体和/或赋形剂。
在某些优选的实施方案中，所述药物组合物还可以包含另外的药学活性剂。
在某些优选的实施方案中，所述另外的药学活性剂是具有抗肿瘤活性的药物，例如烷化剂、有丝分裂抑制剂、抗肿瘤抗生素、抗代谢物、拓扑异构酶抑制剂、酪氨酸激酶抑制剂、放射性核素剂、放射增敏剂(例如吉西他滨、5-氟尿嘧啶、紫杉烷、顺铂等)、 抗血管生成剂、细胞因子(例如GM-CSF、IL-7、IL-12、IL-15、IL-18、IL-21等)、分子靶向药物(例如，CD20抗体如利妥昔单抗、Her2抗体如曲妥珠单抗、VEGF抗体如贝伐珠单抗、EGFR抗体如西妥昔单抗等)、免疫检查点抑制剂(例如，PD-1抗体、PD-L1抗体、CTLA-4抗体、LAG-3抗体等)、溶瘤病毒等。
在某些优选的实施方案中，在所述药物组合物中，本发明的抗体或其抗原结合片段、双特异性或多特异性分子、或免疫缀合物与所述另外的药学活性剂作为分离的组分或作为同一组合物的组分提供。因此，本发明的抗体或其抗原结合片段、双特异性或多特异性分子、或免疫缀合物与所述另外的药学活性剂可以同时、分开或相继施用。
在某些示例性实施方案中，所述药物组合物包含无菌可注射液体(如水性或非水性悬浮液或溶液)。在某些示例性实施方案中，此类无菌可注射液体选自注射用水(WFI)、抑菌性注射用水(BWFI)、氯化钠溶液(例如0.9％(w/v)NaCl)、葡萄糖溶液(例如5％葡萄糖)、含有表面活性剂的溶液(例如0.01％聚山梨醇20)、pH缓冲溶液(例如磷酸盐缓冲溶液)、Ringer氏溶液及其任意组合。
在另一个方面，本发明提供了一种降低CLDN6和/或CLDN9在细胞表面的表达水平的方法，其包括将所述细胞与本发明的抗体或其抗原结合片段、双特异性或多特异性分子、免疫缀合物、或药物组合物接触，使得CLDN6和/或CLDN9在所述细胞表面的表达水平降低；其中，所述细胞在其表面表达CLDN6和/或CLDN9。
在某些优选的实施方案中，所述细胞是表达CLDN6和/或CLDN9的肿瘤细胞。
在某些优选的实施方案中，所述方法用于在体外降低CLDN6和/或CLDN9在细胞表面的表达水平用于非诊断目的。
在另一个方面，提供了本发明的抗体或其抗原结合片段、双特异性或多特异性分子、免疫缀合物、或药物组合物在制备药物中的用途，所述药物用于降低CLDN6和/或CLDN9在细胞表面的表达水平。
在另一个方面，提供了本发明的抗体或其抗原结合片段、双特异性或多特异性分子、免疫缀合物、或药物组合物，其用于降低CLDN6和/或CLDN9在细胞表面的表达水平。
在另一个方面，本发明提供了一种抑制表达CLDN6和/或CLDN9的肿瘤细胞生长和/或杀伤所述肿瘤细胞的方法，其包括将所述肿瘤细胞与有效量的本发明的抗体或其抗原结合片段、双特异性或多特异性分子、免疫缀合物、药物组合物、嵌合抗原受体或表达 所述嵌合抗原受体的宿主细胞(例如嵌合抗原受体T细胞(CAR-T))接触。
所述方法可以用于治疗目的，或者非治疗目的。在某些优选的实施方案中，所述方法可以用于非治疗目的，所述方法用于在体外抑制表达CLDN6和/或CLDN9的肿瘤细胞生长和/或杀伤所述肿瘤细胞。
在另一个方面，提供了本发明的抗体或其抗原结合片段、双特异性或多特异性分子、免疫缀合物、药物组合物、嵌合抗原受体或表达所述嵌合抗原受体的宿主细胞(例如嵌合抗原受体T细胞(CAR-T))在制备药物中的用途，所述药物用于抑制表达CLDN6和/或CLDN9的肿瘤细胞生长和/或杀伤所述肿瘤细胞。
在另一个方面，提供了本发明的抗体或其抗原结合片段、双特异性或多特异性分子、免疫缀合物、药物组合物、嵌合抗原受体或表达所述嵌合抗原受体的宿主细胞(例如嵌合抗原受体T细胞(CAR-T))，其用于抑制表达CLDN6和/或CLDN9的肿瘤细胞生长和/或杀伤所述肿瘤细胞。
在另一个方面，本发明提供了一种用于在受试者(例如人)中预防和/或治疗肿瘤的方法，所述方法包括向有此需要的受试者施用有效量的本发明的抗体或其抗原结合片段、双特异性或多特异性分子、免疫缀合物、药物组合物、嵌合抗原受体或表达所述嵌合抗原受体的宿主细胞(例如嵌合抗原受体T细胞(CAR-T))。
在某些优选的实施方案中，所述肿瘤涉及表达CLDN6和/或CLDN9的肿瘤细胞。在某些优选的实施方案中，所述CLDN6和/或CLDN9在所述肿瘤细胞表面上表达。
在某些优选的实施方案中，所述肿瘤表达CLDN6和/或CLDN9。
在某些优选的实施方案中，所述肿瘤选自卵巢癌、睾丸癌、胃癌、子宫内膜癌、肺癌、食管癌、胰腺癌、支气管癌、乳腺癌、耳鼻喉(ENT)癌、结肠癌、肝癌、头颈癌、胆囊癌及其转移癌(例如，胃癌转移，如Krukenberg瘤、腹膜转移或淋巴结转移)。
在某些优选的实施方案中，将本发明的抗体或其抗原结合片段、双特异性或多特异性分子、免疫缀合物、药物组合物、嵌合抗原受体或表达所述嵌合抗原受体的宿主细胞(例如嵌合抗原受体T细胞(CAR-T))与另外的具有抗肿瘤活性的药物联合使用。这种另外的具有抗肿瘤活性的药物可以在施用所述抗体或其抗原结合片段、双特异性或多特异性分子、免疫缀合物、药物组合物、嵌合抗原受体或表达所述嵌合抗原受体的宿主细胞(例如CAR-T)之前、同时或之后施用。
在某些优选的实施方案中，将本发明的抗体或其抗原结合片段、双特异性或多特异 性分子、免疫缀合物、药物组合物、嵌合抗原受体或表达所述嵌合抗原受体的宿主细胞(例如CAR-T)与额外的疗法组合施用。这种额外的疗法可以是已知用于肿瘤的任何疗法，例如手术、化学治疗、放射治疗、靶向治疗、免疫治疗、激素治疗、基因治疗或姑息治疗。这种额外的疗法可以在施用本发明的抗体或其抗原结合片段、双特异性或多特异性分子、免疫缀合物、药物组合物、嵌合抗原受体或表达所述嵌合抗原受体的宿主细胞(例如CAR-T)之前、同时或之后施用。
本发明的抗体或其抗原结合片段、双特异性或多特异性分子、免疫缀合物、药物组合物、嵌合抗原受体或表达所述嵌合抗原受体的宿主细胞(例如T细胞)可以配制成医学领域已知的任何剂型，例如，片剂、丸剂、混悬剂、乳剂、溶液、凝胶剂、胶囊剂、粉剂、颗粒剂、酏剂、锭剂、栓剂、注射剂(包括注射液、注射用无菌粉末与注射用浓溶液)、吸入剂、喷雾剂等。优选剂型取决于预期的给药方式和治疗用途。本发明的药物组合物应当是无菌的并在生产和储存条件下稳定。一种优选的剂型是注射剂。此类注射剂可以是无菌注射溶液。例如，可通过下述方法来制备无菌注射溶液：在适当的溶剂中掺入必需剂量的本发明的抗体，以及任选地，同时掺入其他期望的成分(包括但不限于，pH调节剂，表面活性剂，佐剂，离子强度增强剂，等渗剂、防腐剂、稀释剂，或其任何组合)，随后过滤除菌。此外，可以将无菌注射溶液制备为无菌冻干粉剂(例如，通过真空干燥或冷冻干燥)以便于储存和使用。此类无菌冻干粉剂可在使用前分散于合适的载体中，例如注射用水(WFI)、抑菌性注射用水(BWFI)、氯化钠溶液(例如0.9％(w/v)NaCl)、葡萄糖溶液(例如5％葡萄糖)、含有表面活性剂的溶液(例如0.01％聚山梨醇20)、pH缓冲溶液(例如磷酸盐缓冲溶液)、Ringer氏溶液及其任意组合。
此外，本发明的抗体或其抗原结合片段、双特异性或多特异性分子、免疫缀合物、药物组合物、嵌合抗原受体或表达所述嵌合抗原受体的宿主细胞(例如T细胞)可以以单位剂量形式存在于药物组合物中，以便于施用。
本发明的抗体或其抗原结合片段、双特异性或多特异性分子、免疫缀合物、药物组合物、嵌合抗原受体或表达所述嵌合抗原受体的宿主细胞(例如T细胞)可以通过本领域已知的任何合适的方法来施用，包括但不限于，口服、口腔、舌下、眼球、局部、肠胃外、直肠、叶鞘内、内胞浆网槽内、腹股沟、膀胱内、局部(如，粉剂、药膏或滴剂)，或鼻腔途径。但是，对于许多治疗用途而言，优选的给药途径/方式是胃肠外给药(例如静脉注射或推注，皮下注射，腹膜内注射，肌内注射)。技术人员应理解，给药途径和/ 或方式将根据预期目的而发生变化。在一个优选的实施方案中，本发明的抗体或其抗原结合片段、双特异性或多特异性分子、免疫缀合物、药物组合物、嵌合抗原受体或表达所述嵌合抗原受体的宿主细胞(例如T细胞)通过静脉注射或推注给予。
本发明的药物组合物可以包括“治疗有效量”或“预防有效量”的本发明的抗体或其抗原结合片段、双特异性或多特异性分子、免疫缀合物、药物组合物、嵌合抗原受体或表达所述嵌合抗原受体的宿主细胞(例如T细胞)。“预防有效量”是指，足以预防，阻止，或延迟疾病的发生的量。“治疗有效量”是指，足以治愈或至少部分阻止已患有疾病的患者的疾病和其并发症的量。本发明的抗体或其抗原结合片段的治疗有效量可根据如下因素发生变化：待治疗的疾病的严重度、患者自己的免疫系统的总体状态、患者的一般情况例如年龄，体重和性别，药物的施用方式，以及同时施用的其他治疗等等。
在本发明中，可调整给药方案以获得最佳目的反应(例如治疗或预防反应)。例如，可以单次给药，可以在一段时间内多次给药，或者可以随治疗情况的紧急程度按比例减少或增加剂量。
在本发明中，所述受试者可以为哺乳动物，例如人。
检测方法和试剂盒
本发明的抗体或其抗原结合片段能够特异性结合CLDN6和/或CLDN9，从而可用于检测CLDN6和/或CLDN9在样品中的存在或其水平。
因此，在另一个方面，本发明提供了一种试剂盒，其包括本发明的抗体或其抗原结合片段。在某些优选的实施方案中，本发明的抗体或其抗原结合片段带有可检测的标记。在一个优选的实施方案中，所述试剂盒还包括第二抗体，其特异性识别本发明的抗体或其抗原结合片段。优选地，所述第二抗体还包括可检测的标记。
在本发明中，所述可检测的标记可以是可通过荧光、光谱、光化学、生物化学、免疫学、电学、光学或化学手段检测的任何物质。特别优选的是，此类标记能够适用于免疫学检测(例如，酶联免疫测定法、放射免疫测定法、荧光免疫测定法、化学发光免疫测定法等)。这类标记是本领域熟知的，包括但不限于，酶(例如，辣根过氧化物酶、碱性磷酸酶、β-半乳糖苷酶、脲酶、葡萄糖氧化酶，等)、放射性核素(例如， 3H、 125I、 35S、 14C或 32P)、荧光染料(例如，异硫氰酸荧光素(FITC)、荧光素、异硫氰酸四甲基罗丹明(TRITC)、藻红蛋白(PE)、德克萨斯红、罗丹明、量子点或花菁染料衍生物(例如Cy7、Alexa 750))、发光物质(例如化学发光物质，如吖啶酯类化合物)、磁珠(例如，
Figure PCTCN2021079380-appb-000002
)、测热标记物例如胶体金或有色玻璃或塑料(例如，聚苯乙烯、聚丙烯、乳胶，等)珠、以及用于结合上述标记物修饰的亲和素(例如，链霉亲和素)的生物素。教导该标记物的使用的专利包括，但不限于，美国专利3,817,837；3,850,752；3,939,350；3,996,345；4,277,437；4,275,149；及4,366,241(全部通过引用并入本文)。本发明中涵盖的标记物可通过本领域已知的方法检测。例如，放射性标记可使用摄影胶片或闪烁计算器检测，荧光标记物可使用光检测器检测，以检测发射的光。酶标记物一般通过给酶提供底物及检测通过酶对底物的作用产生的反应产物来检测，及测热标记物通过简单可视化着色标记物来检测。在某些实施方案中，可通过不同长度的接头将如上所述的可检测的标记连接至本发明的抗体或其抗原结合片段，以降低潜在的位阻。
在另一个方面，本发明提供了检测CLDN6和/或CLDN9在样品中的存在或其量的方法，其包括以下步骤：
(1)将所述样品与本发明的抗体或其抗原结合片段接触；
(2)检测所述抗体或其抗原结合片段与CLDN6和/或CLDN9之间复合物的形成或检测所述复合物的量。
所述复合物的形成表明存在CLDN6和/或CLDN9或表达CLDN6和/或CLDN9的细胞。
在某些优选的实施方案中，所述样品是细胞样品，即包含细胞(例如肿瘤细胞)的样品。在此类实施方案中，优选地，所述复合物是由所述抗体、抗原结合片段或缀合物与所述样品中的细胞所表达的CLDN6和/或CLDN9之间形成的。
在一个优选的实施方案中，本发明的抗体或其抗原结合片段还带有可检测的标记。在另一个优选的实施方案中，在步骤(2)中，使用带有可检测的标记的试剂来检测本发明的抗体或其抗原结合片段。
所述方法可以用于诊断目的，或者非诊断目的(例如，所述样品是细胞样品，而非来自患者的样品)。在某些优选的实施方案中，所述CLDN6和/或CLDN9是人CLDN6和/或CLDN9。
在另一个方面，提供了本发明的抗体或其抗原结合片段在制备试剂盒中的用途，所述试剂盒用于检测CLDN6和/或CLDN9在样品中的存在或其量。在某些优选的实施方案中，所述CLDN6和/或CLDN9是人CLDN6和/或CLDN9。
在另一个方面，本发明提供了一种用于检测肿瘤是否能够通过靶向CLDN6和/或 CLDN9的抗肿瘤疗法来治疗的方法，其包括以下步骤：
(1)将含有所述肿瘤细胞的样品与本发明的抗体或其抗原结合片段接触；
(2)检测所述抗体或其抗原结合片段与CLDN6和/或CLDN9之间复合物的形成。
在某些优选的实施方案中，所述复合物是所述抗体或其抗原结合片段与所述样品中的肿瘤细胞所表达的CLDN6和/或CLDN9之间形成的。
在某些优选的实施方案中，所述样品来自受试者，所述受试者患有肿瘤、怀疑患有肿瘤或具有患有肿瘤风险。在某些优选的实施方案中，所述样品来自在组织或器官未患癌症时其中的细胞基本不表达CLDN6和/或CLDN9的组织或器官。在某些优选的实施方案中，所述组织选自胃组织、肺组织、食管组织、胰腺组织或乳腺组织，并且所述组织任选地已被诊断为被癌症影响，例如通过对所述组织或器官的细胞进行目视检查或培养测试被诊断。在某些优选的实施方案中，，所述组织是除胃组织以外的组织。在某些优选的实施方案中，，所述组织是肺组织、食管组织、胰腺组织或乳腺组织。在此类实施方案中，当存在CLDN6和/或CLDN9或表达CLDN6和/或CLDN9的细胞，和/或与参照水平相比(例如与无肿瘤疾病的患者相比)，CLDN6和/或CLDN9或表达CLDN6和/或CLDN9的细胞的量增加时，表明所述受试者适于靶向CLDN6和/或CLDN9的抗肿瘤疗法。
在一个优选的实施方案中，本发明的抗体或其抗原结合片段还带有可检测的标记。在另一个优选的实施方案中，在步骤(2)中，使用带有可检测的标记的试剂来检测本发明的抗体或其抗原结合片段。
在某些优选的实施方案中，所述CLDN6和/或CLDN9是人CLDN6和/或CLDN9。
在某些优选的实施方案中，所述肿瘤选自卵巢癌、睾丸癌、胃癌、子宫内膜癌、肺癌、食管癌、胰腺癌、支气管癌、乳腺癌、耳鼻喉(ENT)癌、结肠癌、肝癌、头颈癌、胆囊癌及其转移癌(例如，胃癌转移，如Krukenberg瘤、腹膜转移或淋巴结转移)。
在另一个方面，提供了本发明的抗体或其抗原结合片段在制备试剂盒中的用途，所述试剂盒用于检测肿瘤是否能够通过靶向CLDN6和/或CLDN9的抗肿瘤疗法来治疗。
在某些优选的实施方案中，所述抗体或其抗原结合片段带有可检测的标记。
在某些优选的实施方案中，所述CLDN6和/或CLDN9是人CLDN6和/或CLDN9。
在某些优选的实施方案中，所述肿瘤选自卵巢癌、睾丸癌、胃癌、子宫内膜癌、肺癌、食管癌、胰腺癌、支气管癌、乳腺癌、耳鼻喉(ENT)癌、结肠癌、肝癌、头颈癌、胆囊癌及其转移癌(例如，胃癌转移，如Krukenberg瘤、腹膜转移或淋巴结转移)。
术语定义
在本发明中，除非另有说明，否则本文中使用的科学和技术名词具有本领域技术人员所通常理解的含义。并且，本文中所用的细胞培养、生物化学、核酸化学、免疫学实验室等操作步骤均为相应领域内广泛使用的常规步骤。同时，为了更好地理解本发明，下面提供相关术语的定义和解释。
如本文中所使用的，术语“CLDN6(Claudin 6，紧密连接蛋白6)”具有本领域技术人员通常理解的含义，其属于密蛋白(Claudin)家族，是上皮与内皮的紧密连接内的跨膜蛋白,可能参与细胞自噬。CLDN6的序列均是本领域公知的，可参见NCBI数据库登录号P56747。如本文中所使用的，术语“CLDN9(Claudin 9，紧密连接蛋白9)”具有本领域技术人员通常理解的含义，其属于密蛋白(Claudin)家族，是上皮与内皮的紧密连接内的跨膜蛋白。CLDN9的序列均是本领域公知的，可参见NCBI数据库登录号O95484。
如本文中所使用的，术语“抗体”是指，通常由两对多肽链(每对具有一条轻链(LC)和一条重链(HC))组成的免疫球蛋白分子。抗体轻链可分类为κ(kappa)和λ(lambda)轻链。重链可分类为μ、δ、γ、α或ε，并且分别将抗体的同种型定义为IgM、IgD、IgG、IgA和IgE。在轻链和重链内，可变区和恒定区通过大约12或更多个氨基酸的“J”区连接，重链还包含大约3个或更多个氨基酸的“D”区。各重链由重链可变区(VH)和重链恒定区(CH)组成。重链恒定区由3个结构域(CH1、CH2和CH3)组成。各轻链由轻链可变区(VL)和轻链恒定区(CL)组成。轻链恒定区由一个结构域CL组成。恒定结构域不直接参与抗体与抗原的结合，但展现出多种效应子功能，如可介导免疫球蛋白与宿主组织或因子，包括免疫系统的各种细胞(例如，效应细胞)和经典补体系统的第一组分(C1q)的结合。VH和VL区还可被细分为具有高变性的区域(称为互补决定区(CDR))，其间散布有较保守的称为构架区(FR)的区域。各V H和V L由按下列顺序：FR1、CDR1、FR2、CDR2、FR3、CDR3、FR4从氨基末端至羧基末端排列的3个CDR和4个FR组成。各重链/轻链对的可变区(VH和VL)分别形成抗原结合部位。氨基酸在各区域或结构域的分配可遵循Kabat,Sequences of Proteins of Immunological Interest(National Institutes of Health,Bethesda,Md.(1987and 1991))，或Chothia&Lesk(1987)J.Mol.Biol.196:901-917；Chothia等人(1989)Nature 342:878-883的定义。
如本文中所使用的，术语“互补决定区”或“CDR”是指抗体可变区中负责抗原结合的氨基酸残基。在重链和轻链的可变区中各含有三个CDR，命名为CDR1、CDR2和CDR3。这些CDR的精确边界可根据本领域已知的各种编号系统进行定义，例如可按照Kabat编号系统(Kabat et al.,Sequences of Proteins of Immunological Interest,5th Ed.Public Health Service,National Institutes of Health,Bethesda,Md.,1991)、Chothia编号系统(Chothia&Lesk(1987)J.Mol.Biol.196:901-917；Chothia等人(1989)Nature 342:878-883)或IMGT编号系统(Lefranc et al.,Dev.Comparat.Immunol.27:55-77,2003)中的定义。对于给定的抗体，本领域技术人员将容易地鉴别各编号系统所定义的CDR。并且，不同编号系统之间的对应关系是本领域技术人员熟知的(例如，可参见Lefranc et al.,Dev.Comparat.Immunol.27:55-77,2003)。
在本发明中，本发明的抗体或其抗原结合片段含有的CDR可根据本领域已知的各种编号系统确定。在某些实施方案中，本发明的抗体或其抗原结合片段含有的CDR优选地通过Kabat、Chothia或IMGT编号系统确定。在某些实施方案中，本发明的抗体或其抗原结合片段含有的CDR优选地通过IMGT编号系统确定。
如本文中所使用的，术语“构架区(framework region)”或“FR”残基是指，抗体可变区中除了如上定义的CDR残基以外的那些氨基酸残基。
术语“抗体”不受任何特定的产生抗体的方法限制。例如，其包括，重组抗体、单克隆抗体和多克隆抗体。抗体可以是不同同种型的抗体，例如，IgG(例如，IgG1，IgG2，IgG3或IgG4亚型)，IgA1，IgA2，IgD，IgE或IgM抗体。
如本文中所使用的，术语抗体的“抗原结合片段”是指包含全长抗体的片段的多肽，其保持特异性结合全长抗体所结合的相同抗原的能力，和/或与全长抗体竞争对抗原的特异性结合，其也被称为“抗原结合部分”。通常参见，Fundamental Immunology,Ch.7(Paul,W.,ed.,第2版，Raven Press,N.Y.(1989)，其以其全文通过引用合并入本文，用于所有目的。可通过重组DNA技术或通过完整抗体的酶促或化学断裂产生抗体的抗原结合片段。抗原结合片段的非限制性实例包括Fab、Fab’、F(ab’) 2、Fd、Fv、互补决定区(CDR)片段、scFv、双抗体(diabody)、单域抗体(single domain antibody)、嵌合抗体、线性抗体(linear antibody)、纳米抗体(技术来自Domantis)、、probody和这样的多肽，其包含足以赋予多肽特异性抗原结合能力的抗 体的至少一部分。工程改造的抗体变体综述于Holliger等,2005；Nat Biotechnol,23:1126-1136中。
如本文中所使用的，术语“全长抗体”意指，由两条“全长重链”和两条“全长轻链”组成的抗体。其中，“全长重链”是指这样的多肽链，其在N端到C端的方向上由重链可变区(VH)、重链恒定区CH1结构域、铰链区(HR)、重链恒定区CH2结构域、重链恒定区CH3结构域组成；并且，当所述全长抗体为IgE同种型时，任选地还包括重链恒定区CH4结构域。优选地，“全长重链”是在N端到C端方向上由VH、CH1、HR、CH2和CH3组成的多肽链。“全长轻链”是在N端到C端方向上由轻链可变区(VL)和轻链恒定区(CL)组成的多肽链。两对全长抗体链通过在CL和CH1之间的二硫键和两条全长重链的HR之间的二硫键连接在一起。本发明的全长抗体可以来自单一物种，例如人；也可以是嵌合抗体或人源化抗体。本发明的全长抗体包含分别由VH和VL对形成的两个抗原结合部位，这两个抗原结合部位特异性识别/结合相同的抗原。
如本文中所使用的，术语“Fd”意指由VH和CH1结构域组成的抗体片段；术语“dAb片段”意指由VH结构域组成的抗体片段(Ward等人,Nature 341:544 546(1989))；术语“Fab片段”意指由VL、VH、CL和CH1结构域组成的抗体片段；术语“F(ab’) 2片段”意指包含通过铰链区上的二硫桥连接的两个Fab片段的抗体片段；术语“Fab’片段”意指还原连接F(ab’) 2片段中两个重链片段的二硫键后所获片段，由一条完整的轻链和重链的Fd片段(由VH和CH1结构域组成)组成。
如本文中所使用的，术语“Fv”意指由抗体的单臂的VL和VH结构域组成的抗体片段。Fv片段通常被认为是，能形成完整的抗原结合位点的最小抗体片段。一般认为，六个CDR赋予抗体的抗原结合特异性。然而，即便是一个可变区(例如Fd片段，其仅仅含有三个对抗原特异的CDR)也能够识别并结合抗原，尽管其亲和力可能低于完整的结合位点。
如本文中所使用的，术语“Fc”意指，由抗体的第一重链的第二、第三恒定区与第二重链的第二、第三恒定区经二硫键结合而形成的抗体片段。抗体的Fc片段具有多种不同的功能，但不参与抗原的结合。
如本文中所使用的，术语“scFv”是指，包含VL和VH结构域的单个多肽链，其中所述VL和VH通过接头(linker)相连(参见，例如,Bird等人,Science 242:423-426(1988)；Huston等人,Proc.Natl.Acad.Sci.USA 85:5879-5883(1988)；和Pluckthun，The Pharmacology of Monoclonal Antibodies，第113卷， Roseburg和Moore编，Springer-Verlag，纽约，第269-315页(1994))。此类scFv分子可具有一般结构：NH 2-VL-接头-VH-COOH或NH 2-VH-接头-VL-COOH。合适的现有技术接头由重复的GGGGS氨基酸序列或其变体组成。例如，可使用具有氨基酸序列(GGGGS) 4的接头，但也可使用其变体(Holliger等人(1993)，Proc.Natl.Acad.Sci.USA 90:6444-6448)。可用于本发明的其他接头由Alfthan等人(1995)，Protein Eng.8:725-731，Choi等人(2001)，Eur.J.Immunol.31:94-106，Hu等人(1996)，Cancer Res.56:3055-3061，Kipriyanov等人(1999)，J.Mol.Biol.293:41-56和Roovers等人(2001)，Cancer Immunol.描述。在一些情况下，scFv的VH与VL之间还可以存在二硫键。
如本文中所使用的，术语“双抗体”意指，其VH和VL结构域在单个多肽链上表达，但使用太短的连接体以致不允许在相同链的两个结构域之间配对，从而迫使结构域与另一条链的互补结构域配对并且产生两个抗原结合部位(参见，例如,Holliger P.等人,Proc.Natl.Acad.Sci.USA 90:6444-6448(1993)，和Poljak R.J.等人,Structure 2:1121-1123(1994))。
如本文中所使用的，术语“单域抗体(single-domain antibody,sdAb)”具有本领域技术人员通常理解的含义，其是指由单个单体可变抗体结构域(例如单个重链可变区)所组成的抗体片段，其保持特异性结合全长抗体所结合的相同抗原的能力。单域抗体也称为纳米抗体(nanobody)。
如本文中所使用的，术语“probody”具有本领域技术人员通常理解的含义，其是指一种经掩蔽的抗体，其在健康组织中保持惰性，但在疾病环境中特异性活化(例如，经由疾病环境中富集或特有的蛋白酶的蛋白酶裂解)。其详细教导可参见，例如Desnoyers等人,Sci.Transl.Med.,5:207ra144,2013。可对本文所描述的任何抗体或其抗原结合部分使用类似掩蔽技术。
上述各个抗体片段均保持了特异性结合全长抗体所结合的相同抗原的能力，和/或与全长抗体竞争对抗原的特异性结合。
可使用本领域技术人员已知的常规技术(例如，重组DNA技术或酶促或化学断裂法)从给定的抗体(例如本发明提供的抗体)获得抗体的抗原结合片段(例如，上述抗体片段)，并且以与用于完整抗体的方式相同的方式就特异性筛选抗体的抗原结合片段。
在本文中，除非上下文明确指出，否则当提及术语“抗体”时，其不仅包括完整抗体，而且包括抗体的抗原结合片段。
如本文中所使用的，术语“单克隆抗体”、“单抗”、“mAb”具有相同的含义且可互换使用可互换，其是指，来自一群高度同源的抗体分子中的一个抗体或抗体的一个片段，也即，除可能自发出现的自然突变外，一群完全相同的抗体分子。单抗对抗原上的单一表位具有高特异性。多克隆抗体是相对于单克隆抗体而言的，其通常包含至少2种或更多种的不同抗体，这些不同的抗体通常识别抗原上的不同表位。此外，修饰语“单克隆”仅表明该抗体的特征为从高度同源的抗体群中获得，不能理解为需要通过任何特定方法来制备所述抗体。
本发明的单克隆抗体可以通过多种技术进行制备，例如杂交瘤技术(参见，例如Kohler等人.Nature,256:495,1975)，重组DNA技术(参见，例如美国专利申请4,816,567)，或噬菌体抗体库技术(参见，例如Clackson等.Nature352：624-628,1991，或Marks等.J.Mol.Biol.222：581-597,1991)。
抗体可通过公知的技术，例如使用蛋白A或蛋白G的亲和层析进行纯化。随后或作为替代，可将特异性抗原(该抗体识别的靶分子)或其抗原表位固定在柱上，并通过免疫亲合层析法来纯化免疫特异性抗体。免疫球蛋白的纯化可参考例如D.Wilkinson(The Scientist,published by The Scientist,Inc.,Philadelphia Pa.,Vol.14,No.8(Apr.17,2000),pp.25-28)。
如本文中所使用的，术语“嵌合抗体(Chimeric antibody)”是指，这样的抗体，其轻链或/和重链的一部分源自一个抗体(其可以源自某一特定物种或属于某一特定抗体类或亚类)，且轻链或/和重链的另一部分源自另一个抗体(其可以源自相同或不同的物种或属于相同或不同的抗体类或亚类)，但无论如何，其仍保留对目标抗原的结合活性(U.S.P 4,816,567 to Cabilly et al.；Morrison et al.,Proc.Natl.Acad.Sci.USA,81:6851 6855(1984))。例如，术语“嵌合抗体”可包括这样的抗体(例如人鼠嵌合抗体)，其中抗体的重链和轻链可变区来自第一抗体(例如鼠源抗体)，而抗体的重链和轻链可变区来自第二抗体(例如人抗体)。
如本文中所使用的，术语“人源化抗体”是指，经基因工程改造的非人源抗体，其氨基酸序列经修饰以提高与人源抗体的序列的同源性。通常而言，人源化抗体的全部或部分CDR区来自于非人源抗体(供体抗体)，全部或部分的非CDR区(例如，可变区FR和/或恒定区)来自于人源免疫球蛋白(受体抗体)。人源化抗体通常保留了供体 抗体的预期性质，包括但不限于，抗原特异性、亲和性、反应性等。供体抗体可以是有预期性质(例如，抗原特异性、亲和性、反应性等)的小鼠、大鼠、兔或非人灵长类动物(例如，食蟹猴)抗体。
在本申请中，本发明抗体的预期性质包括：(1)特异性识别/结合CLDN6和/或CLDN9(特别是人CLDN6和/或人CLDN9)；(2)介导CLDN6内化；(3)通过抗体依赖性细胞介导的细胞毒性(ADCC)来诱导杀伤表达人CLDN6的细胞；(4)通过补体依赖的细胞毒性(CDC)来诱导杀伤表达人CLDN6的细胞；(5)预防和/治疗肿瘤的能力。本发明的抗体具有上述预期性质中的一项或多项。
本发明的嵌合抗体或人源化抗体可以根据上述制备的鼠单克隆抗体的序列进行制备。编码重链和轻链的DNA可以从目标鼠杂交瘤中获得，并且使用标准分子生物学技术进行工程改造以包含非鼠(例如人)免疫球蛋白序列。
为制备嵌合抗体，可使用本领域已知的方法将鼠免疫球蛋白可变区连接至人免疫球蛋白恒定区(参见例如Cabilly等人的美国专利No.4,816,567)。例如，将编码VH的DNA可操作的连接至编码重链恒定区的另一DNA分子以获得全长重链基因。人重链恒定区基因的序列是本领域已知的(参见例如Kabat,E.A.等人(1991)Sequences of Proteins of Immunological Interest,Fifth Edition,U.S.Department of Health and Human Services,NIH Publication No.91-3242)，包含这些区的DNA片段可以通过标准PCR扩增获得。重链恒定区可以是IgG1、IgG2、IgG3、IgG4、IgA、IgE、IgM或IgD恒定区，但是通常优选为IgG1或IgG4恒定区。例如，将编码VL的DNA可操作的连接至编码轻链恒定区CL的另一DNA分子以获得全长轻链基因(以及Fab轻链基因)。人轻链恒定区基因的序列是本领域已知的(参见例如Kabat，E.A.等人(1991)Sequences of Proteins of Immunological Interest，Fifth Edition，U.S.Department of Health and Human Services，NIH Publication No.91-3242)，包含这些区的DNA片段可以通过标准PCR扩增获得。轻链恒定区可以是κ或λ恒定区，但通常优选为κ恒定区。
为制备人源化抗体，可以使用本领域已知的方法将鼠CDR区插入人源框架序列(参见Winter的美国专利No.5,225,539；Queen等人的美国专利Nos.5,530,101；5,585,089；5,693,762和6,180,370；以及Lo,Benny,K.C.,editor,in Antibody Engineering:Methods and Protocols,volume 248,Humana Press,New Jersey,2004)。或者，还可以利用转基因动物，其能够在免疫后不产生内源性免 疫球蛋白、并且能够产生完整人抗体库。例如，已有报道在嵌合和种系突变小鼠中抗体重链连接区(JH)基因的纯合缺失可以完全抑制了内源性抗体产生，然后将人种系免疫球蛋白基因阵列转移到所述种系突变小鼠中将导致该小鼠在遇到抗原刺激时产生人抗体(参见例如，Jakobovits等，1993，Proc.Natl.Acad.Sci.USA 90：2551；Jakobovits等，1993，Nature362：255-258；Bruggermann等，1993，Year in Immunology 7：33；和Duchosal等，1992，Nature 355：258)。上述转基因动物的非限制性实例包括，HuMAb小鼠(Medarex,Inc.)，其含有编码未重排的人重链(μ和γ)和κ轻链免疫球蛋白序列的人免疫球蛋白基因微型基因座(miniloci)，加之使内源μ和κ链基因座失活的靶向突变(参见例如Lonberg等人(1994)Nature 368(6474):856-859)；或携带人重链转基因和人轻链转染色体的“KM小鼠 TM”(参见专利申请WO02/43478)。其他抗体人源化改造的方法还包括噬菌体展示技术(Hoogenboom等，1991，J.Mol.Biol.227：381；Marks等，J.Mol.Biol.1991，222：581-597；Vaughan等，1996，Nature Biotech 14：309)。
如本文中所使用的，术语“胚系抗体基因(germline antibody gene)”或“胚系抗体基因片段(germline antibody gene segment)”是指，存在于生物体的基因组中的编码免疫球蛋白的序列，其没有经历过能够导致表达特异性免疫球蛋白的遗传学重排及突变的成熟过程。在本发明中，表述“重链胚系基因”是指，编码免疫球蛋白重链的胚系抗体基因或基因片段，其包括V基因(variable)、D基因(diversity)、J基因(joining)和C基因(constant)；类似地，表述“轻链胚系基因”是指，编码免疫球蛋白轻链的胚系抗体基因或基因片段，其包括V基因(variable)、J基因(joining)和C基因(constant)。在本发明中，由所述胚系抗体基因或胚系抗体基因片段所编码的氨基酸序列也称为“胚系序列(germline sequence)”。胚系抗体基因或胚系抗体基因片段及其相应的胚系序列是本领域技术人员熟知的，并且可从专业数据库(例如，IMGT、UNSWIg、NCBI或VBASE2)获得或查询。
如本文中所使用的，术语“特异性结合”是指，两分子间的非随机的结合反应，如抗体和其所针对的抗原之间的反应。特异性结合相互作用的强度或亲和力可以该相互作用的平衡解离常数(K D)表示。在本发明中，术语“K D”是指特定抗体-抗原相互作用的解离平衡常数，其用于描述抗体与抗原之间的结合亲和力。平衡解离常数越小，抗体-抗原结合越紧密，抗体与抗原之间的亲和力越高。在某些实施方式中，特异性结合某抗原的抗体(或对某抗原具有特异性的抗体)是指，抗体以小于约10 -9M，例如小 于约10 -9M、10 -10M、10 -11M或10 -12M或更小的亲和力(K D)结合该抗原。两分子间的特异性结合性质可使用本领域公知的方法进行测定，例如使用表面等离子体共振术(SPR)在BIACORE仪中测定。
如本文中所使用的，术语“细胞毒剂”包括对细胞有害(例如杀死细胞)的任何试剂，例如化疗药物、细菌毒素、植物毒素或放射性同位素等。
如本文中所使用的，术语“载体(vector)”是指，可将多聚核苷酸插入其中的一种核酸运载工具。当载体能使插入的多核苷酸编码的蛋白获得表达时，载体称为表达载体。载体可以通过转化，转导或者转染导入宿主细胞，使其携带的遗传物质元件在宿主细胞中获得表达。载体是本领域技术人员公知的，包括但不限于：质粒；噬菌粒；柯斯质粒；人工染色体，例如酵母人工染色体(YAC)、细菌人工染色体(BAC)或P1来源的人工染色体(PAC)；噬菌体如λ噬菌体或M13噬菌体及动物病毒等。可用作载体的动物病毒包括但不限于，逆转录酶病毒(包括慢病毒)、腺病毒、腺相关病毒、疱疹病毒(如单纯疱疹病毒)、痘病毒、杆状病毒、乳头瘤病毒、乳头多瘤空泡病毒(如SV40)。一种载体可以含有多种控制表达的元件，包括但不限于，启动子序列、转录起始序列、增强子序列、选择元件及报告基因。另外，载体还可含有复制起始位点。
如本文中所使用的，术语“宿主细胞”是指，可用于导入载体的细胞，其包括但不限于，如大肠杆菌或枯草菌等的原核细胞，如酵母细胞或曲霉菌等的真菌细胞，如S2果蝇细胞或Sf9等的昆虫细胞，或者如纤维原细胞，CHO细胞，COS细胞，NSO细胞，HeLa细胞，BHK细胞，HEK 293细胞或人细胞等的动物细胞。
如本文中所使用的，术语“同一性”用于指两个多肽之间或两个核酸之间序列的匹配情况。当两个进行比较的序列中的某个位置都被相同的碱基或氨基酸单体亚单元占据时(例如，两个DNA分子的每一个中的某个位置都被腺嘌呤占据，或两个多肽的每一个中的某个位置都被赖氨酸占据)，那么各分子在该位置上是同一的。两个序列之间的“百分数同一性”是由这两个序列共有的匹配位置数目除以进行比较的位置数目×100的函数。例如，如果两个序列的10个位置中有6个匹配，那么这两个序列具有60％的同一性。例如，DNA序列CTGACT和CAGGTT共有50％的同一性(总共6个位置中有3个位置匹配)。通常，在将两个序列比对以产生最大同一性时进行比较。这样的比对可通过使用，例如，可通过计算机程序例如Align程序(DNAstar,Inc.)方便地进行的Needleman等人(1970)J.Mol.Biol.48：443-453的方法来实现。还可使用已整合入ALIGN程序(版本2.0)的E.Meyers和W.Miller(Comput.Appl Biosci.，4:11- 17(1988))的算法，使用PAM120权重残基表(weight residue table)、12的缺口长度罚分和4的缺口罚分来测定两个氨基酸序列之间的百分数同一性。此外，可使用已整合入GCG软件包(可在www.gcg.com上获得)的GAP程序中的Needleman和Wunsch(J MoI Biol.48:444-453(1970))算法，使用Blossum 62矩阵或PAM250矩阵以及16、14、12、10、8、6或4的缺口权重(gap weight)和1、2、3、4、5或6的长度权重来测定两个氨基酸序列之间的百分数同一性。
如本文中所使用的，术语“保守置换”意指不会不利地影响或改变包含氨基酸序列的蛋白/多肽的预期性质的氨基酸置换。例如，可通过本领域内已知的标准技术例如定点诱变和PCR介导的诱变引入保守置换。保守氨基酸置换包括用具有相似侧链的氨基酸残基替代氨基酸残基的置换，例如用在物理学上或功能上与相应的氨基酸残基相似(例如具有相似大小、形状、电荷、化学性质，包括形成共价键或氢键的能力等)的残基进行的置换。已在本领域内定义了具有相似侧链的氨基酸残基的家族。这些家族包括具有碱性侧链(例如，赖氨酸、精氨酸和组氨酸)、酸性侧链(例如天冬氨酸、谷氨酸)、不带电荷的极性侧链(例如甘氨酸、天冬酰胺、谷氨酰胺、丝氨酸、苏氨酸、酪氨酸、半胱氨酸、色氨酸)、非极性侧链(例如丙氨酸、缬氨酸、亮氨酸、异亮氨酸、脯氨酸、苯丙氨酸、甲硫氨酸)、β分支侧链(例如，苏氨酸、缬氨酸、异亮氨酸)和芳香族侧链(例如，酪氨酸、苯丙氨酸、色氨酸、组氨酸)的氨基酸。因此，优选用来自相同侧链家族的另一个氨基酸残基替代相应的氨基酸残基。鉴定氨基酸保守置换的方法在本领域内是熟知的(参见，例如，Brummell等人，Biochem.32:1180-1187(1993)；Kobayashi等人Protein Eng.12(10):879-884(1999)；和Burks等人Proc.Natl Acad.Set USA 94:412-417(1997)，其通过引用并入本文)。
本文涉及的二十个常规氨基酸的编写遵循常规用法。参见例如，Immunology-A Synthesis(2nd Edition,E.S.Golub and D.R.Gren,Eds.,Sinauer Associates,Sunderland,Mass.(1991))，其以引用的方式并入本文中。在本发明中，术语“多肽”和“蛋白质”具有相同的含义且可互换使用。并且在本发明中，氨基酸通常用本领域公知的单字母和三字母缩写来表示。例如，丙氨酸可用A或Ala表示。
如本文中所使用的，术语“嵌合抗原受体(CAR)”是指，具有与T细胞受体的一个或多个细胞内信号结构域接合的细胞外抗体衍生的靶向结构域(例如scFv)的工程化的T细胞受体。在本发明中，术语“嵌合抗原受体T细胞”是表达CAR并且具有由该CAR 的靶向结构域决定的抗原特异性的T细胞。制造CAR(例如，用于癌症治疗)的方法是本领域已知的，可参见例如，Park等人,TrendsBiotechnol.,29:550-557,2011；Grupp等人,NEnglJMed.,368:1509-1518,2013；Han等人,J.HematolOncol.,6:47,2013；PCT专利公开文本WO2012/079000、WO2013/059593；和美国专利公开文本2012/0213783，其全部通过引用整体并入本文。
如本文中所使用的，术语“药学上可接受的载体和/或赋形剂”是指在药理学和/或生理学上与受试者和活性成分相容的载体和/或赋形剂，其是本领域公知的(参见例如Remington's Pharmaceutical Sciences.Edited by Gennaro AR,19th ed.Pennsylvania:Mack Publishing Company,1995)，并且包括但不限于：pH调节剂，表面活性剂，佐剂，离子强度增强剂，稀释剂，维持渗透压的试剂，延迟吸收的试剂，防腐剂。例如，pH调节剂包括但不限于磷酸盐缓冲液。表面活性剂包括但不限于阳离子，阴离子或者非离子型表面活性剂，例如Tween-80。离子强度增强剂包括但不限于氯化钠。防腐剂包括但不限于各种抗细菌试剂和抗真菌试剂，例如对羟苯甲酸酯，三氯叔丁醇，苯酚，山梨酸等。维持渗透压的试剂包括但不限于糖、NaCl及其类似物。延迟吸收的试剂包括但不限于单硬脂酸盐和明胶。稀释剂包括但不限于水，水性缓冲液(如缓冲盐水)，醇和多元醇(如甘油)等。防腐剂包括但不限于各种抗细菌试剂和抗真菌试剂，例如硫柳汞，2-苯氧乙醇，对羟苯甲酸酯，三氯叔丁醇，苯酚，山梨酸等。稳定剂具有本领域技术人员通常理解的含义，其能够稳定药物中的活性成分的期望活性，包括但不限于谷氨酸钠，明胶，SPGA，糖类(如山梨醇，甘露醇，淀粉，蔗糖，乳糖，葡聚糖，或葡萄糖)，氨基酸(如谷氨酸，甘氨酸)，蛋白质(如干燥乳清，白蛋白或酪蛋白)或其降解产物(如乳白蛋白水解物)等。在某些示例性实施方案中，所述药学上可接受的载体或赋形剂包括无菌可注射液体(如水性或非水性悬浮液或溶液)。在某些示例性实施方案中，此类无菌可注射液体选自注射用水(WFI)、抑菌性注射用水(BWFI)、氯化钠溶液(例如0.9％(w/v)NaCl)、葡萄糖溶液(例如5％葡萄糖)、含有表面活性剂的溶液(例如0.01％聚山梨醇20)、pH缓冲溶液(例如磷酸盐缓冲溶液)、Ringer氏溶液及其任意组合。
如本文中所使用的，术语“预防”是指，为了阻止或延迟疾病或病症或症状(例如，肿瘤)在受试者体内的发生而实施的方法。如本文中所使用的，术语“治疗”是指，为了获得有益或所需临床结果而实施的方法。为了本发明的目的，有益或所需的临床结果包括但不限于，减轻症状、缩小疾病的范围、稳定(即，不再恶化)疾病的状态，延迟 或减缓疾病的发展、改善或减轻疾病的状态、和缓解症状(无论部分或全部)，无论是可检测或是不可检测的。此外，“治疗”还可以指，与期望的存活期相比(如果未接受治疗)，延长存活期。
如本文中使用的，术语“受试者”是指哺乳动物，例如灵长类哺乳动物，例如人。在某些实施方式中，所述受试者(例如人)患有肿瘤(例如表达CLDN6和/或CLDN9的肿瘤)，或者，具有患有上述疾病的风险。
如本文中所使用的，术语“有效量”是指足以获得或至少部分获得期望的效果的量。例如，预防疾病(例如，肿瘤)有效量是指，足以预防，阻止，或延迟疾病(例如，肿瘤)的发生的量；治疗疾病有效量是指，足以治愈或至少部分阻止已患有疾病的患者的疾病和其并发症的量。测定这样的有效量完全在本领域技术人员的能力范围之内。例如，对于治疗用途有效的量将取决于待治疗的疾病的严重度、患者自己的免疫系统的总体状态、患者的一般情况例如年龄，体重和性别，药物的施用方式，以及同时施用的其他治疗等等。
如本文中所使用的，术语“免疫效应细胞”包括具有造血的起源并在免疫应答中起作用的细胞，例如淋巴细胞，例如B细胞和T细胞；天然杀伤细胞；髓样细胞，例如单核细胞、巨噬细胞、嗜曙红细胞、肥大细胞、嗜碱细胞和粒细胞。在某些优选的实施方案中，所述免疫效应细胞是T细胞。
如本文中所使用的，术语“转移”是指，指癌细胞从其原始部位扩散到身体的其他部位。转移的形成是非常复杂的过程，并依赖于恶性细胞从原发肿瘤中脱离、侵袭胞外基质、透过内皮基底膜以进入体腔和血管以及其后由血液转运后浸润靶器官。最后，新肿瘤(即继发性肿瘤或转移性肿瘤)在靶部位的生长依赖于血管发生。肿瘤转移经常甚至在切除原发肿瘤后发生，因为肿瘤细胞或组分可能残留并发展出转移潜力。在一个实施方案中，根据本发明的术语“转移”涉及“远端转移”，这涉及远离原发肿瘤和局部淋巴结系统的转移。继发性或转移性肿瘤的细胞与原始肿瘤中的细胞类似。这意味着例如如果卵巢癌转移至肝，则所述继发性肿瘤由异常的卵巢细胞(而不是异常的肝细胞)构成。则肝中的肿瘤被称为转移性卵巢癌(而不是肝癌)。
发明的有益效果
与现有技术相比，本发明的技术方案具有以下有益效果：
本发明的抗体能够特异性识别/结合CLDN6和/或CLDN9，并且能够通过ADCC和/或 CDC来诱导杀伤表达CLDN6的细胞(例如，肿瘤细胞)。因此，本发明的抗体具有用于预防和/或治疗肿瘤(特别是表达CLDN6)的潜力。本发明的人源化抗体不仅保留了亲本抗体的功能和性质，而且具有较高的人源化程度，从而可安全地施用给人受试者，而不引发免疫原性反应。特别的，本发明的抗体几乎不结合CLDN家族中的其他蛋白(例如，CLDN3和CLDN4)。因此，本发明的抗体(特别是人源化抗体)具有重大的临床价值。
下面将结合附图和实施例对本发明的实施方案进行详细描述，但是本领域技术人员将理解，下列附图和实施例仅用于说明本发明，而不是对本发明的范围的限定。根据附图和优选实施方案的下列详细描述，本发明的各种目的和有利方面对于本领域技术人员来说将变得可实施。
附图说明
图1A-1D分别显示了抗CLDN6鼠源抗体15H2与不同细胞表面CLDN蛋白的结合活性测定结果。图1A:CHOS-hCLDN6；图1B：CHOS-CLDN3；图1C：CHOS-CLDN4；图1D：CHOS-CLDN9。
图2A-2D分别显示了抗CLDN6鼠源抗体9H3与不同细胞表面CLDN蛋白的结合活性测定结果。图2A:CHOS-hCLDN6；图2B：CHOS-CLDN3；图2C：CHOS-CLDN4；图2D：CHOS-CLDN9。
图3A-3D分别显示了人源化抗体7008-01和7008-03对天然表达人CLDN6的四种肿瘤细胞的结合结果。图3A:OV90；图3B：NEC8；图3C：NTERA2；图3D：Bewo。
图4A-4D分别显示了人源化抗体7008-01和7008-03诱导效应细胞对天然表达人CLDN6的四种肿瘤细胞的抗体依赖的细胞毒杀作用结果。图4A:OV90；图4B：NEC8；图4C：NTERA2；图4D：Bewo。
图5显示了人源化抗体7008-01和7008-03诱导补体对天然表达人CLDN6的NTERA2肿瘤细胞的补体依赖的毒杀作用结果。
图6A-6D分别显示了热点突变抗体与不同的CLDN6表达肿瘤细胞的结合结果。图6A:15H2抗体与NEC8的结合结果；图6B：15H2抗体与Bewo的结合结果；图6C：9H3抗体与NEC8的结合结果；图6D：9H3抗体与Bewo的结合结果。
序列信息
本发明涉及的部分序列的信息提供于下面的表中。
Figure PCTCN2021079380-appb-000003
Figure PCTCN2021079380-appb-000004
Figure PCTCN2021079380-appb-000005
具体实施方式
现参照下列意在举例说明本发明(而非限定本发明)的实施例来描述本发明。
除非特别指明，本发明中所使用的分子生物学实验方法和免疫检测法，基本上参照J.Sambrook等人，分子克隆：实验室手册，第2版，冷泉港实验室出版社，1989，以及F.M.Ausubel等人，精编分子生物学实验指南，第3版，John Wiley&Sons,Inc.，1995中所述的方法进行；限制性内切酶的使用依照产品制造商推荐的条件。本领域技术人员知晓，实施例以举例方式描述本发明，且不意欲限制本发明所要求保护的范围。
实施例1：抗CLDN6鼠源抗体的产生
通过慢病毒感染的方法(MOI＝3-10，5μg/ml polybrene)在HEK293细胞(ATCC)、CHOS细胞(Invitrogen)上分别过表达人源CLDN6(hCLDN6)或小鼠CLDN6(mCLDN6),或人源CLDN3(CLDN3),或人源CLDN4(CLDN4),或人源CLDN9(CLDN9)。慢病毒由上海 吉凯基因化学技术有限公司提供，细胞感染72小时后加相应抗生素继续培养2-4周，扩增并冻存，得到HEK293-hCLDN6,HKE293-mCLDN6，HEK293-CLDN3,HEK293-CLDN4,HEK293-CLDN9,CHOS-hCLDN6,CHOS-CLDN3,CHOS-CLDN4,CHOS-CLDN9共9株细胞,以用于后续实验。
为了获得抗人CLDN6抗体，使用构建的过表达人源CLDN6的CHOS-hCLDN6细胞免疫Balb/c小鼠(北京维通利华实验动物技术有限公司，品系代码216)；初免佐剂使用完全弗氏佐剂CFA(InvivoGen公司，货号vac-cfa-60)，之后免疫佐剂都使用IFA(InvivoGen公司，货号vac-ifa-60)；免疫途径为皮下多点。多次免疫后将免疫小鼠的脾细胞与小鼠骨髓瘤细胞SP2/0使用聚乙二醇法进行融合，得到既能表达抗体又能在体外无限增殖的B细胞融合，并且在HAT选择培养基中培养。将融合后的杂交瘤细胞铺在96孔细胞培养板中，并且通过对上清中抗体在细胞水平结合CLDN3/4/6/9能力的检测，筛选出目的阳性克隆(仅结合CLDN6，不结合CLDN3/4/9的抗体；同时结合CLDN6/9，不结合CLDN3/4的抗体)进行2-3轮亚克隆。
鼠抗结合细胞水平高通量筛选：在筛选中通过使用人源CLDN3/4/6/9表达的细胞(CHOS-hCLDN6,CHOS-CLDN3,CHOS-CLDN4,CHOS-CLDN9)分别进行铺板。将10000个细胞稀释于100μL完全培养基中，使用平底96孔板，过夜使细胞贴壁或沉于孔底，第二天去掉上清。将100μL待筛选杂交瘤上清加入细胞板中，室温孵育1小时。去掉上清后，每孔加入100μL第二抗体(DyLight488山羊抗鼠IgG(Abcam目录编号ab97015)，浓度为5μg/mL，室温孵育0.5小时。染色完成后去掉上清后每孔加入100μL DPBS，上机器进行读数。使用全视野细胞扫描分析仪(Nexcelom，型号
Figure PCTCN2021079380-appb-000006
Image Cytometer)对实验板进行测定读数。测定时选择第二抗体对应荧光通道和明场通道同时对孔内细胞进行高速扫描成像。荧光通道得到的成像根据有荧光标记的细胞形态和荧光强度设定参数对抗体结合的细胞进行计数，明场通道得到的成像根据细胞形态设定参数对贴壁细胞进行计数，然后两组数据相除得到和抗体结合的显示荧光的细胞占细胞总数的百分比。根据该比例判定融合瘤上清中抗体与表达CLDN3/4/6/9的细胞的结合效果。
鼠抗与CLDN3/4/6/9的结合的流式评价：将500,000个CLDN6表达细胞(CHOS-hCLDN6,CHOS-CLDN3,CHOS-CLDN4,CHOS-CLDN9)置于FACS buffer(PBS+2％FBS)/孔中，加入待测鼠源抗体后4摄氏度孵育1小时。离心去掉上清，使用FACS buffer清洗两遍，加入第二抗体(DyLight488山羊抗鼠IgG，Abcam目录编号ab97015)4摄氏度孵育0.5小时。染色完成后离心去掉上清，用FACS buffer清洗两次后使用FACS buffer 重悬细胞，然后上机器进行读数。使用流式细胞分析仪(BD公司，型号CantoII)对实验细胞进行测定读数。测定时先根据FCS和SSC圈定细胞位置，然后选择第二抗体对应荧光通道和SSC对细胞进行分析。
鼠源抗体15H2与CHOS-hCLDN6，CHOS-CLDN3，CHOS-CLDN4，CHOS-CLDN9结合情况如图1A-1D所示，如图所示的，同型对照抗体ISO(Beyotime,CatA7028)不与CHOS-hCLDN6，CHOS-CLDN3，CHOS-CLDN4，CHOS-CLDN9细胞结合，抗体15H2能够与CHOS-hCLDN6细胞结合，而几乎不与CHOS-CLDN3，CHOS-CLDN4和CHOS-CLDN9细胞结合；鼠源抗体9H3与CHOS-hCLDN6，CHOS-CLDN3，CHOS-CLDN4，CHOS-CLDN9结合情况如图2A-2D所示，如图所示的，同型对照抗体ISO不与CHOS-hCLDN6，CHOS-CLDN3，CHOS-CLDN4，CHOS-CLDN9细胞结合，抗体9H3能够与CHOS-hCLDN6和CHOS-CLDN9细胞结合，而几乎不与CHOS-CLDN3和CHOS-CLDN4细胞结合。
实施例2：抗CLDN6鼠源抗体的可变区序列测定
离心收集杂交瘤细胞，每5-10×10 6细胞加入1ml TRIzol和0.2ml氯仿，剧烈振荡15秒，室温放置3分钟，离心取水相加入0.5ml异丙醇，室温放置10分钟后收集沉淀，乙醇洗涤后干燥得到RNA。在冰浴离心管里面加入模板RNA和引物，使引物和模板正确配对后进行反转录过程，再进行PCR扩增。4个微量离心管中各加入dNTP/ddNTP混合物2.5μl,混合物37℃温浴5min,备用。在一个空的微量离心管中加入1pmol的PCR扩增双链DNA,10pmol测序引物,2μl 5×测序缓冲液,加双蒸水至总体积10μl,96℃加热8min,冰浴泠却1min,4℃10000g离心10s。加入2μl预冷的标记混合物(dCTP、dGTP、dTTP各0.75μmol/L),1μl 0.1mol/L DDT,测序酶2U,加水至15μl,混匀后置冰上2min,标记新合成的DNA链。3.5μl标记反应混合物加入到准备好的4个微量离心管中,37℃温浴5min.每管各加入4μl终止液。样品在80℃的水浴中热变性5min,每一泳道加2μl加到测序胶上,电泳分离这些片段，收集序列信息。
2株鼠源抗体的VH和VL序列如表1所示。进一步，通过IMGT编号系统确定了2株鼠源单抗的CDR序列。
表1：鼠源抗体的序列信息
Figure PCTCN2021079380-appb-000007
实施例3：嵌合抗CLDN6抗体的重组表达
在抗体基因序列验证后，鼠源抗体的可变区连接人源抗体的恒定区(人源IgG1)，将含有抗体基因的表达质粒转染至哺乳动物细胞。收获培养瓶生长的含有抗体克隆的哺乳动物细胞上清液，使用protein A柱纯化，并且使用100mM醋酸pH3.0洗脱抗体蛋白。然后将纯化的抗体蛋白上样到分子排阻层析柱上进一步分离纯化。将对应于单体的抗体蛋白配制于PBS缓冲液中，配制品缓冲液补充有20％甘油。
实施例4：鼠抗人CLDN6抗体的人源化和翻译后修饰热点突变
为提高候选抗体与人源抗体的序列的同源性，减少抗体对人的免疫原性，可以对以上实施例提供的鼠源抗体进行人源化设计和制备，使用本领域已知的方法将鼠CDR区插入人源框架序列(参见Winter的美国专利No.5,225,539；Queen等人的美国专利Nos.5,530,101；5,585,089；5,693,762和6,180,370；以及Lo,Benny,K.C.,editor,in Antibody Engineering:Methods and Protocols,volume 248,Humana Press,New Jersey,2004)。
具体而言，将鼠源抗体15H2和9H3的重链和轻链CDR区分别构建到对应的人源化模板的FR框架上，并对人源化模板的FR区氨基酸残基进行了一系列的回复突变，以使人源化抗体尽可能保留鼠源抗体的抗原结合能力。
同时考虑到鼠源抗体CDR区中可能的翻译后修饰热点Post-Translation Modification hotspot,PTM hotspot),如15H2 HCDR2中天冬氨酸异构化热点DG，9H3 HCDR2中天冬氨酸异构化热点DG，9H3 LCDR1中脱氨化热点NG，使用本领域已知的方法对这些热点进行突变。如将天冬氨酸异构化热点DG中D突变成E/S/G等，或将DG中G突变成A/S/D等，又如将脱氨化热点NG中N突变成Q/S/A等，或将NG中G突变为A/S/D等，经实验验证，上述提到的大多数突变不改变抗体与CLDN6表达细胞结合的能力(如15H2 HCDR2 DG突变为EG/SG/GG；9H3 LCDR1 NG突变为QG/NA/SG；9H3 LCDR1 NG突变为QG且其HCDR2 DG同时突变为DA)或改变在三倍以内(9H3 LCDR1 NG突变为NA且其HCDR2 DG同时突变为DA；9H3 LCDR1 NG突变为SG且其HCDR2 DG同时突变为DA)。图6A和6B展示了15H2的部分热点突变抗体与CLDN6表达肿瘤细胞NEC8/Bewo的结合，图6C和6D展示了9H3的部分热点突变抗体与CLDN6表达肿瘤细胞NEC8/Bewo的结合。
根据以上方法，本发明人制备获得了鼠源抗体15H2和鼠源抗体9H3的一系列人源化且热点突变抗体，经过与CLDN6表达细胞结合的能力的筛选优选每个鼠抗对应人源化且热点突变抗体各一个，分别命名为7008-01(其重链可变区及轻链可变区分别如SEQ ID NO:19和20所示)和7008-03(其重链可变区及轻链可变区分别如SEQ ID NO:9和10所示)。各抗体的重链恒定区均为SEQ ID NO:21，轻链恒定区均为SEQ ID NO:22。
实施例5：人源化抗CLDN6抗体的抗原结合活性评价
将500,000个CLDN6天然表达肿瘤细胞(OV90,ATCC；NEC8,JCRB；NTERA2,南京科佰生物；Bewo,南京科佰生物)置于FACS buffer中待用，使用圆底低吸附96孔板。抗体样本使用FACS buffer进行梯度稀释。细胞板中加入经稀释的抗体，相应阴性对照孔加入FACS buffer，4摄氏度孵育1小时。离心去掉上清后，使用FACS buffer清洗两遍，每孔加入第二抗体(DyLight488山羊抗人IgG，Abcam目录编号ab97003)4摄氏度再孵育0.5小时。染色完成后离心去掉上清，用FACS buffer清洗两次后每孔加入FACS buffer重悬细胞，然后上机器进行读数。使用流式细胞分析仪(BD公司，型号CantoII)对实验板中细胞进行测定读数。测定时先根据FCS和SSC圈定细胞位置，然后选择第二抗体对应荧光通道和SSC对细胞进行分析，数据分析使用GraphPad，横坐标使用抗体浓度的对数，纵坐标使用平均荧光强度数值，根据曲线拟合出抗CLDN6抗体的EC50。
人源化抗体7008-01和7008-03对天然表达人CLDN6的四种肿瘤细胞(OV90/NEC8/NTERA2/Bewo的结合情况分别如图3A-3D所示。表2列出了两个抗体在肿瘤细胞上结合的EC50和最大结合值(Top MFI)。结果表明，人源化抗体7008-01和7008-03对膜表面CLDN6具备良好的结合活性。
表2.抗体对CLDN6阳性肿瘤细胞的结合
Figure PCTCN2021079380-appb-000008
实施例6：抗体诱导ADCC(Antibody Dependent Cellular Cytotoxicity)作用
靶细胞使用CLDN6天然表达肿瘤细胞(OV90,ATCC；NEC8,JCRB；NTERA2,南京科 佰生物；Bewo,南京科佰生物)，效应细胞使用in-house构建的稳定转染的CD16受体和NFAT(Nuclear Factor of Activated T-cells)反应原件的Jurkat-NFAT-Luc-CD16细胞系，实验在96孔平底细胞板中(Corning 3903)进行。梯度稀释的抗体加入靶细胞中，37℃条件下孵育30分钟。每10000个靶细胞加入60000个效应细胞，37℃条件下进行反应4-6小时，反应结束加入One-GloTM试剂(Promega,E6110)进行荧光显色，细胞板使用Tecan Spark10酶标仪测定发光读数。数据分析使用GraphPad，横坐标使用抗体浓度的对数，纵坐标使用对应孔发光读数，根据曲线拟合出抗CLDN6抗体的抗体依赖的细胞毒杀作用的EC50。
人源化抗体7008-01和7008-03诱导效应细胞对天然表达人CLDN6的四种肿瘤细胞(OV90/NEC8/NTERA2/Bewo)的抗体依赖的细胞毒杀作用分别如图4A-4D所示。表3列出了两个抗体在不同肿瘤细胞ADCC的EC50和最大值(Top Lum)。结果表明，人源化抗体7008-01和7008-03均能有效诱导效应细胞对表达CLDN6的肿瘤细胞的杀伤。
表3.抗体对CLDN6阳性肿瘤细胞ADCC作用
Figure PCTCN2021079380-appb-000009
实施例7：抗体诱导CDC(Complement Dependent Cytotoxicity)作用
靶细胞使用CLDN6天然表达肿瘤细胞NTERA2。靶细胞预先与EuTDA细胞毒性检测试剂盒中的BATDA荧光增强配体试剂(PerkinElmer，AD0116)以1×10 6细胞每毫升添加2微升的比例混合，37℃下孵育20分钟；处理后的靶细胞(5×10 3)与各种不同浓度的抗体和作为补体来源的人血清(TPCS，A515)以1：8的比例混合，在96孔圆底板(Coring，GLS3799)37℃下共同孵育3小时。孵育完成后96孔圆底板中的上清转到加有铕溶液(PerkinElmer，AD0116)的96孔平底板(Coring，货号3903)室温进一步孵育15分钟，在多功能酶标仪(Tecan，Spark10)上检测每个孔内细胞死亡后被释放到上清中的荧光供体受到能量激发后能量转移给受体后受体发出的发射光(激发：320/340nm，发射：615nm)。
使用以下公式计算细胞毒性：细胞毒性百分比＝100×[1–(Max–data)/(Max– Min)]
其中Data是实验的数值(细胞与抗体和补体一起孵育)，Min是最小细胞毒性即实验的本底数值(细胞与培养基和补体)，而Max是最大细胞毒性(细胞与裂解液和补体共同孵育)。数据分析使用GraphPad，横坐标使用抗体浓度的对数，纵坐标使用对应孔荧光读数，根据曲线拟合出抗CLDN6抗体的补体依赖的毒杀作用的EC50。
人源化抗体7008-01和7008-03诱导补体对天然表达人CLDN6的NTERA2肿瘤细胞的补体依赖的毒杀作用如图5所示。结果表明，人源化抗体7008-01和7008-03均能有效诱导补体对表达CLDN6的肿瘤细胞的杀伤。
实施例8：抗CLDN6抗体介导的CLDN6内化
本实施例通过流式细胞术测试抗CLDN6抗体介导的CLDN6内化。测定抗体引起的内化和时间的关系，在37℃/4℃下将CLDN6天然表达的肿瘤细胞(OV90/Bewo)与10μg/mL抗体一起孵育不同时间。用含2％FBS的PBS洗涤若干次后，加入10μg/mL第二抗体4℃下染色30分钟，然后通过流式细胞术分析细胞的CLDN6表达。
MFI37为37℃条件下孵育的样品的MFI；MFI4为4℃条件下孵育的样品的MFI，该条件下只发生结合而不发生内吞，MFI背景为仅有第二抗体的MFI，抗体介导的细胞表面CLDN6内吞百分比由以下公式计算：
内化CLDN6的百分比＝100–100×(MFI4-MFI37)/MFI4
结果如表4所示，人源化抗体7008-01和7008-03介导了不同程度的肿瘤细胞表面上CLDN6的内化。
表4：抗体介导肿瘤细胞表面上CLDN6的内化比例(％)
Figure PCTCN2021079380-appb-000010
尽管本发明的具体实施方式已经得到详细的描述，但本领域技术人员将理解：根据已经公布的所有教导，可以对细节进行各种修改和变动，并且这些改变均在本发明的保护范围之内。本发明的全部分为由所附权利要求及其任何等同物给出。

Claims (32)

  1. 能够特异性结合CLDN6的抗体或其抗原结合片段，所述抗体或其抗原结合片段包含：
    (a)包含下述3个互补决定区(CDR)的重链可变区(VH)：
    (i)VH CDR1，其由下述序列组成：SEQ ID NO:3，或与其相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列，
    (ii)VH CDR2，其由下述序列组成：SEQ ID NO:4或33，或与其相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列，和
    (iii)VH CDR3，其由下述序列组成：SEQ ID NO:5，或与其相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列；
    和/或
    (b)包含下述3个互补决定区(CDR)的轻链可变区(VL)：
    (iv)VL CDR1，其由下述序列组成：SEQ ID NO:6，或与其相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列，
    (v)VL CDR2，其由下述序列组成：SEQ ID NO:7，或与其相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列，和(vi)VL CDR3，其由下述序列组成：SEQ ID NO:8，或与其相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列；
    优选地，(i)-(vi)任一项中所述的置换为保守置换；
    优选地，(i)-(vi)任一项中所述的CDR根据Kabat、IMGT或Chothia编号系统定义；
    优选地，(i)-(vi)任一项中所述的CDR根据IMGT编号系统定义；
    优选地，所述抗体或其抗原结合片段，其包含：如下3个重链CDRs：序列为SEQ ID NO：3的VH CDR1，序列为SEQ ID NO：4的VH CDR2，序列为SEQ ID NO：5的VH CDR3；和/或，如下3个轻链CDRs：序列为SEQ ID NO：6的VL CDR1，序列为SEQ ID NO：7的VL CDR2，序列为SEQ ID NO：8的VL CDR3；或者，
    所述抗体或其抗原结合片段，其包含：如下3个重链CDRs：序列为SEQ ID NO：3的VH CDR1，序列为SEQ ID NO：33的VH CDR2，序列为SEQ ID NO：5的VH CDR3；和/或，如下3个轻链CDRs：序列为SEQ ID NO：6的VL CDR1，序列为SEQ ID NO：7的VL  CDR2，序列为SEQ ID NO：8的VL CDR3；
    优选地，所述抗体或其抗原结合片段，其进一步包含来源于人的框架区序列(例如，人免疫球蛋白)；
    优选地，所述人免疫球蛋选自人重排抗体序列或人胚系抗体序列。
  2. 权利要求1的抗体或其抗原结合片段，其包含：
    (a)包含下述3个互补决定区(CDR)的重链可变区(VH)：
    (i)VH CDR1，其由下述序列组成：SEQ ID NO:3，或与其相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列，
    (ii)VH CDR2，其由下述序列组成：SEQ ID NO:4，或与其相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列，和
    (iii)VH CDR3，其由下述序列组成：SEQ ID NO:5，或与其相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列；
    和/或
    (b)包含下述3个互补决定区(CDR)的轻链可变区(VL)：
    (iv)VL CDR1，其由下述序列组成：SEQ ID NO:6，或与其相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列，
    (v)VL CDR2，其由下述序列组成：SEQ ID NO:7，或与其相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列，和(vi)VL CDR3，其由下述序列组成：SEQ ID NO:8，或与其相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列；
    优选地，(i)-(vi)任一项中所述的置换为保守置换；
    优选地，(i)-(vi)任一项中所述的CDR根据Kabat、IMGT或Chothia编号系统定义；
    优选地，(i)-(vi)任一项中所述的CDR根据IMGT编号系统定义；
    优选地，所述抗体或其抗原结合片段，其包含：如下3个重链CDRs：序列为SEQ ID NO：3的VH CDR1，序列为SEQ ID NO：4的VH CDR2，序列为SEQ ID NO：5的VH CDR3；和/或，如下3个轻链CDRs：序列为SEQ ID NO：6的VL CDR1，序列为SEQ ID NO：7的VL CDR2，序列为SEQ ID NO：8的VL CDR3；
    优选地，所述抗体或其抗原结合片段，其进一步包含来源于人的框架区序列(例如， 人免疫球蛋白)；
    优选地，所述人免疫球蛋选自人重排抗体序列或人胚系抗体序列。
  3. 权利要求2所述的抗体或其抗原结合片段，其中，所述抗体或其抗原结合片段包含：
    (a)重链可变区(VH)，其包含选自下列的氨基酸序列：
    (i)SEQ ID NO:1所示的序列；
    (ii)与SEQ ID NO:1所示的序列相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个，3个，4个或5个氨基酸的置换、缺失或添加)的序列；或
    (iii)与SEQ ID NO:1所示的序列具有至少80％、至少85％、至少90％、至少91％、至少92％、至少93％、至少94％、至少95％、至少96％、至少97％、至少98％、至少99％、或100％的序列同一性的序列；
    和/或，
    (b)轻链可变区(VL)，其包含选自下列的氨基酸序列：
    (iv)SEQ ID NO:2所示的序列；
    (v)与SEQ ID NO:2所示的序列相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个，3个，4个或5个氨基酸的置换、缺失或添加)的序列；或
    (vi)与SEQ ID NO:2所示的序列具有至少80％、至少85％、至少90％、至少91％、至少92％、至少93％、至少94％、至少95％、至少96％、至少97％、至少98％、至少99％、或100％的序列同一性的序列；
    优选地，(ii)或(v)中所述的置换是保守置换；
    优选地，所述抗体或其抗原结合片段包含：具有如SEQ ID NO:1所示的序列的VH和具有如SEQ ID NO:2所示的序列的VL。
  4. 权利要求1的抗体或其抗原结合片段，其包含：
    (a)包含下述3个互补决定区(CDR)的重链可变区(VH)：
    (i)VH CDR1，其由下述序列组成：SEQ ID NO:3，或与其相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列，
    (ii)VH CDR2，其由下述序列组成：SEQ ID NO:33，或与其相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列， 和
    (iii)VH CDR3，其由下述序列组成：SEQ ID NO:5，或与其相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列；
    和/或
    (b)包含下述3个互补决定区(CDR)的轻链可变区(VL)：
    (iv)VL CDR1，其由下述序列组成：SEQ ID NO:6，或与其相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列，
    (v)VL CDR2，其由下述序列组成：SEQ ID NO:7，或与其相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列，和
    (vi)VL CDR3，其由下述序列组成：SEQ ID NO:8，或与其相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列；
    优选地，(i)-(vi)任一项中所述的置换为保守置换；
    优选地，(i)-(vi)任一项中所述的CDR根据Kabat、IMGT或Chothia编号系统定义；
    优选地，(i)-(vi)任一项中所述的CDR根据IMGT编号系统定义；
    优选地，所述抗体或其抗原结合片段，其包含：如下3个重链CDRs：序列为SEQ ID NO：3的VH CDR1，序列为SEQ ID NO：33的VH CDR2，序列为SEQ ID NO：5的VH CDR3；和/或，如下3个轻链CDRs：序列为SEQ ID NO：6的VL CDR1，序列为SEQ ID NO：7的VL CDR2，序列为SEQ ID NO：8的VL CDR3；
    优选地，所述抗体或其抗原结合片段，其进一步包含来源于人的框架区序列(例如，人免疫球蛋白)；
    优选地，所述人免疫球蛋选自人重排抗体序列或人胚系抗体序列。
  5. 权利要求4所述的抗体或其抗原结合片段，其中，所述抗体或其抗原结合片段包含：
    (a)重链可变区(VH)，其包含选自下列的氨基酸序列：
    (i)SEQ ID NO:19所示的序列；
    (ii)与SEQ ID NO:19所示的序列相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个，3个，4个或5个氨基酸的置换、缺失或添加)的序列；或
    (iii)与SEQ ID NO:19所示的序列具有至少80％、至少85％、至少90％、至少91％、至少92％、至少93％、至少94％、至少95％、至少96％、至少97％、至少98％、至少99％、 或100％的序列同一性的序列；
    和/或，
    (b)轻链可变区(VL)，其包含选自下列的氨基酸序列：
    (iv)SEQ ID NO:20所示的序列；
    (v)与SEQ ID NO:20所示的序列相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个，3个，4个或5个氨基酸的置换、缺失或添加)的序列；或
    (vi)与SEQ ID NO:20所示的序列具有至少80％、至少85％、至少90％、至少91％、至少92％、至少93％、至少94％、至少95％、至少96％、至少97％、至少98％、至少99％、或100％的序列同一性的序列；
    优选地，(ii)或(v)中所述的置换是保守置换；
    优选地，所述抗体或其抗原结合片段包含：具有如SEQ ID NO:19所示的序列的VH和具有如SEQ ID NO:20所示的序列的VL。
  6. 能够特异性结合CLDN6和/或CLDN9的抗体或其抗原结合片段，所述抗体或其抗原结合片段包含：
    (a)包含下述3个互补决定区(CDR)的重链可变区(VH)：
    (i)VH CDR1，其由下述序列组成：SEQ ID NO:13，或与其相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列，
    (ii)VH CDR2，其由下述序列组成：SEQ ID NO:14或23，或与其相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列，和
    (iii)VH CDR3，其由下述序列组成：SEQ ID NO:15，或与其相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列；
    和/或
    (b)包含下述3个互补决定区(CDR)的轻链可变区(VL)：
    (iv)VL CDR1，其由下述序列组成：SEQ ID NO:16或24，或与其相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列，
    (v)VL CDR2，其由下述序列组成：SEQ ID NO:17，或与其相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列， 和
    (vi)VL CDR3，其由下述序列组成：SEQ ID NO:18，或与其相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列；
    优选地，(i)-(vi)任一项中所述的置换为保守置换；
    优选地，(i)-(vi)任一项中所述的CDR根据Kabat、IMGT或Chothia编号系统定义；
    优选地，(i)-(vi)任一项中所述的CDR根据IMGT编号系统定义；
    优选地，所述抗体或其抗原结合片段，其包含：如下3个重链CDRs：序列为SEQ ID NO：13的VH CDR1，序列为SEQ ID NO：14的VH CDR2，序列为SEQ ID NO：15的VH CDR3；和/或，如下3个轻链CDRs：序列为SEQ ID NO：16的VL CDR1，序列为SEQ ID NO：17的VL CDR2，序列为SEQ ID NO：18的VL CDR3；或者，
    所述抗体或其抗原结合片段，其包含：如下3个重链CDRs：序列为SEQ ID NO：13的VH CDR1，序列为SEQ ID NO：23的VH CDR2，序列为SEQ ID NO：15的VH CDR3；和/或，如下3个轻链CDRs：序列为SEQ ID NO：24的VL CDR1，序列为SEQ ID NO：17的VL CDR2，序列为SEQ ID NO：18的VL CDR3；
    优选地，所述抗体或其抗原结合片段，其进一步包含来源于人的框架区序列(例如，人免疫球蛋白)；
    优选地，所述人免疫球蛋选自人重排抗体序列或人胚系抗体序列。
  7. 权利要求6的抗体或其抗原结合片段，其包含：
    (a)包含下述3个互补决定区(CDR)的重链可变区(VH)：
    (i)VH CDR1，其由下述序列组成：SEQ ID NO:13，或与其相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列，
    (ii)VH CDR2，其由下述序列组成：SEQ ID NO:14，或与其相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列，和
    (iii)VH CDR3，其由下述序列组成：SEQ ID NO:15，或与其相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列；
    和/或
    (b)包含下述3个互补决定区(CDR)的轻链可变区(VL)：
    (iv)VL CDR1，其由下述序列组成：SEQ ID NO:16，或与其相比具有一个或几个氨 基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列，
    (v)VL CDR2，其由下述序列组成：SEQ ID NO:17，或与其相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列，和
    (vi)VL CDR3，其由下述序列组成：SEQ ID NO:18，或与其相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列；
    优选地，(i)-(vi)任一项中所述的置换为保守置换；
    优选地，(i)-(vi)任一项中所述的CDR根据Kabat、IMGT或Chothia编号系统定义；
    优选地，(i)-(vi)任一项中所述的CDR根据IMGT编号系统定义；
    优选地，所述抗体或其抗原结合片段，其包含：如下3个重链CDRs：序列为SEQ ID NO：13的VH CDR1，序列为SEQ ID NO：14的VH CDR2，序列为SEQ ID NO：15的VH CDR3；和/或，如下3个轻链CDRs：序列为SEQ ID NO：16的VL CDR1，序列为SEQ ID NO：17的VL CDR2，序列为SEQ ID NO：18的VL CDR3；
    优选地，所述抗体或其抗原结合片段，其进一步包含来源于人的框架区序列(例如，人免疫球蛋白)；
    优选地，所述人免疫球蛋选自人重排抗体序列或人胚系抗体序列。
  8. 权利要求7所述的抗体或其抗原结合片段，其中，所述抗体或其抗原结合片段包含：
    (a)重链可变区(VH)，其包含选自下列的氨基酸序列：
    (i)SEQ ID NO:11所示的序列；
    (ii)与SEQ ID NO:11所示的序列相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个，3个，4个或5个氨基酸的置换、缺失或添加)的序列；或
    (iii)与SEQ ID NO:11所示的序列具有至少80％、至少85％、至少90％、至少91％、至少92％、至少93％、至少94％、至少95％、至少96％、至少97％、至少98％、至少99％、或100％的序列同一性的序列；
    和/或，
    (b)轻链可变区(VL)，其包含选自下列的氨基酸序列：
    (iv)SEQ ID NO:12所示的序列；
    (v)与SEQ ID NO:12所示的序列相比具有一个或几个氨基酸的置换、缺失或添加 (例如1个，2个，3个，4个或5个氨基酸的置换、缺失或添加)的序列；或
    (vi)与SEQ ID NO:12所示的序列具有至少80％、至少85％、至少90％、至少91％、至少92％、至少93％、至少94％、至少95％、至少96％、至少97％、至少98％、至少99％、或100％的序列同一性的序列；
    优选地，(ii)或(v)中所述的置换是保守置换；
    优选地，所述抗体或其抗原结合片段包含：具有如SEQ ID NO:11所示的序列的VH和具有如SEQ ID NO:12所示的序列的VL。
  9. 权利要求6的抗体或其抗原结合片段，其包含：
    (a)包含下述3个互补决定区(CDR)的重链可变区(VH)：
    (i)VH CDR1，其由下述序列组成：SEQ ID NO:13，或与其相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列，
    (ii)VH CDR2，其由下述序列组成：SEQ ID NO:23，或与其相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列，和
    (iii)VH CDR3，其由下述序列组成：SEQ ID NO:15，或与其相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列；
    和/或
    (b)包含下述3个互补决定区(CDR)的轻链可变区(VL)：
    (iv)VL CDR1，其由下述序列组成：SEQ ID NO:24，或与其相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列，
    (v)VL CDR2，其由下述序列组成：SEQ ID NO:17，或与其相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列，和
    (vi)VL CDR3，其由下述序列组成：SEQ ID NO:18，或与其相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)的序列；
    优选地，(i)-(vi)任一项中所述的置换为保守置换；
    优选地，(i)-(vi)任一项中所述的CDR根据Kabat、IMGT或Chothia编号系统定义；
    优选地，(i)-(vi)任一项中所述的CDR根据IMGT编号系统定义；
    优选地，所述抗体或其抗原结合片段，其包含：如下3个重链CDRs：序列为SEQ ID  NO：13的VH CDR1，序列为SEQ ID NO：23的VH CDR2，序列为SEQ ID NO：15的VH CDR3；和/或，如下3个轻链CDRs：序列为SEQ ID NO：24的VL CDR1，序列为SEQ ID NO：17的VL CDR2，序列为SEQ ID NO：18的VL CDR3；
    优选地，所述抗体或其抗原结合片段，其进一步包含来源于人的框架区序列(例如，人免疫球蛋白)；
    优选地，所述人免疫球蛋选自人重排抗体序列或人胚系抗体序列。
  10. 权利要求9所述的抗体或其抗原结合片段，其中，所述抗体或其抗原结合片段包含：
    (a)重链可变区(VH)，其包含选自下列的氨基酸序列：
    (i)SEQ ID NO:9所示的序列；
    (ii)与SEQ ID NO:9所示的序列相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个，3个，4个或5个氨基酸的置换、缺失或添加)的序列；或
    (iii)与SEQ ID NO:9所示的序列具有至少80％、至少85％、至少90％、至少91％、至少92％、至少93％、至少94％、至少95％、至少96％、至少97％、至少98％、至少99％、或100％的序列同一性的序列；
    和/或，
    (b)轻链可变区(VL)，其包含选自下列的氨基酸序列：
    (iv)SEQ ID NO:10所示的序列；
    (v)与SEQ ID NO:10所示的序列相比具有一个或几个氨基酸的置换、缺失或添加(例如1个，2个，3个，4个或5个氨基酸的置换、缺失或添加)的序列；或
    (vi)与SEQ ID NO:10所示的序列具有至少80％、至少85％、至少90％、至少91％、至少92％、至少93％、至少94％、至少95％、至少96％、至少97％、至少98％、至少99％、或100％的序列同一性的序列；
    优选地，(ii)或(v)中所述的置换是保守置换；
    优选地，所述抗体或其抗原结合片段包含：具有如SEQ ID NO:9所示的序列的VH和具有如SEQ ID NO:10所示的序列的VL。
  11. 权利要求1-10任一项所述的抗体或其抗原结合片段，其中，所述抗体或其抗原结合片段进一步包含：
    (a)人免疫球蛋白的重链恒定区(CH)或其变体，所述变体与其所源自的野生型序列相比具有一个或多个氨基酸的置换、缺失或添加(例如，至多20个、至多15个、至多10个、或至多5个氨基酸的置换、缺失或添加；例如1个，2个，3个，4个或5个氨基酸的置换、缺失或添加)；和
    (b)人免疫球蛋白的轻链恒定区(CL)或其变体，所述变体与其所源自的野生型序列相比具有至多20个氨基酸的保守置换(例如至多15个、至多10个、或至多5个氨基酸的保守置换；例如1个，2个，3个，4个或5个氨基酸的保守置换)；
    优选地，所述重链恒定区是IgG重链恒定区，例如IgG1、IgG2、IgG3或IgG4重链恒定区；
    优选地，所述抗体或其抗原结合片段包含SEQ ID NO:21所示的重链恒定区(CH)；
    优选地，所述轻链恒定区是κ或λ轻链恒定区；
    优选地，所述抗体或其抗原结合片段包含SEQ ID NO:22所示的轻链恒定区(CL)。
  12. 权利要求1-11任一项所述的抗体或其抗原结合片段，其中，所述抗原结合片段选自Fab、Fab’、(Fab’) 2、Fv、二硫键连接的Fv、scFv、双抗体(diabody)和单域抗体(sdAb)；和/或，所述抗体为鼠源抗体、嵌合抗体、人源化抗体、双特异性抗体或多特异性抗体。
  13. 权利要求1-12任一项所述的抗体或其抗原结合片段，其中，所述抗体或其抗原结合片段带有标记；优选地，所述抗体或其抗原结合片段带有可检测的标记，例如酶(例如辣根过氧化物酶)、放射性核素、荧光染料、发光物质(如化学发光物质)或生物素。
  14. 分离的核酸分子，其编码权利要求1-13任一项所述的抗体或其抗原结合片段，或其重链可变区和/或轻链可变区。
  15. 载体，其包含权利要求14所述的分离的核酸分子；优选地，所述载体为克隆载体或表达载体。
  16. 宿主细胞，其包含权利要求14所述的分离的核酸分子或权利要求15所述的载 体。
  17. 制备权利要求1-13任一项所述的抗体或其抗原结合片段的方法，其包括，在允许所述抗体或其抗原结合片段表达的条件下，培养权利要求16所述的宿主细胞，和从培养的宿主细胞培养物中回收所述抗体或其抗原结合片段。
  18. 双特异性或多特异性分子，其包含权利要求1-13任一项所述的抗体或其抗原结合片段；
    优选地，所述双特异性或多特异性分子特异性结合CLDN6，并且额外地特异性结合一个或多个其他靶标；
    优选地，所述双特异性或多特异性分子还包含至少一种具有针对第二靶标的第二结合特异性的分子(例如第二抗体)。
  19. 免疫缀合物，其包含权利要求1-13任一项所述的抗体或其抗原结合片段以及连接于所述抗体或其抗原结合片段的治疗剂；
    优选地，所述治疗剂选自细胞毒剂；
    优选地，所述治疗剂选自烷化剂、有丝分裂抑制剂、抗肿瘤抗生素、抗代谢物、拓扑异构酶抑制剂、酪氨酸激酶抑制剂、放射性核素剂，及其任意组合；
    优选地，所述免疫缀合物是抗体-药物偶联物(ADC)。
  20. 药物组合物，其含有权利要求1-13任一项所述的抗体或其抗原结合片段、权利要求18所述的双特异性或多特异性分子或者权利要求19所述的免疫缀合物，以及药学上可接受的载体和/或赋形剂；
    优选地，药物组合物还包含另外的药学活性剂；
    优选地，所述另外的药学活性剂是具有抗肿瘤活性的药物，例如烷化剂、有丝分裂抑制剂、抗肿瘤抗生素、抗代谢物、拓扑异构酶抑制剂、酪氨酸激酶抑制剂、放射性核素剂、放射增敏剂、抗血管生成剂、细胞因子、分子靶向药物、免疫检查点抑制剂或溶瘤病毒；
    优选地，所述抗体或其抗原结合片段、双特异性或多特异性分子或免疫缀合物与所述另外的药学活性剂作为分离的组分或作为同一组合物的组分提供。
  21. 试剂盒，其含有权利要求1-13任一项所述的抗体或其抗原结合片段；
    优选地，所述抗体或其抗原结合片段带有可检测的标记，例如酶(例如辣根过氧化物酶)、放射性核素、荧光染料、发光物质(如化学发光物质)或生物素；
    优选地，所述试剂盒还包括第二抗体，其特异性识别权利要求1-13任一项所述的抗体或其抗原结合片段；
    优选地，所述第二抗体还包括可检测的标记，例如酶(例如辣根过氧化物酶)、放射性核素、荧光染料、发光物质(如化学发光物质)或生物素。
  22. 嵌合抗原受体，其包含权利要求1-13任一项所述的抗体或其抗原结合片段的抗原结合结构域；
    优选地，所述抗原结合结构域包含权利要求1-13任一项所述的抗体或其抗原结合片段的重链可变区和轻链可变区；
    优选地，所述抗原结合结构域是scFv；
    优选地，所述抗原结合受体包含权利要求1-13任一项所述的抗体的抗原结合片段；
    优选地，所述抗原结合受体由免疫效应细胞(例如T细胞)所表达。
  23. 分离的核酸分子，其编码权利要求22所述的嵌合抗原受体。
  24. 载体，其包含权利要求23所述的分离的核酸分子；优选地，其用于制备嵌合抗原受体T细胞。
  25. 宿主细胞，其包含权利要求23所述的分离的核酸分子或权利要求24所述的载体；
    优选地，所述宿主细胞是免疫效应细胞(例如，T细胞或NK细胞)；
    优选地，所述宿主细胞是嵌合抗原受体T细胞(CAR-T)。
  26. 一种用于降低CLDN6和/或CLDN9在细胞表面的表达水平的方法，其包括将所述细胞与权利要求1-13任一项所述的抗体或其抗原结合片段，或权利要求18所述的双特异性或多特异性分子，或权利要求19所述的免疫缀合物，或权利要求20所述的药物组合物，或权利要求22所述的嵌合抗原受体，或权利要求25所述的宿主细胞接触，使 得CLDN6和/或CLDN9在所述细胞表面的表达水平降低；其中，所述细胞在其表面表达CLDN6和/或CLDN9；
    优选地，所述细胞是表达CLDN6和/或CLDN9的肿瘤细胞。
  27. 一种抑制表达CLDN6和/或CLDN9的肿瘤细胞生长和/或杀伤所述肿瘤细胞的方法，其包括将所述肿瘤细胞与有效量的权利要求1-13任一项所述的抗体或其抗原结合片段，或权利要求18所述的双特异性或多特异性分子，或权利要求19所述的免疫缀合物，或权利要求20所述的药物组合物，或权利要求22所述的嵌合抗原受体，或权利要求25所述的宿主细胞接触。
  28. 一种用于在受试者(例如人)中预防和/或治疗肿瘤的方法，所述方法包括向有此需要的受试者施用有效量的权利要求1-13任一项所述的抗体或其抗原结合片段，或权利要求18所述的双特异性或多特异性分子，或权利要求19所述的免疫缀合物，或权利要求20所述的药物组合物，或权利要求22所述的嵌合抗原受体，或权利要求25所述的宿主细胞；
    优选地，所述肿瘤表达CLDN6和/或CLDN9；
    优选地，所述肿瘤涉及表达CLDN6和/或CLDN9的肿瘤细胞；优选地，所述CLDN6和/或CLDN9在所述肿瘤细胞表面上表达；
    优选地，所述肿瘤选自卵巢癌、睾丸癌、胃癌、子宫内膜癌、肺癌、食管癌、胰腺癌、支气管癌、乳腺癌、耳鼻喉(ENT)癌、结肠癌、肝癌、头颈癌、胆囊癌及其转移癌(例如，胃癌转移，如Krukenberg瘤、腹膜转移或淋巴结转移)；
    优选地，所述受试者为哺乳动物，例如人；
    优选地，所述方法还包括施用另外的具有抗肿瘤活性的药物，例如烷化剂、有丝分裂抑制剂、抗肿瘤抗生素、抗代谢物、拓扑异构酶抑制剂、酪氨酸激酶抑制剂、放射性核素剂、放射增敏剂、抗血管生成剂、细胞因子、分子靶向药物、免疫检查点抑制剂或溶瘤病毒；
    优选地，所述方法还包括施用另外的抗肿瘤疗法，例如手术、化学治疗、放射治疗、靶向治疗、免疫治疗、激素治疗、基因治疗或姑息治疗。
  29. 权利要求1-13任一项所述的抗体或其抗原结合片段，或权利要求18所述的双特 异性或多特异性分子，或权利要求19所述的免疫缀合物，或权利要求20所述的药物组合物，或权利要求22所述的嵌合抗原受体，或权利要求25所述的宿主细胞，在制备药物中的用途，所述药物用于在受试者(例如人)中预防和/治疗肿瘤；
    优选地，药物还包含另外的药学活性剂；
    优选地，所述另外的药学活性剂是具有抗肿瘤活性的药物，例如烷化剂、有丝分裂抑制剂、抗肿瘤抗生素、抗代谢物、拓扑异构酶抑制剂、酪氨酸激酶抑制剂、放射性核素剂、放射增敏剂、抗血管生成剂、细胞因子、分子靶向药物、免疫检查点抑制剂或溶瘤病毒；
    优选地，所述肿瘤表达CLDN6和/或CLDN9；
    优选地，所述肿瘤涉及表达CLDN6和/或CLDN9的肿瘤细胞；优选地，所述CLDN6和/或CLDN9在所述肿瘤细胞表面上表达；
    优选地，所述肿瘤选自卵巢癌、睾丸癌、胃癌、子宫内膜癌、肺癌、食管癌、胰腺癌、支气管癌、乳腺癌、耳鼻喉(ENT)癌、结肠癌、肝癌、头颈癌、胆囊癌及其转移癌(例如，胃癌转移，如Krukenberg瘤、腹膜转移或淋巴结转移)；
    优选地，所述受试者为哺乳动物，例如人。
  30. 一种检测CLDN6和/或CLDN9(例如人CLDN6和/或人CLDN9)在样品中的存在或其量的方法，其包括以下步骤：
    (1)将所述样品与权利要求1-13任一项所述的抗体或其抗原结合片段接触；
    (2)检测所述抗体或其抗原结合片段与CLDN6和/或CLDN9之间复合物的形成或检测所述复合物的量；
    优选地，所述抗体或其抗原结合片段带有可检测的标记；
    优选地，所述CLDN6是人CLDN6；
    优选地，所述CLDN9是人CLDN9。
  31. 一种用于检测肿瘤是否能够通过靶向CLDN6和/或CLDN9的抗肿瘤疗法来治疗的方法，其包括以下步骤：
    (1)将含有所述肿瘤细胞的样品与权利要求1-13任一项所述的抗体或其抗原结合片段接触；
    (2)检测所述抗体或其抗原结合片段与CLDN6和/或CLDN9之间复合物的形成；
    优选地，所述抗体或其抗原结合片段带有可检测的标记；
    优选地，所述CLDN6是人CLDN6；
    优选地，所述CLDN9是人CLDN9；
    优选地，所述肿瘤选自卵巢癌、睾丸癌、胃癌、子宫内膜癌、肺癌、食管癌、胰腺癌、支气管癌、乳腺癌、耳鼻喉(ENT)癌、结肠癌、肝癌、头颈癌、胆囊癌及其转移癌(例如，胃癌转移，如Krukenberg瘤、腹膜转移或淋巴结转移)。
  32. 权利要求1-13任一项所述的抗体或其抗原结合片段在制备试剂盒中的用途，所述试剂盒用于检测肿瘤是否能够通过靶向CLDN6和/或CLDN9的抗肿瘤疗法来治疗；
    优选地，所述抗体或其抗原结合片段带有可检测的标记；
    优选地，所述CLDN6是人CLDN6；
    优选地，所述CLDN9是人CLDN9；
    优选地，所述肿瘤选自卵巢癌、睾丸癌、胃癌、子宫内膜癌、肺癌、食管癌、胰腺癌、支气管癌、乳腺癌、耳鼻喉(ENT)癌、结肠癌、肝癌、头颈癌、胆囊癌及其转移癌(例如，胃癌转移，如Krukenberg瘤、腹膜转移或淋巴结转移)。
PCT/CN2021/079380 2021-03-05 2021-03-05 抗cldn6抗体及其用途 Ceased WO2022183502A1 (zh)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CN202180095157.5A CN116940377A (zh) 2021-03-05 2021-03-05 抗cldn6抗体及其用途
PCT/CN2021/079380 WO2022183502A1 (zh) 2021-03-05 2021-03-05 抗cldn6抗体及其用途
CA3212530A CA3212530A1 (en) 2021-03-05 2021-03-05 Anti-cldn6 antibody and use thereof
US18/280,379 US20240150455A1 (en) 2021-03-05 2021-03-05 Anti-cldn6 antibody and use thereof
EP21928585.5A EP4302777A4 (en) 2021-03-05 2021-03-05 ANTI-CLDN6 ANTIBODY AND ITS USE
KR1020237033643A KR20230154317A (ko) 2021-03-05 2021-03-05 항-cldn6 항체 및 이의 용도
JP2023553642A JP7734753B2 (ja) 2021-03-05 2021-03-05 抗ｃｌｄｎ６抗体およびその使用
TW111107215A TW202235441A (zh) 2021-03-05 2022-03-01 抗cldn6抗體及其用途
JP2025140700A JP2026000918A (ja) 2021-03-05 2025-08-26 抗ｃｌｄｎ６抗体およびその使用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2021/079380 WO2022183502A1 (zh) 2021-03-05 2021-03-05 抗cldn6抗体及其用途

Publications (1)

Publication Number Publication Date
WO2022183502A1 true WO2022183502A1 (zh) 2022-09-09

Family

ID=83154900

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/079380 Ceased WO2022183502A1 (zh) 2021-03-05 2021-03-05 抗cldn6抗体及其用途

Country Status (8)

Country Link
US (1) US20240150455A1 (zh)
EP (1) EP4302777A4 (zh)
JP (2) JP7734753B2 (zh)
KR (1) KR20230154317A (zh)
CN (1) CN116940377A (zh)
CA (1) CA3212530A1 (zh)
TW (1) TW202235441A (zh)
WO (1) WO2022183502A1 (zh)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024165057A1 (en) * 2023-02-07 2024-08-15 LaNova Medicines Limited Antibodies and antibody-drug conjugates targeting claudin 6
CN118754987A (zh) * 2024-08-21 2024-10-11 广州百吉生物制药有限公司 一种紧密连接蛋白抗体h04及其应用
CN118812714A (zh) * 2024-08-21 2024-10-22 广州百吉生物制药有限公司 一种紧密连接蛋白抗体b3及其应用
WO2024227424A1 (zh) * 2023-04-30 2024-11-07 泰诚思(上海)生物医药有限公司 hCLDN6的抗原结合蛋白和其用途
US20250121084A1 (en) * 2023-10-17 2025-04-17 Adc Therapeutics Sa Anti-claudin-6 conjugates
WO2025083067A1 (en) * 2023-10-17 2025-04-24 Adc Therapeutics Sa Anti-claudin-6 conjugates
WO2025162270A1 (zh) * 2024-02-01 2025-08-07 江苏恒瑞医药股份有限公司 抗cldn6抗体、其抗体-药物偶联物及其医药用途
US12528863B2 (en) 2019-07-10 2026-01-20 Chugai Seiyaku Kabushiki Kaisha Claudin-6 binding molecules and uses thereof

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7689666B2 (ja) * 2021-12-17 2025-06-09 国立大学法人 筑波大学 ヒト化抗ｄｎａｍ－１抗体
CN118772280B (zh) * 2024-06-13 2025-04-04 广州百吉生物制药有限公司 一种抗人cldn6单域抗体及其应用
CN119462928B (zh) * 2024-11-08 2025-09-05 深圳豪石生物科技有限公司 特异性靶向cldn6的抗体及其在制备car-t细胞中的应用

Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3850752A (en) 1970-11-10 1974-11-26 Akzona Inc Process for the demonstration and determination of low molecular compounds and of proteins capable of binding these compounds specifically
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO2002043478A2 (en) 2000-11-30 2002-06-06 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
CN101918450A (zh) * 2008-01-11 2010-12-15 国立大学法人东京大学 抗cldn6抗体
WO2012079000A1 (en) 2010-12-09 2012-06-14 The Trustees Of The University Of Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US20120213783A1 (en) 2009-10-01 2012-08-23 Rosenberg Steven A Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
WO2013059593A1 (en) 2011-10-20 2013-04-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cd22 chimeric antigen receptors
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
CN105813650A (zh) * 2013-11-06 2016-07-27 施特姆森特克斯股份有限公司 新型抗-密蛋白抗体和使用方法
CN106432500A (zh) * 2009-11-11 2017-02-22 加尼梅德药物公司 密蛋白6（cldn6）特异性的抗体
CN107207580A (zh) * 2014-11-05 2017-09-26 艾伯维施特姆森特克斯有限责任公司 抗‑cldn嵌合抗原受体和使用方法
WO2020191342A1 (en) * 2019-03-20 2020-09-24 The Regents Of The University Of California Claudin-6 antibodies and drug conjugates

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7682797B2 (ja) 2019-03-20 2025-05-26 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア クローディン６二重特異性抗体

Patent Citations (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3850752A (en) 1970-11-10 1974-11-26 Akzona Inc Process for the demonstration and determination of low molecular compounds and of proteins capable of binding these compounds specifically
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4366241B1 (zh) 1980-08-07 1988-10-18
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5693762A (en) 1988-12-28 1997-12-02 Protein Design Labs, Inc. Humanized immunoglobulins
US5585089A (en) 1988-12-28 1996-12-17 Protein Design Labs, Inc. Humanized immunoglobulins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6180370B1 (en) 1988-12-28 2001-01-30 Protein Design Labs, Inc. Humanized immunoglobulins and methods of making the same
WO2002043478A2 (en) 2000-11-30 2002-06-06 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
CN101918450A (zh) * 2008-01-11 2010-12-15 国立大学法人东京大学 抗cldn6抗体
US20120213783A1 (en) 2009-10-01 2012-08-23 Rosenberg Steven A Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
CN106432500A (zh) * 2009-11-11 2017-02-22 加尼梅德药物公司 密蛋白6（cldn6）特异性的抗体
CN111875703A (zh) * 2009-11-11 2020-11-03 安斯泰来制药股份有限公司 密蛋白6(cldn6)特异性的抗体
WO2012079000A1 (en) 2010-12-09 2012-06-14 The Trustees Of The University Of Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2013059593A1 (en) 2011-10-20 2013-04-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cd22 chimeric antigen receptors
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
CN105813650A (zh) * 2013-11-06 2016-07-27 施特姆森特克斯股份有限公司 新型抗-密蛋白抗体和使用方法
CN107207580A (zh) * 2014-11-05 2017-09-26 艾伯维施特姆森特克斯有限责任公司 抗‑cldn嵌合抗原受体和使用方法
WO2020191342A1 (en) * 2019-03-20 2020-09-24 The Regents Of The University Of California Claudin-6 antibodies and drug conjugates

Non-Patent Citations (56)

* Cited by examiner, † Cited by third party
Title
"Immunology-A Synthesis", 1991, SINAUER ASSOCIATES, SUNDERLAND, MASS.
"NCBI", Database accession no. 095484
ALFTHAN ET AL., PROTEIN ENG., vol. 8, 1995, pages 725 - 731
ALLEN, T.M., NAT. REV. CANCER, vol. 2, 2002, pages 750 - 763
BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426
BRENNAN ET AL., SCIENCE, vol. 229, 1985, pages 81
BRENTJENS ET AL., MOLECULAR THERAPY, vol. 18, no. 4, 2010, pages 666 - 668
BRUGGERMANN ET AL., YEAR IN IMMUNOLOGY, vol. 7, 1993, pages 33
BRUMMELL ET AL., BIOCHEM., vol. 32, 1993, pages 1180 - 1187
BURKS ET AL., PROC. NATL ACAD. SET USA, vol. 94, 1997, pages 412 - 417
CHOI ET AL., EUR. J. IMMUNOL., vol. 31, 2001, pages 94 - 106
CHOTHIA ET AL., NATURE, vol. 341, 1989, pages 544 - 546
CHOTHIALESK, J. MOL. BIOL., vol. 196, 1987, pages 901 - 917
CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628
D. WILKINSON: "The Scientist", vol. 14, 17 April 2000, THE SCIENTIST, INC., pages: 25 - 28
DESNOYERS ET AL., SCI. TRANSL. MED., vol. 5, 2013, pages 207ra144
DUCHOSAL ET AL., NATURE, vol. 355, 1992, pages 258
E. MEYERSW. MILLER, COMPUT. APPL BIOSCI., vol. 4, 1988, pages 11 - 17
ENGINEERED ANTIBODY VARIANTS ARE REVIEWED IN HOLLIGER, 2005
F. M. AUSUBEL ET AL.: "Molecular Biology Experimental Guide", 1995, MACK PUBLISHING COMPANY
GRUPP ET AL., NENGLJMED., vol. 368, 2013, pages 1509 - 1518
HAN ET AL., J. HEMATOL ONCOL., vol. 6, 2013, pages 47
HAN ET AL., J.HEMATOL ONCOL., vol. 6, 2013, pages 47
HOLLIGER P. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 2551 - 6448
HOOGENBOOM ET AL., J. MOL. BIOL., vol. 227, 1991, pages 381 - 597
HU ET AL., CANCER RES., vol. 56, 1996, pages 3055 - 3061
HUDSON, CURR. OPIN. IMMUNOL., vol. 11, 1999, pages 548 - 557
HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 5879 - 5883
J. SAMBROOK ET AL.: "Molecular Cloning: A Laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY PRESS
JAKOBOVITS ET AL., NATURE, vol. 362, 1993, pages 255 - 258
KABAT, E.A. ET AL.: "U.S. Department of Health and Human Services", 1991, NIH PUBLICATION, article "Sequences of Proteins of Immunological Interest", pages: 3242
KIPRIYANOV ET AL., J. MOL. BIOL., vol. 293, 1999, pages 41 - 56
KOBAYASHI ET AL., PROTEIN ENG., vol. 12, no. 10, 1999, pages 879 - 884
KOHLER ET AL., NATURE, vol. 256, 1975, pages 495
KOJIMA MANABU, SUGIMOTO KOTARO, TANAKA MIZUKO, ENDO YUTA, KATO HITOMI, HONDA TSUYOSHI, FURUKAWA SHIGENORI, NISHIYAMA HIROSHI, WATA: "Prognostic Significance of Aberrant Claudin-6 Expression in Endometrial Cancer", CANCERS, vol. 12, no. 10, pages 2748, XP055963951, DOI: 10.3390/cancers12102748 *
LEFRANC ET AL., DEV. COMPARAT. IMMUNOL., vol. 27, 2003, pages 55 - 77
LITTLE ET AL., IMMUNOL. TODAY, vol. 21, 2000, pages 364 - 370
LOBENNY, K.C.: "Antibody Engineering: Methods and Protocols", vol. 248, 2004, HUMANA PRESS
LONBERG ET AL., NATURE, vol. 368, no. 6474, 1994, pages 856 - 859
MORGAN ET AL., MOLECULAR THERAPY, 23 February 2010 (2010-02-23), pages 1 - 9
MORIMOTO ET AL., J. BIOCHEM. BIOPHYS. METHODS, vol. 24, 1992, pages 107 - 117
MORRISON ET AL.: "81", PROC. NATL. ACAD. SCI. USA, 1984, pages 544 546
NAT BIOTECHNOL, vol. 23, pages 1126 - 1136
NEEDLEMAN ET AL., J. MOL. BIOL., vol. 48, 1970, pages 443 - 453
NEEDLEMANWUNSCH, J MOI BIOL., vol. 48, 1970, pages 444 - 453
PARK ET AL., TRENDS BIOTECHNOL., vol. 29, 2011, pages 550 - 557
PASTAN, I.KREITMAN, R.J., CURR. OPIN. INVESTIG. DRUGS, vol. 3, 2002, pages 1089 - 1091
PAYNE, G., CANCER CELL, vol. 3, 2003, pages 207 - 212
POLJAK R. J. ET AL., STRUCTURE, vol. 113, 1994, pages 1121 - 1123
ROOVERS ET AL., CANCER IMMUNOL, 2001
SAITO, G. ET AL., ADV. DRUG DELIV. REV., vol. 55, 2003, pages 199 - 215
See also references of EP4302777A4
SENTER, P.D.; SPRINGER, C.J., ADV. DRUG DELIV.REV, vol. 53, 2001, pages 247 - 264
TILL ET AL., BLOOD, vol. 112, 2008, pages 2261 - 2271
TRAIL, P.A. ET AL., CANCER IMMUNOL. IMMUNOTHER, vol. 52, 2003, pages 328 - 337
VAUGHANMAN ET AL., NATURE BIOTECH, vol. 14, 1996, pages 309

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12528863B2 (en) 2019-07-10 2026-01-20 Chugai Seiyaku Kabushiki Kaisha Claudin-6 binding molecules and uses thereof
WO2024165057A1 (en) * 2023-02-07 2024-08-15 LaNova Medicines Limited Antibodies and antibody-drug conjugates targeting claudin 6
US12180276B2 (en) 2023-02-07 2024-12-31 LaNova Medicines Limited Antibodies and antibody-drug conjugates targeting claudin 6
WO2024227424A1 (zh) * 2023-04-30 2024-11-07 泰诚思(上海)生物医药有限公司 hCLDN6的抗原结合蛋白和其用途
US20250121084A1 (en) * 2023-10-17 2025-04-17 Adc Therapeutics Sa Anti-claudin-6 conjugates
WO2025083067A1 (en) * 2023-10-17 2025-04-24 Adc Therapeutics Sa Anti-claudin-6 conjugates
WO2025162270A1 (zh) * 2024-02-01 2025-08-07 江苏恒瑞医药股份有限公司 抗cldn6抗体、其抗体-药物偶联物及其医药用途
CN118754987A (zh) * 2024-08-21 2024-10-11 广州百吉生物制药有限公司 一种紧密连接蛋白抗体h04及其应用
CN118812714A (zh) * 2024-08-21 2024-10-22 广州百吉生物制药有限公司 一种紧密连接蛋白抗体b3及其应用
CN118754987B (zh) * 2024-08-21 2025-02-11 广州百吉生物制药有限公司 一种紧密连接蛋白抗体h04及其应用

Also Published As

Publication number Publication date
JP2026000918A (ja) 2026-01-06
EP4302777A1 (en) 2024-01-10
US20240150455A1 (en) 2024-05-09
CN116940377A (zh) 2023-10-24
EP4302777A4 (en) 2025-07-02
CA3212530A1 (en) 2022-09-09
JP7734753B2 (ja) 2025-09-05
JP2024512337A (ja) 2024-03-19
TW202235441A (zh) 2022-09-16
KR20230154317A (ko) 2023-11-07

Similar Documents

Publication Publication Date Title
CN112912396B (zh) 抗cldn18.2抗体及其用途
JP7734753B2 (ja) 抗ｃｌｄｎ６抗体およびその使用
US12297265B2 (en) Antibody and use thereof
US20230312739A1 (en) Anti-cd73 antibody and use thereof
ES3039621T3 (en) Anti-cd3 antibody, and molecule containing said antibody
CN110734493B (zh) 抗pd-1抗体及其用途
EP4596582A1 (en) B7-h3 binding protein and use thereof
WO2024007671A1 (zh) 特异性结合cd24的抗体及其用途
KR20250042908A (ko) 항-메소텔린 항체 및 이의 용도
WO2024000259A1 (zh) Cd22特异性结合抗体及其制备方法和其在双特异cart上的用途
RU2797709C2 (ru) Антитело к cldn18.2 и его применения
US20250092154A1 (en) Anti-mesothelin antibodies and uses thereof
HK40044791A (zh) 抗cldn18.2抗体及其用途
TW202140551A (zh) 抗cldn18.2抗體及其用途
HK40044791B (zh) 抗cldn18.2抗体及其用途
KR20250126941A (ko) 항-메소텔린 인간화 항체 및 이의 용도
HK40083261A (zh) 抗cd73抗体及其用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21928585

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2023553642

Country of ref document: JP

Ref document number: 202180095157.5

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 18280379

Country of ref document: US

Ref document number: 3212530

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 20237033643

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2021928585

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2021928585

Country of ref document: EP

Effective date: 20231005

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 11202500642W

Country of ref document: SG

WWP Wipo information: published in national office

Ref document number: 11202500642W

Country of ref document: SG